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Abstract 
 
Introduction: High blood pressure is recognized as a leading risk factor for 
stroke and death in sub-Saharan Africa (sSA). While many studies have 
examined the role of established risk factors such as obesity and salt 
consumption, less is known about other factors, such as infection, that could 
be of particular importance in sSA. Ambulatory blood pressure measurement 
has emerged as the optimal method in recent years in Western settings, but 
there has been limited use to date in sSA. This work presents the results of a 
study investigating whether malaria, which is widespread in sSA could 
contribute to the development of high blood pressure using ambulatory 
measurements. 
Methods: Preliminary work involved determining the prevalence of 
hypertension in Kilifi, Kenya and examining the population-level effects of 
using ambulatory blood pressure monitoring (ABPM) for diagnosing 
hypertension. A literature review outlining the basis of the malaria-high blood 
pressure hypothesis and the Mendelian randomization method for testing the 
hypothesis was conducted. Sickle cell trait and alpha (+) thalassemia were 
chosen as instrumental variables to represent malaria exposure because they 
protect against malaria. Two studies were performed in Nairobi, Kenya among 
the same cohort to confirm that sickle-cell trait and alpha-thalassemia do not 
influence blood pressure in the absence of malaria and were therefore valid 
instrumental variables to test the malaria-high blood pressure hypothesis in 
Kilifi where there is malaria transmission. A Mendelian randomization study 
was then conducted in Kilifi, Kenya where 24-hour blood pressure and arterial 
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stiffness indices were compared in individuals with and without sickle cell trait 
and alpha thalassemia. 
Results: The prevalence of hypertension in Kilifi, a rural area, was found to 
be as high as in urban areas of Kenya despite the low frequency of classical 
risk factors such as obesity and excessive salt consumption. Use of 
ambulatory blood pressure monitoring for diagnosing hypertension was found 
to improve the accuracy of detection of high blood pressure.  
Neither Sickle-cell trait (SCT) nor alpha+ thalassemia influenced blood 
pressure or arterial stiffness indices among adolescents that had been lifelong 
residents of Nairobi, where there is no malaria transmission. Among 
individuals that had been lifelong residents of Kilifi, Kenya where there has 
been on-going malaria transmission, blood pressure was found to be lower 
among individuals with SCT, which protects against malaria episodes 
compared to those without SCT. The difference in BP by SCT status was 
larger in women than in men. There were no significant differences in arterial 
stiffness based on SCT status.  
Conclusion: This work suggests that malaria contributes to the burden of 
hypertension in sSA, and the control of malaria may  lead to a reduction in 
blood pressure in this group. Future work should focus on confirming the 
findings using alternative study designs such as examining blood pressure in 
cohorts born before and after complete malaria elimination in parts of the 
world where this has been achieved. Subsequent work would involve 
delineating the pathophysiological mechanisms involved in malaria induced 
BP elevation with a view to generating new drugs to control hypertension. 
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Preface 
This thesis comprises four published and one as yet unpublished research 
papers focusing on the malaria-high blood pressure hypothesis. Although the 
papers are from and form one body of work, they also stand alone as 
independent research contributions. As such, there will be several instances 
where the setting, definitions and other descriptions are repeated. For the 
sole purpose of making the thesis easier to read and annotate, for the four 
published papers I have included the final word-processed document in this 
thesis rather than the published proofs. Internet links to the published 
versions are provided in the preface to each paper. 
The introductory chapter looks at the importance of hypertension in Africa, 
followed by a description of how I came up with the malaria-high blood 
pressure hypothesis and considerations that I made in designing the studies 
to test it. Chapters 2-6 are a series of research papers beginning with a 
descriptive study of hypertension in Kilifi, Kenya (Chapter 2), a review of the 
literature in support of the hypothesis tested (Chapter 3) and finally 3 papers 
(Chapters 4-6) presenting data from studies done in order to test the 
hypothesis. Chapter 7 is a discussion of the results of the studies and their 
implications and it outlines what direction future research should take.  
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Chapter 1.  Introduction  
A. The Changing Epidemiology of High Blood Pressure in Africa 
Early studies of hypertension in sub-Saharan Africa suggested that population 
mean blood pressure levels in the region were low. In one of the earliest 
papers on high blood pressure in sub-Saharan Africa, published in the Lancet 
in 1929, C.P. Donnison reported a mean systolic blood pressure of 106 mm 
Hg and mean diastolic blood pressure of 67 mm Hg among 1,800 apparently 
healthy adults aged 15 years and above at Kisii District Hospital located in the 
highlands of Western Kenya.1 This was in comparison to average values of 
140/90 mmHg among Europeans and Americans at the time. He reported that 
only 2 subjects (who had not shown any signs of nervousness) had systolic 
blood pressures in the hypertensive range; one had a recording of 172 mm 
Hg and the other had a reading of 150 mm Hg. Unfortunately he was not able 
to follow up these 2 individuals and study them further. In a 1961 study by 
Shaper et al among the Samburu, Turkana and Rendile in semi-arid northern 
Kenya, no participant had a systolic blood pressure above 160 mm Hg.2 
Similar findings were reported by Beiser et al in Senegal in 19763 and Pobee 
et al in rural Ghana in 1977.4  
In recent years there has been a proliferation of studies suggesting an 
increasing burden of high blood pressure in Africa.5-10These have been 
summarized in systematic reviews and meta-analyses, each addressing 
slightly different questions, that were conducted by Addo et al,11 
Twagirumukiza et al6, and Ataklte et al10. Although these studies all had some 
significant shortcomings, they revealed the following: 
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- limited population-level data on hypertension epidemiology in many 
African countries 
- extensive variation in the prevalence of hypertension both within and 
between studies included in the meta-analyses 
- an age-related increase in the prevalence of hypertension 
- a higher prevalence of hypertension in urban areas compared to rural 
areas 
- low levels of awareness of hypertension in those with blood pressure 
above the normal range 
- low levels of treatment among those previously diagnosed as 
hypertensive 
- low levels of blood pressure control among those on medications for 
hypertension 
Partly in response to deficiencies identified in the individual studies that 
contributed to the meta-analyses cited above, a number of World Health 
Organization (WHO) supported STEPwise surveys have been conducted to 
determine the prevalence of hypertension and other risk factors for non-
communicable diseases in several countries in Africa.12 The surveys are 
referred to as STEPwise (STEPS) because the data are collected in 3 steps; 
step 1 uses a questionnaire to collect demographic and lifestyle data; step 2 
involves measurements of height, weight, blood pressure, waist and hip 
circumference; and step 3 uses laboratory (biochemistry) investigations. 
Although no formal meta-analysis of the STEPs surveys has been conducted 
to date, these surveys have come up with essentially similar findings to 
previously conducted studies, as exemplified in one that was conducted in 
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Malawi.13 A point to note though is that a recently conducted STEPs survey in 
Kenya found a marginally higher prevalence of hypertension in rural areas 
compared to urban regions.14 The findings of the Kenyan STEPs survey are 
discussed in more detail in the first paper in this thesis. 
The consequences of uncontrolled hypertension are significant. The 
Interstroke study established that hypertension accounts for the largest share 
of the population attributable risk for stroke15 in low and middle income 
countries. Stroke is a leading cause acquired disability in these countries, 
many of which are in Africa.16 The Interheart study similarly established that 
hypertension plays a major role in the development of myocardial infarction in 
black Africans.17 In a study looking at the causes of heart failure in 9 African 
countries, hypertension was identified as the leading risk factor for the 
condition.18 Hypertension is also associated with the increasing burden of 
renal disease in sub-Saharan Africa.5,19 
B. Defining hypertension: use of cut-offs and examining BP as a 
continuous variable 
The aim of this section is to define the cut-offs used in defining hypertension 
in the studies in this thesis, as well as briefly discuss the pros and cons of 
using cut-offs versus examining blood pressure as a continuous variable.  
Among adult (age >16 years) participants in the studies in this thesis I have 
used clinic and ambulatory blood pressure thresholds that have been defined 
by the European Society of Hypertension.20 These are as follows: 
- Clinic systolic BP of 140 mm Hg or above and/or diastolic BP of 90 mm 
Hg or above. The technique used in clinic BP measurement is a casual 
one (as opposed to ambulatory blood pressure monitoring) and 
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therefore the term clinic BP is sometimes referred to as casual BP or 
screening BP. 
- When using ambulatory blood pressure monitoring, a participant 
meeting any one of the following thresholds is defined as having 
hypertension: 
i. 24-hours systolic BP ≥130 mm Hg and/or 24-hour diastolic BP ≥90 
mm Hg 
ii. Daytime systolic BP ≥135 mm Hg and/or daytime diastolic BP ≥85 
mm Hg 
iii. Nighttime systolic BP ≥ 120 mm Hg and/or nighttime diastolic BP ≥ 
70 mm Hg 
Among adolescents (age 11-16 years), the international consensus is to use 
percentile distributions to define hypertension as no outcome studies have 
been conducted to determine thresholds above which cardiovascular risk in 
increased. Using guidelines from the Paediatric working group of the 
European Society of Hypertension21, an adolescent with a clinic or ambulatory 
blood pressure value above the 95th percentile for their age and sex is 
considered to be hypertensive. 
The advantage of using thresholds for defining hypertension is that it makes it 
possible to easily compare prevalences of hypertension in different study 
settings and also enables the application of simple treatment protocols based 
on a simple dichotomization of individuals into those with and without 
hypertension. This simplification however comes with several disadvantages: 
i) The thresholds used were defined using populations that are different from 
those used in this thesis. The implications of this are discussed in Chapter 7. 
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ii) It is now recognized that the risk of cardiovascular events increases linearly 
with blood pressure elevation even at levels below current cut-offs22, therefore 
the use of thresholds carries the risk of failing to identify and advise 
individuals with BP below current cut-offs that they need to put in place 
strategies to reduce their blood pressure.23 
C. Aetiology of Hypertension in Africa  
Few studies have examined risk factors that are unique to sub Saharan Africa 
in the aetiology of hypertension. Risk factors identified to date are mostly 
similar to those implicated in other parts of the world. Dietary factors (excess 
salt and energy intake, insufficient potassium intake) and adiposity have been 
shown in numerous studies to contribute to the development of essential 
hypertension and likely account for most of the increase in the burden of 
hypertension that has been observed with increasing urbanization in 
Africa.24,25 Other factors that may be of particular relevance among African 
populations include: 
iv. Low plasma renin: This is thought to be due to abnormalities in 
sodium handling such as excessive renal reabsorption of sodium 
(see below), and may explain the poor response to angiotensin 
converting enzyme inhibitor therapy that has been observed in 
African populations.5,26 
v.  Sodium sensitivity: This refers to an abnormal blood pressure 
response to increased sodium intake that may be due to hereditary 
and/or environmental factors, and appears to be more common in 
African populations.5,24,27 
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vi. Abnormalities in the renin angiotensin-aldosterone system: 
Polymorphisms of the promoter region of the angiotensinogen and 
the aldosterone synthase gene have been identified in previously 
untreated black South Africans and may play a role in blood 
pressure elevation.28 In addition a polymorphism in the ACE gene 
has been associated with protection against cerebral malaria while 
increasing the risk of hypertension29,30 (see section on the High 
blood pressure-malaria protection hypothesis below). 
vii. HIV infection: Africa has the highest incidence and prevalence of 
HIV worldwide and a number of studies demonstrate that HIV 
infection as well as drugs used in its treatment may result in 
elevation of blood pressure.31-34 
viii. The prevalence of diabetes mellitus (DM) is on an upward trend in 
Africa.35 DM is an established risk factor for the development of 
hypertension.36,37 
The emerging consensus is that the development of hypertension is multi-
factorial featuring interplay between environmental and genetic factors, 
although the individual contributions of each are not well ascertained.5,24 
Figure 1-1 below is a schematic diagram that summarizes current opinion.  
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Figure 1-1: Aetiology of hypertension and its consequences 
 
 
CVD: Cardiovascular disease 
DM: Diabetes Mellitus 
LBW: Low birth weight 
RAAS: Renin-angiotensin-aldosterone system  
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The studies in this thesis tested a unique risk factor, malaria whose potential 
contribution to the development of hypertension has not previously been 
considered. In the next sections I describe how I came up with the hypothesis 
and considerations I made in deciding how to go about testing it. The final 
chapter of this thesis (Chapter 7) contains a discussion of the apparent 
contradiction between this hypothesis and previous studies.  
D. Observations Suggesting the Role of Malaria in the Aetiology of 
Raised Blood Pressure 
The idea that malaria could be linked to hypertension may appear speculative 
at first, but it was informed by a series of observations, which were however 
not conclusive, therefore necessitating a formal study of the subject. I 
highlight these observations here. The hypothesis is discussed in more detail 
in Chapter 3. 
 Sub-Saharan African Populations have higher Age-Standardized Blood Pressures 
 than other Populations  
Systematic reviews of blood pressure levels across the world have revealed 
that age-standardized blood pressures are higher in sub-Saharan Africa 
compared to that in high-income countries where the incidence of malaria is 
much lower.38,39 There is a lot of heterogeneity in malaria transmission across 
Africa and if malaria raises blood pressure, it would be expected that blood 
pressure levels would be higher in parts of Africa that experience more 
malaria than others. Few studies have examined geographical variation in 
blood pressure in Africa apart from those looking at the urban-rural 
differences, which are subject to multiple confounders. Van der Sande et al in 
 
20 
the Gambia between 1996-1998 performed a study40 where they found that 
even within rural communities where there is minimal effect of urbanization, 
there were significant differences in the prevalence of hypertension. These 
variations were not explained by differences in age or the prevalence of 
obesity. Apart from the limited number of such studies (of geographical 
variation in blood pressure), ecological analyses to prove the malaria-high 
blood pressure link are also limited by the coarse nature of blood pressure 
measurements. The majority of studies on hypertension in Africa have used 
the casual method of blood pressure measurement6,11, which as discussed at 
several points in this thesis has limitations. 
 Obesity and excessive salt intake are not as common in Kilifi despite high levels of  
cardiovascular disease 
In an analysis of admissions at Kilifi District Hospital for the period from 2007-
2012, I found that although infectious diseases dominated by HIV related 
illnesses were the leading cause of admissions, there was a large burden of 
cardiovascular disease which ranked second in burden.41 I had also 
anecdotally noted that most of the patients I was seeing with hypertension 
appeared to lack the classical lifestyle related risk factors for the condition 
such as obesity. This was confirmed in a sub-component of the hypertension 
prevalence study that I conducted in Kilifi (reported in Chapter 2) where I 
found that despite having blood pressure levels similar to that found in urban 
areas of Kenya, the Kilifi population had generally low body mass index and 
urinary sodium levels.42 
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Malaria is common in Kilifi and is associated with factors known to cause 
hypertension 
Kilifi has low to moderate malaria transmission.43 Malaria is known to cause 
low-birth weight, childhood malnutrition and inflammation.44-46 All of these 
factors have been shown in developed world settings to be associated with 
the development of non-communicable diseases including hypertension. 
David .J Barker, whose hypothesis I outline in more detail below47, first 
proposed the link between low-birth weight (LBW) and high blood pressure 
and cardiovascular disease in adult life. The respective roles of childhood 
malnutrition and inflammation are discussed in detail in Chapter 3. 
The Barker Hypothesis 
In a landmark study, Barker et al described an inverse relationship between 
birth weight and incidence of adult cardiovascular disease.47 He and others 
subsequently demonstrated similarly consistent relationships between low 
birth weight and the prevalence of hypertension and other traditional 
cardiovascular risk factors during adulthood.48 The explanation for these 
findings appears to be that of the thrifty phenotype that develops as a result of 
fetal-maternal conflict as elegantly described by Robert Trivers in 1974.49 It is 
theorized that in an in-utero environment of scarcity as would happen to LBW 
babies, fetal programming allows the fetus to anticipate the environment that 
it will encounter at birth. However if this fetus that is programmed for scarcity 
is born into an environment of excess, the programming is inappropriate and 
leads to the development of the metabolic syndrome. The effect of intra-
uterine programming that is most closely associated with a predisposition to 
hypertension is the effect of fetal growth retardation on glomerular number 
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and filtration surface50, both of which are reduced, requiring the pressure-
natriuresis mechanism to operate in a higher blood pressure range.51 
The  High Blood Pressure-Malaria Protection Hypothesis 
One potential explanation for the geographical association between malaria 
and high blood pressure is based on the idea of genetic selection; for 
example, if genes that led to abnormalities in the RAAS were simultaneously 
protective against severe forms of malaria disease, the gene frequency would 
increase in settings with high malaria mortality.  This idea was first proposed 
by Gallego-Delgado et al30 on the basis of a study of 426 adults in India.29 
Unfortunately, the malariagen consortium study52, which is the largest (n 
>29,000) study conducted to date examining which genetic variants are 
protective against malaria did not reveal any polymorphisms involving the 
renin-angiotensin system suggesting that the result of Dhangadamajhi et al29 
in India may have been a false positive. 
Despite the malaria-high blood pressure hypothesis being well grounded, 2 
major issues on how to test it arose. Both had to do with measurement, which 
is a critical issue in epidemiology. These issues were how to determine 
exposure to malaria and how to measure blood pressure (the outcome). I will 
in the next section discuss the issue of blood pressure measurement followed 
by a discussion on determining past malaria exposure and how the principle 
of Mendelian randomization that I used in the study works. 
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E. Blood pressure measurement 
Several authors53-57 have described the rich history of the evolution of blood 
pressure measurement, that I paraphrase here as a background to 
ambulatory blood pressure measurement. 
The first recorded instance of the measurement of blood pressure (BP) was in 
a horse in 1733, performed by the Reverend Stephen Hales in Kent, 
England.54,56 He had entered St Benedicts’ College in Cambridge, UK in order 
to study religion and natural philosophy. After graduating in 1703, he became 
fascinated by the doctrines of the iatrophysicists, Giovanni-Alfonso Borelli, 
Robert Boyle and Giorgio Baglivi. The Reverend Hales, together with his 
friend William Stukeley, a pre-medical student, studied anatomy and repeated 
some of the experiments that had been conducted by Boyle. In 1733, his 
manuscript, Haemastatics, appeared describing the classical experiments by 
which blood pressure was first measured: 
“ In December, I caused a mare to be tied down alive on her back. A fistula 
was placed on her withers…having laid open the left crural (femoral) artery 
about three inches from her belly, I inserted into it a brass pipe whose bore 
was one sixth of an inch in diameter, and to that, by means of another brass 
pipe which was fitly adapted to it, I fixed a glass tube, of nearly the same 
diameter, which was nine feet in length: then untying the ligature of the artery, 
the blood rose in the tube 8 feet 3 inches perpendicular above the level of the 
left ventricle of the heart...when it was at its full height, it would rise and fall at 
and after each pulse 2,3 or 4 inches; … then I took away the glass tube, and 
let the blood from the artery mount up in open air, when the greatest height of 
its jet was not above 2 feet. I measured the blood as it ran out of the artery, 
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and after each quart was run out, I refixed the glass tube to the artery to see 
how much force the blood was abated; this I repeated to the 8th quart, and 
then its force being much abated, I applied the glass tube after each pint had 
flowed out”. 54,56 
For the next 150 years, BP measurement technology continued to improve 
through the efforts of many great physicians such as Poisseuille (1799-1869), 
Carl Ludwig (1816-1895), Karl von Vierordt (1818-1884) Robert Ellis Dudgeon 
(1820-1904) and Samuel Siegfried Karl Ritter von Basch (1837-1905). 
However, for all their work, all the devices invented were invasive and difficult 
to use. It is perhaps because of this difficulty in using them that blood 
pressure measurement was not accepted as a valuable diagnostic tool. The 
British Medical Journal went as far as mentioning that by using the 
sphygmomanometer “we pauperize our senses and weaken clinical acuity”.53 
Scipione Riva-Rocci (1863-1937) was an Italian internist, pathologist and 
paediatrician , who in 1896 published four articles in the Gazetta Medica di 
Torino describing a new sphygmomanometer and the technique of non-
invasive BP measurement.55 Although his was not the first 
sphygmomanometer, his ingeniously simple idea of constricting the brachial 
artery and registering the cuff pressure at which the radial pulse was 
obliterated as determined by palpation offered medical practitioners an 
efficient method for obtaining relatively accurate readings.  
Harvey Cushing, an American neurosurgeon who visited Riva-Rocci in Pavia 
in 1901, found Riva-Rocci’s sphygmomanometer a valuable means of 
reducing mortality from anesthesia. Cushing sketched the mercury 
sphygmomanometer, and on returning to Baltimore, USA, he introduced blood 
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pressure measurement of anesthetized patients especially during intra-cranial 
surgery, thus playing a major role in spreading the use of the instrument.58 
The palpation technique however did not allow the measurement of diastolic 
BP. One year after Riva-Rocci described his technique, Hill and Barnard in 
England reported an apparatus with an arm-encircling inflatable cuff and 
needle pressure gauge that allowed measurement of diastolic pressure by the 
oscillatory method.58 In 1900, von Recklinghausen, recognizing that Riva-
Rocci’s device had a significant flaw in accuracy increased the width of the 
cuff from 5 cm to 13 cm.59  
Nikolai Sergeyevich Korotkoff, a Russian army physician based at the military 
hospital in the town of Tsarskoye-Selo, was the first to observe the sounds 
made by the constriction of an artery in 1905, a discovery that enabled the 
estimation of diastolic blood pressure.57 Korotkoff was working to find 
indications that would allow a surgeon to predict an outcome of ligation of 
arteries of traumatised limbs, i.e to predict whether the limb would recover or 
die after surgery. Korotkoff used a stethoscope and the apparatus proposed 
by Riva-Rocci in 1896 and established that specific sounds could be heard 
during the decompression of the arteries. This auscultatory method proved to 
be more reliable than previous palpation techniques and became the standard 
practice for over 100 years.56,57 
Despite the technology of BP measurement being available, it took several 
decades for the scientific community to discover and accept that elevated BP 
was a major risk factor for cardiovascular disease.60 The medical care 
provided to President Franklin D. Roosevelt of the USA (as reviewed by 
Mahmood et al) 60 who died of heart failure in 1945 serves as a good, if not 
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painful illustration of the poor understanding of hypertension as a risk factor 
for cardiovascular disease at that time. In 1932, Roosevelt’s campaign office 
released medical records showing his blood pressure to be 140/100 mm Hg, 
which did not prompt any medical intervention. The following year the 
President-elect chose an ear, nose, and throat specialist, Admiral Ross 
McIntyre, as his personal physician because headaches and sinus problems 
were predicted to be his main health concern.61 Between 1935 and 1941, 
Roosevelt’s blood pressure gradually rose from 136/78 mm Hg to 188/105 
mm Hg. Despite his rising blood pressure, his personal physician insisted that 
the President was healthy, and that his blood pressure was “no more than 
normal for a man of his age”. On March 27, 1944, as planning of the Allied 
landings at Normandy, France, was underway, the President’s daughter Anna 
Roosevelt insisted on a second opinion, and he was admitted to Bethesda 
Naval Hospital for dyspnoea on exertion, diaphoresis, and abdominal 
distension. Cardiologist Howard G Bruenn, one of only a few hundred such 
specialists in the entire country, attended to the President. Bruenn noted that 
the patient appeared “slightly cyanotic”, with “blood pressure 186/108” mm Hg 
and a chest radiograph showing an “increase in size of the cardiac shadow”. 
Bruenn gave Roosevelt his first diagnosis of “hypertension, hypertensive 
heart disease, and cardiac failure”.60,62 Roosevelt died on April 12, 1945, at 
the age of 63, from cerebral haemorrhage, with a blood pressure of 300/190 
mm Hg.62  
Epidemiological data obtained from the Framingham Heart Study, established 
by President Harry Truman who had been President Roosevelt’s Vice 
President eventually led to the medical community accepting that 
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hypertension was a major cardiovascular risk factor.63 In one of the first iof 
many seminal papers to come from the Framingham Heart Study, Dawber et 
al in 1957 reported that hypertension defined as BP ≥160/95 mmHg was 
associated with a nearly four-fold increase in incidence of coronary heart 
disease.63 In 1965, Kannel et al reported results of 12 years of observation of 
5,106 Framingham participants, finding that high blood pressure was 
associated with a five-fold increase in the risk of stroke.64 These findings have 
been replicated in many parts of the world including Africa. In the InterStroke 
study, 3,000 cases (patients with first time stroke) and an equal number of 
controls were studied in 22 low and middle-income countries. Hypertension 
(self reported or blood pressure >160/90 mm Hg) was associated with a 
Population Attributable Risk for stroke of 51.8%.15 In the African InterHeart 
study, self reported hypertension was associated with a Population 
Attributable Risk for myocardial infarction of 30%.17 
Accuracy of blood pressure measurement   
In Riva-Rocci’s seminal paper of 1896 he went to great length to discuss 
possible sources of error in BP measurement and how to minimize them. He 
noted that BP variability due to the mental state of the patient could affect BP 
readings and recommended that one could take 3 measurements in 3 
minutes or 5 measurements over a period of 5 minutes to get a more accurate 
measure. He emphasized the need to have standardized conditions under 
which the measurements were taken for the procedure to be genuinely useful 
in clinical practice adding that, “if the procedures are neglected, and the 
doctor is satisfied with a crude reading, the method will become useless and 
will be quickly abandoned as a scientists’ indulgence.” C.P. Donnison whose 
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paper in the Lancet in 1929 I have referred to earlier1, described the BP 
measurement technique in his study as follows:  
“The instrument used was an aneroid sphygmomanometer made by 
Messrs. Down Bros. The rules for taking the readings, described by 
Halls Daly were followed closely. The first reading was always 
disregarded, as it was found that the African native, like his white 
brethren, suffers from apprehension and nervousness which frequently 
affect his blood pressure; in fact, in a few cases no constant reading 
could be obtained and no record could be made. After a few minutes a 
second reading was taken. The pulse rate was then noted, and a third 
reading taken, and if a constant figure was obtained in the last two 
readings a record was made.”  
It is readily apparent from the above that accuracy of blood pressure 
measurement had been recognized as a problem from very early on. 
Ambulatory Blood Pressure Monitoring 
Kain et al65 in 1964 were among the first to report on the use of ambulatory 
blood pressure monitors. In the introduction to their paper published in 
Circulation they noted that ‘casual readings of blood pressure recorded in a 
physician’s office or in an outpatient clinic may not be representative of the 
patient’s usual blood pressure”, a fact has been confirmed in many other 
studies.20 Using a semi automatic portable blood pressure recorder that 
patients wore “with little inconvenience while going about their usual routine” 
Kain et al found significant differences between BP measurements taken in 
the clinic and those taken over a longer period while subjects underwent their 
 
29 
normal daily activities.65 Over the course of the last 50 years numerous 
technological advances have been made that have resulted in smaller and 
more convenient ABPM devices, driving their use in more subjects.66  
Numerous studies have shown that the more precise measurements resulting 
from repeated inflations and more standardized procedures in ABPM make it 
a much better predictor of cardiovascular events than other BP measurement 
methods.20 In the Ohasama study conducted in Japan, 1,332 subjects were 
followed up for 10.8 years. Ambulatory systolic blood pressure values 
consistently showed stronger predictive power for cardiovascular mortality risk 
than did casual blood pressure.67 Similar conclusions were drawn from the 
PAMELA study conducted in Monza, Italy.68 Recent studies have, in addition, 
shown that nighttime BP measurements are more predictive of cardiovascular 
outcomes than daytime or 24-hour measures.20 Two sets of reasons for this 
have been postulated: 
 a) Those related to improved measurement; better standardization at night of 
the measurements in terms of physical and mental activity as well as body 
position, and;  
b) Physiologic reasons, namely alterations in the sympathetic modulation of 
nighttime blood pressure69, disturbed baroreflex sensitivity70, sleep apnea71, 
or an increased salt sensitivity necessitating a higher blood pressure at night 
to drive pressure natriuresis72,73. 
Apart from obtaining a more accurate measure of a person’s usual BP, ABPM 
use (as well as home BP monitoring) has led to the discovery of 2 previously 
undescribed BP phenotypes: white coat hypertension, in which office BP is 
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elevated but out of office BPs are normal; and masked hypertension, in which 
office BPs are normal but out of office BPs are elevated. 
Although numerous studies have demonstrated the advantages of 
ABPM20,66,67,74-79, the great majority of these have been conducted in 
developed countries. In addition, apart from the Jackson Heart Study that 
conducted ABPM on 1,015 African Americans80, no large ABPM studies have 
been done among individuals of African descent. A number of studies utilizing 
ABPM have been conducted in Africa (Summarized in the Table below), but 
these have been small and have not been conducted in population-based 
samples.32,81-93 To my knowledge, the studies outlined in this thesis are the 
first large population-based studies conducted in sub Saharan Africa where 
ABPM has been used.  
Table 1-1: Published studies of ABPM in Africa 
First Author 
 
Country 
 Population studied/Sampling 
scheme 
 Sample 
size 
Bhagat92  Zimbabwe  Hypertensive women  25 
Bochud81  Seychelles  76 families  314 
Borkum32  South Africa  HIV positive clinic patients  30 
Ikama86  R. Congo   Hypertensive patients  620 
Ivy87  Tanzania  ≥ 70 year olds   79 
Kengne94  Cameroon  Diabetic patients  71 
Malan90   South Africa  Male teachers  94 
Morar95  South Africa  Medical students (83 were Indian)  154 
Nong-
Libend96  Cameroon  Diabetic patients  51 
Nwafor88  Nigeria  Hypertensive patients  412 
Polonia 82  Mozambique  Hypertensive patients  548 
Radevski93  South Africa  Clinical trial in hypertensive patients  42 
Schutte85  South Africa  Teachers  409 
Skoularigis91  South Africa  Clinical trial in hypertensive patients  50 
Takah83  Cameroon  Patients referred to cardiology clinic  500 
Thompson84  South Africa  
20-30 year olds with normal clinic 
BP  352 
Data obtained from a search of Pubmed.gov using the terms ABPM AND Africa   
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F. Determining past exposure to malaria 
In order to determine whether malaria results in elevated blood pressure, we 
first need to find a reliable indicator of previous exposure to malaria.  
Unfortunately as is the case in many acute infectious diseases, immunological 
markers indicating past exposure to malaria suffer from several short-comings 
97,98 that limit their use in determining long-term effects of the exposure: 
(i) Both humoral and cellular responses to malaria are poorly understood-they 
do not develop in everyone exposed to malaria; 
(ii) The duration of humoral and possibly cellular responses may vary 
according to host factors as well as repeat exposure patterns 
(ii) Responses differ depending on age at exposure and transmission 
intensity. 
An alternative to using immunological markers for determining past malaria 
exposure would be to recruit participants who had been part of malaria cohort 
studies and were known to have experienced malaria during the time that 
they were being followed up. Such a cohort exists in Kilifi, where children are 
followed from infancy to about 10 years of age.99 However this and other 
similar cohorts in Africa have been present for not more than 25 years which 
is below the age at which the incidence of hypertension starts to rise.100  
Several randomized controlled trials of malaria interventions have been 
conducted in Kilifi e.g. testing the effect of bednets.101 These would provide 
two groups of individuals that would only differ by malaria exposure and thus I 
could have tested the hypothesis by comparing blood pressure in these 
groups. The challenge in using these individuals for the studies again was 
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that the interventions had only been used for a short period and although they 
had worked it was likely that the randomized groups had had similar levels of 
exposure to malaria prior to the trial and after the trials resulting in 
contamination. 
Mendelian Randomization (MR) is a relatively new study design in 
epidemiology that overcomes the weaknesses of traditional observational 
studies and also enables inferences to be made in situations where 
randomized trials are not feasible or are unethical.102 MR uses genetic 
variations with known biological effects as instrumental variables to represent 
an environmental exposure. MR exploits the principle that genotypes are not 
generally associated with confounders in the population and should be 
immune to reverse causation bias.103 These properties reflect both the fixed 
nature of genetic variants as well as Mendel’s first (segregation of genes) and 
second (independent assortment) laws of inheritance. After finding genetic 
polymorphisms to use as proxies, or “instruments,” for a target exposure the 
association of the genetic instrument with the outcome of interest is then 
tested.102 An important advantage of MR is that genotypes can be measured 
with very high accuracy and reflect long-term patterns of exposure. Thus, MR 
approaches are less susceptible to biases arising from measurement error.103  
There are three main requirements when conducting MR studies as explained 
below and in Figure 1-2.103 This is followed by a discussion of the 
considerations that led to the choice of the genetic variants that I used in my 
studies. 
Figure 1-2: Causal diagram showing requirements of MR studies 
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Absence of arrows between two variables indicates no relationship between them. Numbers 
(1, 2, 3) represent MR assumptions (explained in the text) and dashed arrows indicate 
possible violations of these assumptions.  
 
(1) The genetic variant should have a true association with the exposure of 
interest:  
Malaria has exerted the strongest known selective pressure on the human 
genome.104 Of all the known malaria associated polymorphisms, sickle cell 
trait (SCT) provides the highest level of protection and also has the advantage 
of being relatively common.52 SCT has been used in two MR studies in Africa, 
one by Professor Anthony Scott et al showing that malaria is associated with 
bacteremia105 and another by Kang et al demonstrating increased risk of 
malnutrition in children who suffered from malaria.45 Alpha thalassemia, which 
is even more common than SCT106 provides comparatively less protection 
against malaria episodes107 and could be used to check for a dose response 
effect if the malaria-high blood pressure hypothesis is true (provided that 
neither SCT nor alpha thalassemia violate the other assumptions). 
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(2) The genetic instrument should not be associated with any confounders of 
the exposure-outcome relationship 
This can be examined by comparing different characteristics in the two 
genetic groups. It should be noted however that despite the supposedly 
random distribution of possible confounders between genetic groups, many 
MR studies (e.g. in Palmer et al108, Ehret et al109 and Ferrence et al110) usually 
adjust for age and sex, which usually have very strong influences on most 
outcomes. The analysis plan for the MR study (contained in the Appendix) 
delves further into the issue of adjusting for confounders. 
(3) The genetic instrument should not influence the outcome in the absence of 
the exposure. 
This is a special form of confounding, also known as pleiotropy.102 This meant 
that in order to use SCT and alpha thalassemia to examine whether malaria 
influences blood pressure, I would first need to confirm that these genetic 
variants do not influence blood pressure in the absence of malaria. I checked 
whether this was the case using the same cohort for alpha thalassemia and 
sickle cell trait in Nairobi and the results of this investigation are as outlined in 
Chapters 4-6. 
A potential disadvantage of using SCT as a marker for exposure to malaria is 
that it is a non-specific marker in that it protects against both severe and non-
severe malaria. In addition, it’s possible effect on maternal malaria is not 
backed by many studies111 and it also does not protect against asymptomatic 
malaria parasitaemia.112 The implications of this are discussed further in 
Chapter 7.  
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G. Background Information on the Study Populations used in this 
Thesis 
The studies in this thesis were conducted among participants derived from the 
Nairobi Urban Health and Demographic Surveillance System (NUHDSS) and 
the Kilifi Health and Demographic Surveillance System (KHDSS). Here I 
briefly describe important characteristics of the populations at these two sites. 
The NUHDSS (Figure 1-3) is located in Viwandani and Korogocho, two slums 
in Nairobi and has a total population of ~70,000.113 The prevalence of 
hypertension (using clinic BP measurements) in the area is 18% while 
diabetes is present in 6% of the population.25 Obesity (BMI >25 kg/m2) is 
present in 42% of women in the area and 16% of men.25 The major causes of 
death (using verbal autopsy records) are HIV (17%), injuries (21%) and 
cardiovascular disease (8%).114  
Figure 1-3: Location of NUHDSS and Population Structure 
 (adapted from Beguy et al113) 
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The KHDSS is located within Kilifi County (Figure 1-4) along the Indian Ocean 
coast and has a total population of ~300,000.115 The prevalence of 
hypertension (using clinic BP measurements) in the area is 26% and 17% 
when using ambulatory blood pressure monitoring.42 Body mass index and 
salt consumption appear to be low in this population.42 Diabetes is the third 
leading cause of Disability Adjusted Life Years lost in the area.41 The major 
causes of death in adults (as assessed using verbal autopsy) are HIV, stroke 
and neoplasms.116 
Figure 1-4: Location of KHDSS and Population Structure 
(adapted from Scott et al115) 
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Summary 
In this chapter I have reviewed the literature of the epidemiology of high blood 
pressure in Africa, described the antecedents of the malaria-high blood 
pressure hypothesis and justified the use of Mendelian Randomization to test 
the hypothesis using ambulatory blood pressure monitoring. The remainder of 
the thesis is structured as follows: 
(1) A descriptive population-based study in Kilifi to examine the effect of using 
ambulatory blood pressure monitoring on population estimates of 
hypertension (Chapter 2) 
(2) An outline of the epidemiological and pathophysiologic basis for the 
malaria-high blood pressure hypothesis (Chapter 3) 
(3) Results of the Mendelian Randomization studies testing the hypothesis 
(Chapters 4-6). 
(4) Discussion of the results of the studies and their implications (Chapter 7). 
 
It is hoped that by providing a better description of the problem of blood 
pressure elevation and malaria as a possible underlying cause, the studies in 
this thesis will catalyze an improvement in public health measures to mitigate 
its consequences. 
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ABSTRACT 
Background 
The clinical and epidemiological implications of using ambulatory blood 
pressure monitoring (ABPM) for the diagnosis of hypertension have not been 
studied at population level in sub-Saharan Africa. We examined the impact of 
ABPM use among Kenyan adults. 
Methods & Results 
We performed a nested case-control study of diagnostic accuracy. We 
selected an age-stratified random sample of 1,248 adults from the list of 
residents of the Kilifi Health and Demographic Surveillance System in Kenya. 
All participants underwent screening blood pressure measurement. All with 
screening BP ≥ 140/90mmHg and a random subset of those with screening 
BP <140/90mmHg were invited to undergo ABPM. Based on the two tests, 
participants were categorized as: sustained hypertensive, masked 
hypertensive, white-coat hypertensive or normotensive. 
Analyses were weighted by probability of undergoing ABPM. Screening BP 
≥140/90mmHg was present in 359/986 individuals, translating to a crude 
population prevalence of 23.1% (95%CI 16.5-31.5). Age standardized 
prevalence of screening BP ≥140/90 mmHg was 26.5 (19.3-35.6) %. On 
ABPM, 186/415 individuals were confirmed hypertensives, crude prevalence 
15.6(9.4-23.1)%, age-standardized prevalence 17.1(11.0-24.4) %. Age 
standardized prevalence of masked and white-coat hypertension were 
7.6(2.8-13.7) % and 3.8(1.7-6.1) % respectively. The sensitivity and specificity 
of screening BP measurements were 80 (73-86) % and 84(79-88) % 
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respectively. BP indices and validity measures showed strong age related 
trends.  
Conclusions  
Screening BP measurement significantly overestimated hypertension 
prevalence while failing to identify ~50% of true hypertensives diagnosed by 
ABPM. Our findings suggest significant clinical and epidemiological benefits 
of ABPM use for diagnosing hypertension in Kenyan adults. 
Key words 
Ambulatory blood pressure monitoring; Sub-saharan Africa; Hypertension; 
Diagnostic accuracy; Masked hypertension; White coat hypertension 
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INTRODUCTION 
Across sub Saharan Africa (sSA), numerous studies have been conducted to 
estimate the prevalence of hypertension in various settings.1,2 These data are 
necessary for planning public health activities, especially given the projected 
increase in the burden of non-communicable disease in the region.3 There 
however remains a substantial contribution of communicable diseases, 
increasing the need for accurate data to guide resource allocation between 
competing health priorities.4  
The measurement of blood pressure (BP) is subject to multiple sources of 
variation5 that will have an impact on both the epidemiology and clinical 
management of hypertension. Measurement error arising from technical 
problems has been minimized by using validated criteria for BP monitors.6 It is 
possible to minimize observer error in reading BP values by using automated 
devices and following a defined measurement procedure. Despite such 
improvements, these protocols only provide a momentary assessment of BP, 
which can be influenced by a range of environmental and psychological 
factors.7 Ambulatory blood pressure monitoring (ABPM) reduces this limitation 
and is increasingly used for both clinical and epidemiological purposes.7,8 In 
high-income settings ABPM is a significantly better predictor of future 
cardiovascular risk than office or home measurement.7 It is also the only way 
to detect abnormal nocturnal dipping patterns that are an independent risk 
factor for future cardiovascular events9 and appear to be more common in 
populations of African descent.10 11 In addition ABPM enables the 
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measurement of the ambulatory arterial stiffness index (AASI), an 
independent predictor of cardiovascular outcomes, especially stroke. 12  
The use of ABPM facilitates better prescription patterns among established 
hypertensive individuals and helps identify masked hypertensives and 
individuals with abnormal dipping patterns who would otherwise be missed 
when using casual (standard) BP measurement methods. The increased 
diagnostic performance of ABPM makes it cost effective in both primary and 
specialist care in developed world settings.13,14 The high initial cost of ABPM 
devices has, however, precluded their widespread use in low- income settings 
in sSA and there is little information to assess the potential clinical and public 
health benefits of ABPM in such settings. 
We conducted Shinikizo la Damu (ShinDa), a population-based study in rural 
coastal Kenya to determine 24-hour BP profiles in adults and compare these 
with parameters derived from screening BP measurements. 
METHODS 
This study was conducted from April 2013 to May 2014 in the Kilifi Health and 
Demographic Surveillance System (KHDSS) located along the coast of 
Kenya. The 900km2 covered by the KHDSS and a population of 300,000 
people makes it one of the largest demographic surveillance areas in Africa 
both in terms of area and population.15 Within the KHDSS the total fertility rate 
(4.73), crude birth rate (34.7/1000/year), population growth rate (2.79%/year) 
and proportion of the population aged <15 years (49%) are similar to those 
across Kenya. However, the under 5-mortality ratio (41 per 1,000 births) and 
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HIV prevalence (4.9% among antenatal clinic attendees) are lower than the 
national averages (74 per 1,000 births and 8.0%, respectively).16 We have 
previously documented a double burden of infectious and non-communicable 
disease in the area, similar to other parts of the developing world.17  
We selected an age-stratified random sample of 1248 adults from the list of 
KHDSS residents. The sample size was designed to generate a population 
level estimate of the true prevalence of hypertension with confidence intervals 
of approximately ± 5%. We have previously documented a significant distance 
related bias in presentation to hospital in the study area.17 In order to 
minimize this bias, study procedures were carried out at the participants’ 
homesteads. Trained staff visited all subjects who had been selected to 
participate in the study at their homes. A total of three attempts were made at 
finding a selected subject before concluding that they could not be found. No 
replacement was done for participants who could not be found. Women who 
reported that they were pregnant were excluded from the study. 
We used a nested case-control diagnostic accuracy study design in which all 
subjects with elevated screening BP and a random subset of those with 
normal screening BP were invited to undergo ABPM.18 We weighted analyses 
to account for differential probability of undergoing ABPM based on the result 
of screening BP measurement 18. We aimed to have 24-hour ABPM 
performed on equal numbers of subjects with and without elevated screening 
measurements (≥140/90mmHg), assuming that the prevalence of elevated 
screening BP would be ~30%.  
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All subjects were first asked whether they had had a previous diagnosis of 
hypertension and whether they were on anti-hypertensive medication. We 
then took a screening BP measurement using a validated Omron™ M10-IT 
blood pressure machine. An appropriately sized cuff was placed on the non-
dominant arm after the subject had been seated for at least 5 minutes. Three 
BP measurements were taken over a 5-minute period and the mean of the 
last 2 measurements was recorded as the screening BP value. All participants 
whose screening BP was ≥140 and/or 90mmHg were invited to undergo 24- 
hour ABPM. A random sample of 292 (~30%) of individuals with screening BP 
<140/90mmHg were invited for ABPM, and analyses were weighted (see 
statistical analyses section below) to account for this. We used validated 
Omron™ M24/7 ambulatory blood pressure machines for the 24hr ABPM 
measurements.19 The machines were programmed to take BP measurements 
every 20-30 minutes from 0600-2200 hrs and every 40 minutes from 2200-
0600 hrs. Ambulatory blood pressure monitoring was performed within one 
week of the screening BP measurements in all cases. The same field staff 
conducted the screening and ABPM measurements and were not blinded to 
any of the results.  
A subset of 200 individuals was selected at random from the original sample 
of 1248 individuals and requested to participate in additional investigations. 
We first measured their weight and height using a validated SECA 874™ 
weighing machine and a portable stadiometer (Seca 213™), respectively. We 
then requested them to provide a spot urine sample as well as a 24-hour 
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urine sample for determination of sodium, potassium, albumin and creatinine 
levels. 
Statistical methods 
ABPM data were excluded from the analyses if they failed the following 
criteria, as specified by the European Society of Hypertension: minimum 20 
daytime and minimum 7 nighttime readings, where day was defined as 0900-
2100 hrs and night as 0100-0600 hrs.7 The same time periods were used to 
determine average daytime and nighttime blood pressures and to evaluate 
dipping status. Time weighting was applied in calculating average BP values 
for all time periods.20  
We defined screen positives as subjects whose last 2 screening BP 
measurements had a mean ≥140/90 mmHg and confirmed hypertensives 
were defined as those who met any of the following three criteria: 24-hr BP 
average ≥130/80mmHg; isolated daytime hypertension (daytime BP average 
≥135/85mmHg and nighttime BP average <120/70mmHg); isolated nocturnal 
hypertension (nighttime BP average ≥120/70 mmHg and daytime BP average 
< 135/85 mmHg).7  
Validity measures were computed using data from participants who were not 
taking anti-hypertensive medications. We categorized these subjects using 
the combination of screening BP measurements and ABPM into four groups: 
sustained hypertensives (screen positive and confirmed hypertensive on 
ABPM); white coat hypertensives (screen positive, not confirmed hypertensive 
on ABPM); masked hypertensives (screen negative, confirmed hypertensive 
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on ABPM) or normotensives (screen negative, not confirmed hypertensive on 
ABPM).21 The four categories were used to compute age stratified measures 
of validity of the screening BP measurements with ABPM as the reference 
standard.22,23 All summary measures were weighted according to the 
probability of investigation with ABPM in the design.24 Confidence intervals for 
these measures were obtained using the recommended bootstrap procedure 
with 1000 replications.24  
In subjects who reported that they were taking anti-hypertensive medications, 
those who met the criteria for white coat hypertension were labeled as having 
pseudo-resistant hypertension7 while those who met the criteria for masked 
hypertension were labeled as masked uncontrolled hypertensives.7  
Dipping status was defined using ABPM data only, using previously described 
methods.25  
We computed two additional indices using the ABPM data; 24-hour pulse 
pressure (the mean of the differences between systolic and diastolic BP 
values) and the ambulatory arterial stiffness index (AASI) using previously 
published methods.26  
We calculated the local prevalence of each index by weighting the age 
specific proportions by the age-structure of the Kilifi population. Age 
standardization for all summary population parameters was performed using 
weights derived from the WHO standard population.27 Summary statistics 
computed included means, medians, proportions and rates as appropriate. 
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All analyses were conducted using Stata™ Version 12 software (College 
Station, Texas). 
The Kenya Medical Research Institute’s Ethical Review Committee approved 
the study and all subjects provided written informed consent. 
RESULTS 
Of the 1248 subjects selected to participate in the study, 1150 (92%) were 
found at home and invited to participate in the study. Of these, 986 (86%) 
gave consent and underwent screening BP measurement (Figure 2-1). Of 
these, 359 (36%) subjects were screen positive for hypertension (screening 
BP ≥140/90 mmHg). All 359 screen positives and 292 screen negatives were 
invited to undergo ABPM. Of all those invited to undergo ABPM, 477 (73%) 
actually underwent it. Of the 200 individuals selected to have urine electrolyte 
and anthropometric measurements, 164 (82%) did so. 
Table 1 compares the characteristics of all 986 subjects who had screening 
BP measurements, the subset of 651 selected to undergo ABPM and the 477 
who actually underwent ABPM. The group of subjects that had ABPM 
performed had higher screening systolic BP (+5mmHg CI 4.2-5.9) and were 
older (+3.9 years 95% CI 3.4-4.3) compared to the entire group of subjects 
that was selected for the study. There were no significant differences between 
those selected to undergo ABPM (n=651) and those who actually underwent 
the procedure (n=477).  
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Of the 477 subjects undergoing ABPM 415 (87%) had acceptable readings; 
unacceptable (<20 daytime and/or <7 nighttime) readings were significantly 
more common among screen negatives than among screen positives (17% 
vs. 11%, p=0.036). Data from subjects with unacceptable ABPM readings 
were dropped from further analyses.  
Six of the 415 subjects with acceptable ABPM recordings were on anti 
hypertensive medication.  
Relationship between screening BP measurements and ABPM derived 
measures 
Among the 415 subjects who had both screening and 24-hour ABPM 
measurements, mean screening systolic and diastolic BP were 140mmHg 
(95% CI 138-143) and 84mmHg (95%CI 83-85) respectively. Corresponding 
mean 24-hour ABPM systolic and diastolic BPs were 123mmHg (95%CI 121-
125) and 72mmHg (95%CI 71-73). The average difference between mean 
systolic screening and 24 hr ABPM values was 16.8mmHg (95% CI 15-18.6). 
Mean screening diastolic BPs were 12.2 (95% CI 11.2-13.2) mmHg higher 
than corresponding 24-hour ABPM values (Figure 2-2). 
 Age-standardized mean screening systolic and diastolic blood pressures for 
the population in Kilifi were 128mmHg (95%CI 102-162) and 79mmHg 
(95%CI 62-101) respectively. 24-hour mean systolic and diastolic blood 
pressures for the population were 117mmHg (95%CI 114-120) and 70mmHg 
(95%CI 68-72), respectively.  
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ABPM-derived mean BPs were lower than those obtained using screening 
measurement methods for all age groups (Table 2-2). The relationship 
between 24-hour ABPM derived parameters (except for AASI and diastolic 
BPs) and age approximated a J-shape. Mean AASI and pulse pressure 
increased linearly with age (AASI, 0.03 [CI 0.02-0.05] and pulse pressure 3.3 
[CI 1.5-5] per 10 year increase in age. The difference between ABPM derived 
and screening BP values increased with age.  
Prevalence of hypertension using casual BP measurement and ABPM 
All reported KHDSS population parameters are age standardized unless 
otherwise specified. The crude prevalence of hypertension in the KHDSS 
using screening measurements only was 23.1%(95%CI 16.5-31.5). The crude 
prevalence of hypertension in the KHDSS using ABPM was 15.6% (95%CI 
9.4-23.1). Using only screening BP values, the reported age-standardized 
prevalence of hypertension would have been 26.5% (95%CI 19.3-35.6). The 
age-standardized prevalence of true hypertension (as determined by ABPM) 
in the KHDSS was 17.1% (95%CI 11.0-24.4) (Table 2-2). There was a 
marked increase in prevalence of screen positives and true hypertension with 
increasing age (Table 2-3). 
 The prevalence of masked hypertension overall was 7.6% (95% CI 2.8-
13.7%) and this was inversely associated with increasing age. White coat 
hypertension was present in 3.8% (95%CI 1.7-6.1%) of the population and its 
prevalence increased with age. The non-dipping blood pressure pattern was 
present in 8.5% (95%CI 3.1-15.3%) of the population, its prevalence being 
highest in the 70-79 year age band. Figure 2-3 displays the standardized 
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population prevalences of screen positives, true hypertensives, white coat 
hypertensives, masked hypertensives and non-dippers. 
Two of the six individuals on anti-hypertensive medication who underwent 
ABPM had pseudo resistant hypertension. No cases of masked uncontrolled 
hypertension were detected. 
Validity of screening BP measurements 
The overall sensitivity and specificity of screening BP measurements for 
diagnosing hypertension in the population were 80% (95% CI 73-86%) and 
84% (95%CI 79-88%), respectively. Sensitivity improved with increasing age 
while specificity decreased (Table 2-4). Overall positive and negative 
predictive values were 80% (95% CI 74-85%) and 84% (95%CI 79-89%), 
respectively. Sensitivity and PPV increased with age; specificity and NPV 
decreased with age. The likelihood ratio (LR) positive was 4.9 (95%CI 3.7-
6.8). LR positive was highest in the 30-49 year age groups although the 
confidence intervals were wide. Likelihood ratio negative overall was 0.2 
(95%CI 0.2-0.3). No significant age related trend was observed in the LR 
negative values. Interval likelihood ratios based on quintiles of the screening 
systolic and diastolic blood pressures are displayed in Table 2-5. Screening 
BP measurements performed best in predicting true diagnostic category in 
individuals with diastolic BPs of less than 80mmHg and systolic BP of 118-
129mmHg. 
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DISCUSSION 
This is, to our knowledge, the first population based study that has assessed 
the validity of screening BP measurements versus ABPM in sub-Saharan 
Africa. We found a high prevalence of hypertension and poor validity of the 
screening BP measurements. 
As well as inflating the true prevalence of hypertension in the community by 
53% (from 17% to 27%), screening BP measurements failed to identify a 
significant proportion of the population that were identified as having 
hypertension using ABPM: nearly half of the hypertensive individuals in this 
study had masked hypertension. Screening BP measurements would have 
failed to identify this population. In addition, 4% of the population had white 
coat hypertension and were at risk of being unnecessarily placed on 
treatment.28,29 Overestimating the total number of individuals with 
hypertension while failing to identify a significant proportion of the population 
with the condition would lead to inefficient and ineffective use of scarce health 
resources. Our findings imply that similar to the situation in developed country 
settings, efforts to control the burden and consequences of hypertension in 
sub Saharan Africa are likely to be significantly impaired by current screening 
methods.  
The prevailing consensus is that hypertension in developing countries is more 
prevalent in urban than rural areas.30 However, data from our study, 
conducted in rural Kenya, indicate that hypertension is not exclusively an 
urban disease, and this is supported by the previously documented finding of 
a high burden of stroke and heart failure in the area17 as well as the recently 
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published 2015 Kenyan Ministry of Health STEPs survey, which using 
methods similar to the screening strategy employed here, found a prevalence 
of raised BP of 25% in rural areas, remarkably similar to what we found on 
screening in this study.31 The prevalence of raised BP in urban areas in the 
same (STEPs) survey was 21%. Lifestyle habits related to urbanization may 
therefore have a smaller role in elevating BP in African population than 
previously thought.  
Urinary sodium levels in Kilifi were comparable to those reported by Dahl in 
Alskan eskimos in 1958 where the prevalence of hypertension was zero.32 In 
contrast, results from Nairobi, Kenya in the Intersalt study found lower median 
24hr sodium levels of 53mmol/day, with a prevalence of hypertension of 5%33, 
although this was not age-standardized. Mean Body Mass Index (BMI) levels 
in our population were well within the normal ranges. This combination of a 
high prevalence of hypertension in a rural region with relatively low levels of 
classical risk factors calls for more detailed study into the pathogenesis of this 
important condition in tropical Africa.  
Previous studies in sSA utilizing ABPM have found a high prevalence of the 
white coat effect among treated hypertensives.34 Although we found white 
coat hypertension to be present in 4% of the population, the more significant 
finding was the high prevalence of masked hypertension at 8% of the 
population. Given the increased risk of cardiovascular events in this 
population21,35, strategies aimed at identifying these individuals are urgently 
needed. The observation that younger age is associated with masked 
hypertension36 may help direct targeted ABPM at this group. It may also be 
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possible to identify individuals with masked hypertension by measuring 
arterial stiffness indices.35 
The strengths of this study include its population-based design, the use of 
reference standard methods for determining BP and utilizing a large and 
representative age-stratified sample. Limitations include the potential bias 
introduced by the nested case-control design used despite demonstration that 
this approach yields essentially similar validity results as compared to full 
cohort studies.18 As expected from the sampling strategy used, individuals 
who underwent ABPM had higher screening systolic BP and were slightly 
older than the baseline group. Weighting of analyses to correct for the 
differential probability of undergoing ABPM based on screening results may 
not have completely eliminated the bias. In addition a larger proportion of 
screen negatives had poor quality ABPM readings; these limitations mean 
that although our reported prevalence of masked hypertension was similar to 
that reported in other studies21,37,38, it may well have been an under-estimate. 
The fact that BP measurements were done at home and by non-medical 
personnel could also have reduced our ability to detect the white-coat effect. 
Taken together, probable underestimation of masked and white-coat 
hypertension suggest that there could have been more subjects who were 
misclassified using the screening measurement method, possibly 
strengthening the case for use of ABPM. 
Several issues however need to be considered before a recommendation to 
adopt ABPM for diagnosis of hypertension in sSA is made; We observed a 
modest response rate with 27% of those referred for ABPM failing to undergo 
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the procedure. This suggests that there may be difficulties regarding 
acceptability of ABPM in the population. Cost effectiveness studies assessing 
the potential benefit of ABPM in sSA settings are also needed, as are studies 
to determine whether blood pressure defined by ABPM provides better 
targeting of blood pressure reduction strategies to reduce vascular morbidity.  
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TA
B
LES  
Table 2-1: C
haracteristics of study subjects 
  
All 
 (N
=986) 
Selected to 
undergo A
BPM
 
(N
=651) 
ABP
M
  
perform
ed 
(N
=477) 
W
om
en (n, %
) 
588(60) 
400(61) 
302(63) 
Age in years (m
ean, sd) 
50(19) 
53(18) 
54(18)  ± 
Screening BP in m
m
H
g (m
ean, sd) 
  Systolic 
  D
iastolic 
 
134(26) 
81(13)  
 
142(28) 
84(15) 
 
139(28) ± 
82(15) 
§B
M
I, kg/m
2 (m
edian, IQ
R
) 
21(19-24) 
21(19-24) 
21(19-23) 
§N
a excretion m
m
ol/24h(m
edian, IQ
R
) 
63(47-92) 
62(47-90) 
61(47-80) 
§K excretion m
m
ol/24h (m
edian, IQ
R
) 
25 (18-38) 
25(19-38) 
25(19-38) 
§Spot U
rine Album
in to C
reatinine ratio m
g/m
g (m
edian, IQ
R
) 
0.02 (0.01-0.04) 
0.02 (0.01-0.04) 
0.02 (0.01-0.04) 
O
n m
edication for hypertension (n, %
) 
22(2) 
16(2) 
7(1) 
 Abbreviations: AB
PM
, Am
bulatory blood pressure m
onitoring: BM
I, B
ody m
ass index: IQ
R
, interquartile range: SD
, Standard deviation. 
§ B
M
I, N
a, K, U
AC
r ratio based on 164 subjects.  
± p < 0.001 (C
om
parison betw
een all screened subjects (N
=986) and those that underw
ent AB
PM
 (N
=477). 
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Table 2-2: M
ean BP
, pulse pressure and A
A
SI, by age, derived from
 screening B
P
 and 24 hour A
BP
M
 
A
ge 
G
roup 
M
ean S
creening BP 
24 hour A
BP
M
 m
easures 
D
aytim
e m
ean 
N
ight tim
e m
ean 
24 hour m
ean 
M
ean S
tiffness indices 
S
ystolic 
D
iastolic 
S
ystolic 
D
iastolic 
S
ystolic 
D
iastolic 
S
ystolic 
D
iastolic 
P
ulse 
P
ressure 
A
AS
I 
18-29 
120(102-144) 
76(60-92) 
118(115-122) 
71(69-73) 
107(103-112) 
60(58-63) 
115(111-118) 
68(66-70) 
47(45-49) 
0.31(0.27-0.36) 
30-39 
120(96-151) 
77(61-101) 
112(110-115) 
71(69-73) 
101(98-105) 
60(58-63) 
109(106-112) 
68(66-70) 
41(40-43) 
0.38(0.34-0.43) 
40-49 
128(100-164) 
81(64-104) 
119(116-122) 
74(72-76) 
106(104-109) 
63(61-65) 
115(112-118) 
70(68-72) 
45(43-46) 
0.41(0.37-0.45) 
50-59 
135(100-176) 
83(61-106) 
125(122-128) 
76(74-79) 
114(111-117) 
66(64-68) 
122(119-125) 
73(71-75) 
49(47-50) 
0.41(0.38-0.45) 
60-69 
147(109-196) 
85(66-112) 
131(128-134) 
77(75-79) 
122(119-125) 
68(66-71) 
127(125-131) 
74(72-76) 
53(51-56) 
0.49(0.46-0.52) 
70-79 
153(116-196) 
84(63-107) 
132(128-135) 
72(70-74) 
129(125-133) 
66(64-68) 
131(127-134) 
70(68-72) 
60(58-63) 
0.53(0.48-0.57) 
80+ 
156(113-217) 
86(56-110) 
137(130-143) 
75(70-80) 
129(123-135) 
68(64-71) 
134(127-140) 
72(68-77) 
62(57-66) 
0.52(0.47-0.56) 
 Abbreviations: AA
SI, Am
bulatory arterial stiffness index: AB
PM
, am
bulatory blood pressure m
onitoring: BP, blood pressure. 
N
ote: U
nits for all m
easurem
ents except AA
SI are in m
m
H
g. AAS
I is an index w
ith no units. S
tatistics are m
ean and 95%
 confidence interval. 
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Table 2-3: A
ge specific prevalence of hypertension using screening m
easurem
ent and ABP
M
 
 Age 
Screen Positives 
H
ypertension
§ 
M
asked H
T
± 
W
hite coat H
T
∞ 
N
on dipping status
¶ 
18-29 
11.0(6.5-17.3) 
10.9(4.3-19.5) 
10.9(4.3-19.5) 
2.9(1.5-4.4) 
6.5(0.0-15.2) 
30-39 
13.1(8.1-20.1) 
12.5(5.7-21.2) 
11.5(4.9-19.7) 
1.0(0.2-2.0) 
9.8(3.3-18.0) 
40-49 
26.8(19.3-36.2) 
11.0(6.5-16.1) 
4.5(1.1-9.0) 
3.7(1.6-6.2) 
5.3(2.0-9.5) 
50-59 
43.8(34.4-55.0) 
20.2(15.6-25.5) 
2.8(0.7-5.6) 
7.0(3.8-10.3) 
6.8(3.6-10.7) 
60-69 
55.4(44.7-67.8) 
33.4(27.7-39.2) 
3.1(1.0-5.7) 
3.9(1.3-7.1) 
12.1(7.7-16.5) 
70-79 
65.0(51.4-81.1) 
47.1(39.7-52.6) 
2.7(0.5-4.8) 
10.0(5.0-16.0) 
24.2(17.4-31.0) 
80+ 
68.8(47.3-96.6) 
46.9(35.2-58.3) 
3.9(0.0-7.8) 
8.6(0.0-17.2) 
12.2(4.0-22.4) 
A
ll** 
26.5(19.3-35.6) 
17.1(11.0-24.4) 
7.6(2.8-13.7) 
3.8(1.7-6.1) 
8.5(3.1-15.3) 
 Abbreviations: AB
PM
, am
bulatory blood pressure m
onitoring: BP
, blood pressure: H
T, hypertension. 
N
otes: 
§H
ypertension defined according to European S
ociety of H
ypertension 2013 guidelines
1: 24hr B
P > 130/80 m
m
H
g O
R
 day B
P > 135/85 m
m
H
g O
R
 nocturnal 
BP > 120/70 m
m
H
g. N
ighttim
e= 0100-0600 hrs. D
aytim
e = 0900-2100 hrs 1 .  
±M
asked hypertension: casual B
P <140/90 m
m
H
g but m
eets criteria for hypertension on AB
PM
 1. Individuals w
ith m
asked hypertension are included in the 
group w
ith true hypertension. 
∞W
hite coat hypertension: C
asual B
P >140/90 m
m
H
g, but not m
eeting criteria for hypertension on AB
PM
1. 
¶ N
on-dipping status: R
atio of average nighttim
e B
P
 to average daytim
e B
P
 ≥1.0. 
**Sum
m
ary prevalences are age standardized to W
orld H
ealth O
rganization population. 
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Table 2-4: Validity of m
easures of casual B
P
 m
ethod com
pared to AB
P
M
 
Age category 
Sensitivity 
Specificity 
PP
V
 
N
PV
 
LR
 positive 
LR
 negative 
18-29 
0.0(0.0-0.0) 
95.0(90.5-98.0) 
0.0(0.0-0.0) 
83.3(69.7-96.1) 
0.0(0.0-0.0) 
1.1(1.0-1.1) 
30-39 
9.7(2.5-24.9) 
98.4(96.5-99.6) 
55.6(23.6-88.9) 
84.1(73.2-93.3) 
6.1(1.3-31.5) 
0.9(0.8-1.0) 
40-49 
60.8(35.8-88.7) 
91.8(85.4-96.6) 
63.6(45.1-83.3) 
90.9(80.5-97.7) 
7.5(3.4-20.8) 
0.4(0.1-0.7) 
50-59 
87.5(74.8-96.9) 
74.8(62.0-86.0) 
72.3(59.5-84.5) 
88.6(76.1-97.1) 
3.4(2.2-6.3) 
0.2(0.0-0.3) 
60-69 
91.2(83.4-97.0) 
71.6(53.3-87.4) 
86.0(75.9-94.3) 
80.6(64.5-92.9) 
3.2(1.9-7.0) 
0.1(0.0-0.3) 
70-79 
94.2(88.1-98.9) 
24.4(8.5-49.2) 
81.7(70.4-90.9) 
54.5(25.0-85.7) 
1.2(1.0-1.8) 
0.2(0.0-0.8) 
80+ 
92.1(81.5-100.0) 
31.2(0.0-100.0) 
84.2(64.7-100.0) 
50.0(0.0-100.0) 
1.3(0.9-3.0) 
0.2(0.0-1.1) 
A
ll § 
79.9(73.0-86.0) 
83.7(79.1-87.9) 
79.5(74.0-84.6) 
84.2(78.6-89.3) 
4.9(3.7-6.8) 
0.2(0.2-0.3) 
 Abbreviations: AB
PM
, am
bulatory blood pressure m
onitoring: BP
, blood pressure: LR
, likelihood ratio: N
PV
, negative predictive value: P
PV, positive 
predictive value. 
§Sum
m
ary m
easures are age standardized to W
orld H
ealth O
rganization population. 
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Table 2-5: Interval likelihood ratios for screening systolic and diastolic blood pressures 
Systolic BP Interval LR
s 
D
iastolic BP Interval LR
s 
SBP interval 
(m
m
H
g) 
LR
 positive 
LR
 negative 
D
BP interval 
(m
m
H
g) 
LR
 positive 
LR
 negative 
<118 
0.0(0.0-0.0) 
1.0(1.0-1.0) 
<73 
7.3(2.4-31.4) 
0.6(0.4-0.9) 
118-129 
7.2(1.4-39.0) 
0.8(0.6-1.0) 
74-80 
9.8(4.5-38.7) 
0.3(0.1-0.6) 
130-142 
3.1(1.7-6.1) 
0.4(0.2-0.7) 
80-85 
4.6(2.5-10.9) 
0.4(0.2-0.6) 
143-159 
1.0(1.0-1.0) 
- 
86-94 
1.6(1.1-2.3) 
0.3(0.0-0.7) 
>160 
1.0(1.0-1.0) 
- 
>95 
1.0(1.0-1.0) 
- 
 Abbreviations: LR
, likelihood ratio: D
BP, diastolic blood pressure: SB
P, systolic blood pressure. 
N
otes:  
SB
P and D
BP
 intervals w
ere determ
ined by dividing the screening blood pressure values into quintiles.  
Em
pty cells indicate that there w
as insufficient data to calculate validity m
easures. 
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Figure Legends: 
Figure 2-1:  
Study recruitment profile 
Abbreviations: ABPM, ambulatory blood pressure monitoring: BP, blood pressure: KHDSS, 
Kilifi Health and Demographic Surveillance System 
Figure 2-2: Comparison of screening and ABPM blood pressure distributions 
A. Systolic 
B. Diastolic 
ABPM indicates ambulatory blood pressure monitoring 
Figure 2-3: Population prevalences of different BP indices. Data are derived 
from Table 2-3 
HTN indicates hypertension 
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Figure 2-1: Study recruitment profile 
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Figure 2-2: Comparison of screening and ABPM blood pressure distributions 
A 
 
B 
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Figure 2-3: Population prevalences of different BP indices 
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Abstract 
Rationale: Several studies have demonstrated links between infectious 
diseases and cardiovascular conditions. Malaria and hypertension are 
widespread in many low and middle-income countries but the possible link 
between them has not been considered. 
Objective: In this article we outline the basis for a possible link between 
malaria and hypertension, and discuss how the hypothesis could be 
confirmed or refuted. 
Methods and Results: We reviewed published literature on factors 
associated with hypertension and checked whether any of these were also 
associated with malaria. We then considered various study designs that could 
be used to test the hypothesis. Malaria causes low birth weight, malnutrition 
and inflammation, all of which are associated with hypertension in high-
income countries. The hypothetical link between malaria and hypertension 
can be tested through the use of ecological, cohort or Mendelian 
randomization studies, each of which poses specific challenges.  
Conclusions: Confirmation of the existence of a causative link with malaria 
would be a paradigm shift in efforts to prevent and control hypertension and 
would stimulate wider research on the links between infectious and non-
communicable disease. 
Keywords: Blood pressure; Arterial stiffness; Inflammation; sub-Saharan 
Africa; Malaria
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Nonstandard abbreviations and acronyms 
Ang-2: Angiopoietin-2 
BP: Blood pressure  
HIV: Human Immunodeficiency Virus 
LBW: Low birth weight 
LMIC: Low and middle-income countries 
MR: Mendelian Randomization 
SCT: Sickle cell trait 
 sSA: sub-Saharan Africa 
Introduction 
Age standardized mean blood pressures (BP) are higher in many parts of 
Asia and sub-Saharan Africa (sSA) than in high-income countries.1 Despite 
the high burden of cardiovascular disease in low and middle-income countries 
(LMIC), few studies have examined their aetiology, pathophysiology or 
treatment.2,3 While demographic and lifestyle changes including urbanization4 
contribute substantially to the burden of hypertension in LMICs, examining 
factors unique to or more prevalent in LMIC settings might reveal new 
pathophysiological mechanisms that could aid efforts to control the condition. 
The rise of cardiovascular disease in LMIC is occurring against the 
background of continuing high burden of infectious diseases.5,6 Several 
studies in more developed settings have reported links between infectious or 
inflammatory conditions and cardiovascular disease. In this article we outline 
the hypothesis that hypertension, the leading risk factor for death in LMIC 7, 
could be linked to one of the leading infectious conditions in the same region, 
malaria.  
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The malaria hypertension hypothesis 
We postulate that malaria contributes to the burden of hypertension in LMIC 
in the following ways (figure): 
(1) Malaria in pregnancy leads to low birth weight (LBW) through 
pathophysiologically connected mechanisms.8 In areas with high malaria 
endemicity where women are likely to have acquired immunity to prevent 
most febrile episodes, LBW results from fetal growth restriction which is a 
consequence of impaired uteroplacental blood flow9 and maternal anemia 
(which is itself due to malaria).10,11 Febrile malaria episodes which are more 
likely among women with low immunity, are thought to induce uterine 
contractions which are mediated by elevated levels of TNF-alpha leading to 
preterm birth.12,13 Malaria is also associated with hypertensive disorders of 
pregnancy such as gestational hypertension and preeclampsia in young 
primigravid women 14-16 and these are risk factors for LBW.17 Low birth weight 
children have an increased incidence of hypertension in later life.18-21 In a 
study conducted in Ibadan, Nigeria, infants of mothers who experienced 
malaria during pregnancy had a higher increase in BP levels during the first 
year of life compared to those who did not.22 Because BP levels track strongly 
through to adulthood, such differences could significantly influence the 
prevalence of adult hypertension.23-25 By virtue of its association with 
hypertensive disorders of pregnancy that are themselves risk factors for 
essential hypertension in women26,27, malaria likely contributes to an inter-
generational vicious cycle of disease susceptibility as hypertensive parents 
bear children who develop hypertension more frequently.28,29  
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(2) Malaria is associated with stunting and malnutrition in childhood30,31 which 
predisposes to the development of hypertension in later life.19,23,32 
Although the biological pathways have not been fully characterized, 
postulated mechanisms involved in the development of hypertension following 
stunting and chronic malnutrition include reduced nephron numbers18 and 
premature senescence in the kidney which is particularly prominent when 
there is rapid weight gain after growth restriction.33 In addition, Jamaican 
survivors of severe acute malnutrition in childhood were found at age 30 
years to have markedly smaller left ventricular outflow tracts with reduced 
cardiac output in the presence of elevated peripheral resistance, a pattern of 
changes that is likely to lead to hypertension in later life.34  
(3) Malaria is a cause of chronic inflammation35 and inflammation predisposes 
to cardiovascular diseases in high-income countries.36 In a prospective study 
of 20525 female US health professionals, there was a linear relationship 
between baseline C-reactive protein levels and incident hypertension.37 
Patients with inflammatory bowel disease and rheumatoid arthritis have 
increased arterial stiffness, which precedes hypertension.38-40 The link 
between inflammatory conditions and hypertension may be related to 
perturbations in the levels of endothelial-based growth factors. Angiopoietin-2 
(Ang-2) is a multimeric ligand of the Tie 2 receptor, part of a vascular specific 
tyrosine kinase signaling pathway that is essential for vessel development 
and stability.41 Ang-2 is predominantly secreted by endothelial cells and some 
smooth muscle cells in many inflammatory and angiogenic states. Ang-2 
levels are elevated in children with severe malaria in several different 
settings35,42-45 and in returning travellers infected with malaria46. Ang-2 levels 
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predict cardiovascular disease in children with chronic kidney disease.47 
Although no causal association has been established, several studies have 
demonstrated an association between Ang-2 levels and arterial stiffness and 
BP in adults.48,49 
Testing the hypothesis 
Observational studies 
Ecological studies examining BP levels in relation to malaria incidence are 
hampered by the lack of finely scaled data on the relevant BP distributions. A 
worldwide study on BP levels had scarce raw data on BP from sSA where 
most malaria endemic countries are situated.1 In contrast there are good 
epidemiological data on the spatial and temporal distribution of malaria.50  
Although traditional case-control studies (with malaria as the exposure and 
hypertension as the outcome) could provide an efficient way to test the 
hypothesis, they are limited by the non-specificity and non-durability of 
immunological markers for malaria, a prerequisite for identifying individuals 
who have previously been exposed to malaria.51-53 This limitation also applies 
to the potential use of propensity scores 54 to assemble groups that are 
comparable in their risk of malaria: in order to generate such scores reliable 
immunological markers of malaria exposure would be needed. 
A life-course epidemiological approach with longitudinal cohorts from the 
antenatal period or birth would allow the study of many of the postulated 
pathways through which malaria could be leading to hypertension in LMIC. 
Studies of pregnant women and children exposed to malaria in demographic 
surveillance systems with good quality ascertainment of exposure status are 
necessary. However most demographic surveillance systems in LMIC were 
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only set up in the last 15 years, and therefore may not have accumulated 
enough follow-up time to examine these outcomes, assuming that the biases 
of such retrospective studies can be overcome. Prospective surveillance on 
the other hand would also require long follow-up and be expensive to 
conduct.  
Randomized intervention studies  
Because malaria is of such great public interest, there have been and will 
continue to be a succession of randomized controlled trials of interventions 
tested at population level such as vaccines, bed nets and drug treatments. 
For those interventions that turn out to be effective it might be possible to 
examine their effect on arterial stiffness and blood pressure. Prospective 
studies of interventions known to be effective as well as studies of controlled 
human malaria infection55 can not be used here because although they satisfy 
the criterion of having 2 randomized groups with and without malaria, the fact 
that the vascular outcomes being tested are potentially irreversible pose an 
ethical challenge.56 As with observational studies, extended follow up might 
be needed as vascular differences in trial groups due to the effects of malaria 
may take longer to be apparent compared to the anti-malarial effects of the 
interventions. 
Animal studies are hampered by the fact that murine models of malaria and 
hypertension are imperfect approximations of their human analogues that 
have complex pathophysiology. 57,58 
Genetic studies 
Mendelian randomization (MR) studies, where genetic polymorphisms are 
used as instrumental variables representing malaria exposure, would be 
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particularly attractive for answering the question as they overcome many of 
the limitations of observational and intervention studies described above. 59 
Several hemoglobin polymorphisms provide some level of protection against 
malaria including Hemoglobin C and S, and thalassemia.60-62 A comparison of 
arterial stiffness indices and BP in subjects with and without the 
polymorphisms in regions where they have been exposed to malaria in 
childhood would provide a robust test of the effect of malaria exposure on the 
development of hypertension.  
An important prerequisite for using MR to make causal inferences regarding 
the effects of environmental exposures, is that the polymorphisms should not 
display pleiotropic effects, i.e. they should not influence the outcome being 
studied through a pathway that is independent of the environmental exposure 
that they are being used as a proxy for.59 Some studies suggest that 
individuals with the sickle cell trait (SCT) are more likely to suffer from 
cardiovascular events especially under extreme conditions such as military 
training or athletics.63,64 A recent study among African Americans found 
similar baseline BP in those with and without SCT although on follow up there 
was an increased incidence of chronic kidney disease in individuals with 
SCT.65 To exclude the possibility of confounding by pleiotropy, it may be 
necessary to include a control group that has not been exposed to malaria or 
use additional independent genetic polymorphisms, such as alpha 
thalassemia. If malaria causes hypertension and there are no pleiotropic 
effects of SCT, then one would expect to find higher BP in individuals without 
SCT compared to those with SCT in groups that have been exposed to 
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malaria. Conversely there would be no difference in BP based on trait status 
among those who have not been exposed to malaria. 
 Implications of the hypothesis 
Current efforts at understanding hypertension in LMIC have had a narrow 
focus anchored on traditional risk factors identified among populations in high-
income countries. Confirmation of the causative role of malaria in elevating 
BP would be of immense scientific interest and could lead to a paradigm shift 
on how to control hypertension in LMIC.  
Malaria is only one of many infectious diseases that have a high incidence 
across LMICs. The inflammatory pathways activated in malaria infection are 
similar to those of other illnesses.66 It is therefore likely that if malaria 
contributes to the burden of hypertension through inflammation, the same 
could be true of other chronic infections such as HIV and tuberculosis, 
providing a novel impetus for the study and control of these infections. 
Currently most treatment for infectious illnesses is focused on eliminating the 
pathogen with little regard for modulating the inflammatory responses that 
might result in adverse vascular consequences later. Elucidating these 
inflammatory pathways and their consequences would pave the way for trials 
of adjunctive therapy such as statins or specific cytokine antagonists to 
prevent adverse vascular remodeling as a result of infection. 
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Novelty and Significance 
What is known? 
x Malaria and high blood pressure are widespread in low and middle-
income countries. 
x Malaria is known to cause low birth weight, stunting and inflammation. 
x Low birth weight, stunting and inflammation are associated with the 
development of arterial stiffness and high blood pressure in developed 
countries. 
What new information does this article contribute? 
x We outline the likely pathophysiological mechanisms of the 
hypothesized association between malaria and high blood pressure in 
low and middle-income countries. 
x This hypothesis can be tested through well designed ecological and 
cohort studies or using Mendelian randomization techniques. 
Despite the knowledge that malaria causes low birth weight, inflammation and 
stunting, all of which have been associated with the development of 
hypertension, no attempt has been made to link the two conditions. In this 
article we review the literature in support of the hypothesis that malaria could 
be contributing to the widespread problem of hypertension in low and middle-
income countries. We also outline several ways in which this hypothesis could 
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be proven or refuted. If proven, this link would be a paradigm shift in efforts to 
prevent and control high blood pressure in low and middle-income countries. 
 
Figure 3-1: The malaria-high blood pressure hypothesis 
 
Figure legend: The malaria-high blood pressure hypothesis 
Malaria is known to cause low birth weight, inflammation as well as stunting. 
All these factors have been separately associated with the development of 
high blood pressure in high-income countries. Studies are needed to confirm 
whether malaria contributes to the development of high blood pressure in low 
and middle-income countries. 
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Chapter 4. Research paper III: Blood Pressure and Arterial 
Stiffness in Kenyan Adolescents With α(+)Thalassemia. 
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ABSTRACT 
Background 
Recent studies have discovered that D-globin is expressed in blood vessel 
walls where it plays a role in regulating vascular tone. We tested the 
hypothesis that blood pressure might differ between normal individuals and 
those with D+thalassemia, in whom the production of D-globin is reduced.  
Methods and Results 
The study was conducted in Nairobi, Kenya, among 938 adolescents aged 
11-17 years. 24-hour ambulatory blood pressure monitoring (ABPM) and 
arterial stiffness measurements were performed using an arteriograph device. 
We genotyped for D+thalassemia by PCR. Complete data for analysis were 
available for 623 subjects; 223 (36%) were heterozygous (-α/αα) and 47 (8%) 
were homozygous (-α/-α) for D+thalassemia while the remaining 353 (55%) 
subjects were normal (αα/αα). Mean 24-hour systolic BP±SD was 118±12 
mmHg in αα/αα, 117±11 mmHg in -α/αα and 118±11 mmHg in -α/-α subjects 
respectively. Mean 24-hour diastolic BP ±SD in these groups was 64±8 
mmHg, 63±7 mmHg and 65±8 mmHg respectively. Mean pulse wave velocity 
(PWV)±SD was 7±0.8 ms-1, 7±0.8 ms-1 and 7±0.7 ms-1 respectively. No 
differences were observed in PWV and any of the 24-hour ABPM derived 
measures between those with and without D+thalassemia.  
Conclusion 
These data suggest that the presence of D+thalassemia does not affect blood 
pressure and/or arterial stiffness in Kenyan adolescents. 
Keywords 
D+thalassemia, ambulatory blood pressure monitoring, adolescents
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INTRODUCTION 
The thalassemias, in which there is disordered or absent production of the D- 
or E-globin chains that make up normal hemoglobin, are the most common 
monogenic disorders of humans.1 The geographical distribution of 
D+thalassemia, in which there is deletion of one or more of the HBA genes 
that encode D-globin (HbD) production, closely mirrors that of malaria 
transmission2 and it has been demonstrated that these deletions confer 
protection against both severe and non-severe malaria.2-5 
While it has long been believed that HbD expression is limited to red blood 
cells, it has recently been demonstrated that HbD is also expressed in mouse 
endothelial cells where it plays a role in nitric oxide (NO) signaling, influencing 
vascular smooth muscle tone in resistance arteries.6,7 A macromolecular 
complex formed by HbD and endothelial Nitric Oxide Synthase (eNOS), 
regulates NO signaling at myoendothelial junctions (MEJ).8 Disruption of this 
complex lowers BP in both normotensive and hypertensive mice.8 It has also 
been shown that resistance arteries from mice lacking 2 of the 4 Dglobin 
genes (-DD have reduced contractility after treatment with the 
vasoconstrictor phenylephrine.9 Individuals with D+thalassemia have been 
shown to have higher microvasculature tortuosity.10 From the foregoing it 
could be expected that individuals with D+thalassemia might have lower BP 
compared to those with normal hemoglobin. However the few studies 
conducted in humans have yielded inconsistent results. While one review11 
suggested that D+thalassemic individuals have moderate hypotension, other 
investigators have found elevated BPs in subjects with this condition.12,13 
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These studies were limited by small sample sizes and the failure to use 24-
hour ambulatory blood pressure monitoring (ABPM) to measure BP. It is 
known that one-off office/clinic BP measurements can be influenced by a 
variety of environmental and psychological factors14, limitations that are 
overcome by the use of ABPM, which is considered the reference standard 
for BP measurement.14,15  
If arterial stiffness and/or BP are influenced by Hbα genotype, this would an 
important step that could aid the development of compounds either mimicking 
or antagonizing Hbα as potential therapies for hypertension. In the current 
study, we have tested the hypothesis that 24-hour BP and arterial stiffness is 
different in subjects with D+thalassemia than in normal individuals.  
METHODS 
This population-based study was a cross-sectional sample of residents of the 
Nairobi Urban Health and Demographic Surveillance System (NUHDSS)16 in 
Kenya, and was conducted between December 2015 and June 2016. Nairobi, 
the capital city of Kenya was chosen for this study for 2 reasons. First, Nairobi 
is located at high altitude (1800 meters above sea-level) and there is no 
evidence of malaria transmission.17 This made it possible to study the effect of 
D+thalassemia on BP unconfounded by the presence of malaria, which could 
potentially influence BP18 and which D+thalassemia protects against. Second, 
the population of Nairobi is composed of ethnic groups originating from all 
parts of the country including those whose ancestral lands were endemic for 
malaria (e.g. Luhya, Luo, Teso, Mijikenda), in whom the frequency of 
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D+thalassemia is significantly higher.2 In order to increase our efficiency in 
recruiting participants with D+thalassemia, we limited our recruitment to those 
who identified themselves as genetically derived from one of these ethnic 
groups.  
The NUHDSS conducts population-wide censuses within the study area 4 
times each year.16 Using NUHDSS data we selected all children currently 
aged 11-17 years who had a continuous record of residence within the study 
area since birth. Continuous residency was a requirement in order to minimize 
potential exposure to malaria as a result of migration. Trained staff visited all 
subjects who had been selected to participate in the study at their homes. 
Parents of the children were then asked to bring them to the nearer of two 
study clinics within the area to undergo study procedures. Up to three 
attempts were made at finding a selected subject before concluding that they 
could not be found. Subjects who failed to come to the clinic within 3 months 
of being invited were considered to have declined to participate in the study.  
Recruited subjects first underwent an interview where they answered 
questions about their past medical history and their socioeconomic status 
based on the multi-dimensional poverty (MDP) index.19 Weight and height 
were measured using a validated SECA 874™ weighing machine and a 
portable stadiometer (SECA 213™), respectively. Mid-upper-arm 
circumference (MUAC) was measured in a standardized manner using 
TALC™ MUAC tapes. We then took a screening BP measurement using a 
validated Omron™ M10-IT sphygmomanometer. An appropriately sized cuff 
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was placed on the non-dominant arm after the subject had been seated for at 
least 5 minutes. Three BP measurements were taken over a 5-minute period 
and the mean of the last 2 measurements was recorded as the screening BP 
value. All participants were subsequently fitted with a validated 
Arteriograph24™ device for 24-hour ABPM as well as pulse wave velocity 
(PWV) determination.20 These devices were programmed to take 
measurements every 20 minutes from 0600-2200 hrs and every 40 minutes 
from 2200-0600 hrs. 
 As there are no published criteria for acceptable ABPM data in children, we 
used guidelines for completeness of ABPM data in adults from the 
International Database of Ambulatory blood pressure in relation to 
Cardiovascular Outcomes (IDACO) study.21 Specifically, ABPM data were 
considered of acceptable quality if they included a minimum 10 daytime and 
minimum 5 nighttime readings, where daytime was defined as 1000-2200 hrs 
and nighttime as 0000-0600 hrs.21 The same time periods were used to 
determine average daytime and nighttime blood pressures and to evaluate 
dipping status. Time weighting was applied in calculating average BP values 
for all time periods.22  
We defined screen positives for hypertension as individuals whose mean of 
the last 2 clinic BP measurements was above the 95th percentile for their age, 
sex and height.15 Confirmed hypertensives were those whose 24hr systolic 
and/or diastolic BP averages respectively were above the 95th percentile for 
their sex, age and height.15  
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We categorized all subjects who were not on anti-hypertensive medication 
using the combination of clinic BP measurements and ABPM into four 
categories: sustained hypertensives (screen positive and confirmed 
hypertensive on ABPM); white coat hypertensives (screen positive, not 
confirmed hypertensive on ABPM); masked hypertensives (screen negative, 
confirmed hypertensive on ABPM) or normotensives (screen negative, not 
confirmed hypertensive on ABPM).23  
Dipping status was defined using ABPM data only, using day and night 
periods as defined above. Subjects were classified using the following four 
categories, based on the night/day ratio of mean systolic and/or diastolic BPs: 
rising or absence of dipping (ratio ≥1.0); mild dipping (0.9 < ratio ≤1.0); 
dipping (0.8 < ratio ≤ 0.9); and extreme dipping (ratio≤0.8).24 
Laboratory procedures 
We collected 10ml of blood from participants for full blood count, 
determination of D+thalassemia genotype and serum electrolytes. After 
performing automated full blood counts using an ACT 5™ machine, whole 
blood samples were frozen at -80ºC and then transported to the KEMRI-
Wellcome Trust Research Programme laboratories in Kilifi, Kenya for 
genotyping. DNA was extracted retrospectively from the frozen samples by 
use of Qiagen™ DNA blood mini-kits (Qiagen, Crawley, United Kingdom) and 
typed for the common African -3.7kb HBA deletion by PCR.25 
Serum and urine samples collected from participants were frozen at -80ºC 
within 4 hours of collection and later transported to Kilifi, Kenya for 
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subsequent analysis. We determined sodium and potassium, urea and 
creatinine levels in these samples using ion electrophoresis and the Jaffe 
method, respectively.26 We additionally determined albumin levels in the urine 
samples by immunoturbidometry using a Quantex™ microalbumin kit. 
Estimated glomerular filtration rate (eGFR) was calculated using the Schwarz 
formula.27 
Statistical methods 
Based on an expected minimum prevalence for heterozygous D+thalassemia 
(-α/αα) of 20% in the ethnic groups we were studying, a systolic BP standard 
deviation of 15 mmHg, and 30% attrition due to poor quality ABPM data, we 
estimated that a total of 472 participants would provide 80% power to detect 
1/3rd of a standard deviation (5 mmHg) difference in 24 hour systolic BP 
between -α/αα and αα/αα individuals.  
Summary statistics that were computed included means, medians and 
proportions as appropriate. We used Student’s t-test to separately compare 
continuous variables in –α/αα  and –α/–α  to αα/αα individuals. The F2 test 
was used to compare categorical variables. We conducted multiple regression 
analyses to determine whether inclusion of α+thalassemia genotype predicted 
24-hour systolic and/or diastolic BP. Age, sex, BMI, eGFR, and PWV, which 
have all been previously associated with BP were included as covariates in 
the base model. To determine whether α+thalassemia genotype influenced 
24-hour BP, we added it to the base model and used the likelihood ratio test 
to determine if it improved the fit. We additionally tested for interaction with 
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the sickle cell trait, as it has previously been associated with cardiovascular 
and renal events28-31. All analyses were conducted using Stata™ Version 12 
software (College Station, Texas). 
The Kenya Medical Research Institute’s Ethical Review Committee approved 
the study. Written informed consent was obtained from parents of study 
participants. Participating children also provided written assent.  
RESULTS 
Of the 938 subjects invited to participate in the study, 686 completed 
enrollment (Figure 4-1). None of the participants were previously aware of 
their α+thalassemia status. The 252 adolescents that were not recruited into 
the study were 0.6 years (95% CI 0.3-0.9) older than study participants, but 
with a similar sex distribution (53% female) to those that participated in the 
study. Data on α+thalassemia genotype were available for 664 (97%) 
participants. 246 (37%) were heterozygous (-α/αα) and 49 (7%) were 
homozygous (-α/-α) for D+thalassemia while the remaining 369 (56%) of 
subjects were normal (αα/αα). One hundred and three (15.5%) of the 
adolescents were carriers of the sickle cell trait, distributed equally among the 
D+thalassemia genotypic groups (14%, 17% and 16% in αα/αα, -α/αα and -α/-
α subjects respectively, p=0.652). After excluding those with poor quality 
ABPM data, 623 (94%) subjects provided quality data for the analysis (Figure 
4-1). A slightly lower proportion of -α/αα participants had complete ABPM data 
(91%) compared to αα/αα (95%) and -α/-α subjects (97%). Mean clinic 
BP±SD among all participants was 98±11 mmHg systolic and 64±8 mmHg 
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diastolic. The mean 24-hour BP±SD for all participants was 117±12 mmHg 
systolic and 64±8 mmHg diastolic. Mean 24-hour Pulse Wave Velocity 
(PWV)±SD was 7±0.8 ms-1. The study had >98% power to detect 1/3rd of a 
standard deviation (SD) difference in either systolic or diastolic BP (4mmHg 
and 2.7mmHg respectively) between αα/αα individuals and those with -α/αα, 
and a 0.3 ms-1 (1/3rd SD) difference in PWV between αα/αα individuals and 
those with -α/αα. The study had >90% power to detect differences equivalent 
to 0.5 SDs in BP and PWV between αα/αα and  -α/-α individuals. 
Table 4-1 displays the characteristics of study participants according to 
D+thalassemia genotype. As expected, hemoglobin concentrations were 
significantly lower in -α/-α than in -α/αα or αα/αα subjects. BMI was lower in   -
α/αα than in αα/αα individuals (18.2 vs 19.2;  p=0.0004) while mid upper arm 
circumference was significantly smaller in -α/αα compared to αα/αα 
individuals. There were no statistically significant differences in the 
prevalence of masked hypertension, white coat hypertension or in the pattern 
of non-dipping BP by D+thalassemia genotype. PWV was also similar in all 3 
groups. 
Figure 4-2 displays mean 24-hour, daytime and nighttime blood pressures in 
study participants by D+thalassemia genotype. All measures were similar for 
all three groups.  
The results of regression analyses are displayed in Table 4-2. Age, sex, BMI, 
eGFR and PWV were all independent predictors of 24-hour systolic BP while 
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PWV was the only independent predictor of 24-hour diastolic BP. 24-hour BP 
values were not associated with D+thalassemia genotype in any of our 
regression models and its inclusion in the final model did not improve the fit 
(likelihood ratio test p=0.96 for systolic BP and p=0.75 for diastolic BP). 
Adjustment for proxy markers of hemolysis (hemoglobin level, mean 
corpuscular volume and mean corpuscular hemoglobin concentration) made 
no difference to the results, and neither did the inclusion of interaction terms 
for sex and sickle cell trait status. 
DISCUSSION 
The D+thalassemias are the most common human monogenic disorders1. 
Demonstration of altered BP in individuals with any of the mutations would be 
of immense importance, as it would improve the understanding of BP 
regulation and aid the development of new drugs. In this detailed study of BP 
phenotypes and arterial stiffness among adolescents, we did not find any 
differences between those with and without D+thalassemia. Because the 
exposure measurement was a genetic trait acquired at conception and the 
participants were ascertained to have remained in the same malaria-free 
environment since birth we believe that this study suggests that a direct effect 
of D+thalassemia on BP and indices of arterial stiffness within the first 11-17 
years of life is highly improbable. 
On the face of it, our results do not align with findings from other studies that 
have suggested the possibility that expression of Hbα might affect blood 
pressure.6,8,11 These studies were either done in-vitro or in mouse models 
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with very limited sample sizes (N=6).8 The review by Butcher et al11 that 
reported an association between D+thalassemia and moderate hypotension 
did not refer to a primary publication. It is possible that the lower BPs 
observed in subjects with D+thalassemia who are relatively protected from 
malaria could actually be a confirmation that malaria raises blood pressure as 
we have previously hypothesized.18 An alternative explanation for similar BP 
despite the presence of Hbα deletions could be due to canalization, a 
phenomenon where individuals or organisms develop the same phenotype 
despite differences in their genetic make up.32 Reddy et al33 have shown that 
infusion of HbH (levels of which are elevated in D+thalassemia) into rats 
results in elevation of BP as a result of HbH having higher affinity for Nitric 
Oxide than HbA.34 It is therefore possible that the BP lowering effect of 
D+thalassemia is cancelled out by the opposing effect of elevated levels of 
HbH. This would also suggest that recently developed molecules that mimic 
alpha globin35, may have reduced effectiveness in individuals with 
D+thalassemia. Additional studies are needed to fully understand these 
seemingly contrasting effects and generate a unified model incorporating both 
environmental conditions and genetic effects. 
A major strength of this study was the use of ABPM, which is considered the 
reference standard for blood pressure measurement in children.15 The study 
was well powered to detect very small differences in BP and PWV. Although it 
could be argued that PWV is predominantly a measure of large conduit 
arteries which do not express Hb alpha  integrates the 
interface between small arteries and resistance vessels-as for instance in 
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diabetes where small vessel damage is as frequent as large.36 An additional 
strength of the study is that we used health and demographic surveillance 
system (HDSS) records that were prospectively collected in order to ascertain 
residence in a non-malaria zone, there being no better method of doing this in 
sub-Saharan Africa. 
One limitation of this study was the limited age range of subjects recruited, 
necessitated by the fact that there were no long-term residency records for 
older individuals. Most HDSSs in sSA were established in the late 1990’s to 
early 2000’s.37 Recruiting older individuals would have compromised data on 
residency status in childhood, the period when malaria risk is highest. While 
BP differences are likely to be larger at older ages, it is known that differences 
in adult BP emerge in childhood38,39 and that childhood BP levels are 
predictive of adult BP.40 The absence of even a small difference in carefully 
measured BP and arterial stiffness in our study of adolescents therefore 
suggests that it is very unlikely such differences would emerge in future. 
A second limitation of the study is the fact that we did not measure levels of 
markers of hemolysis such as HbH and haptoglobin and other potential 
compensatory mechanisms such as (decreased) eNOS or guanylyl cyclase 
expression, or increased catecholamine levels among study participants. This 
would have helped to either confirm or refute the possibility of canalization 
explaining the lack of an effect of D+thalassemia on BP levels. This could form 
the basis of future studies to better understand the seemingly contrasting 
findings of experimental and human studies. 
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It is also important to note that no studies have to date established whether 
alpha hemoglobin is expressed in endothelial cells of human subjects and if 
the 3.7kb deletion, the most common defect causing D+ thalassemia1 in 
humans, also results in reduced endothelial expression of alpha hemoglobin. 
Additional studies are required to determine if there is endothelial expression 
of alpha hemoglobin in humans, whether the 3.7kb deletion results in reduced 
endothelial D globin expression and whether other defects resulting in 
Dthalassemia present with the same vascular phenotype that we observed. 
In summary, we have demonstrated that there are no differences in BP and 
arterial stiffness based on D+thalassemia genotype in Kenyan adolescents 
living within a non-malaria-endemic environment. Additional studies are 
required to explain the apparent contradictory results of experimental studies. 
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Table 4-1: C
haracteristics of S
tudy P
articipants  
C
haracteristic 
N
orm
al 
(αα/αα) 
N
=353 
 
H
eterozygous 
(-α/αα) 
N
=223 
 
H
om
ozygous 
(-α/-α) 
N
=47 
 
p-value
1 
 
p-value
2 
n (%
) 
 
n (%
) 
 
n (%
) 
 
 
Fem
ale 
187 (53) 
 
132 (59) 
 
28 (58) 
 
0.3 
 
0.3 
W
hite coat hypertension 
15 (4) 
 
8 (4) 
 
3 (6) 
 
0.2 
 
0.4 
M
asked hypertension 
25 (7) 
 
21 (9) 
 
7 (15) 
 
1.0 
 
0.073 
 
m
ean (S
D
) 
 
m
ean (S
D
) 
 
m
ean (S
D
) 
 
p-
value
1 
 
p-
value
1 
Age, years 
13.4 (2.2) 
 
13.0 (2.2) 
 
13.4 (2.4) 
 
0.0289 
 
0.9 
BM
I 1, kg/m
2 
19.2 (3.2) 
 
18.3 (2.6) 
 
19.2 (3.6) 
 
0.0004 
 
0.9 
M
U
AC
2, cm
 
23.7 (3.9) 
 
22.7 (3.1) 
 
23.2 (4) 
 
0.0007 
 
0.4 
H
em
oglobin, m
g/dL 
13.5 (1.5) 
 
13.1 (1.4) 
 
12.2 (1.6) 
 
0.0004 
 
<0.0001 
M
ean cell volum
e, fL 
84 (5) 
 
79 (5) 
 
70 (5) 
 
<0.0001 
 
<0.0001 
Socioeconom
ic status, M
D
PI 3 score 
2.0 (1.2) 
 
2.3 (1.4) 
 
2.4 (1.1) 
 
0.0126 
 
0.3 
M
ean corpuscular hem
oglobin 
concentration, g/dL 
32 (2) 
 
31 (2) 
 
31 (2) 
 
0.0003 
 
<0.0001 
24-hour S
BP, m
m
H
g 
118 (12) 
 
117 (11) 
 
118 (11) 
 
0.1 
 
1.0 
24-hour D
B
P, m
m
H
g 
64 (8) 
 
63 (7) 
 
65 (8) 
 
0.1 
 
0.6 
24-hour P
ulse w
ave velocity, m
s
-1 
7.0 (0.8) 
 
7.0 (0.8) 
 
7.0 (0.7) 
 
0.2 
 
0.5 
S
ystolic M
orning B
P surge ,m
m
H
g 
 
9 (12) 
 
8 (12) 
 
11 (10) 
 
0. 6 
 
0.2 
Augm
entation index, %
 
17 (6) 
 
17 (6) 
 
16 (5) 
 
0.8 
 
0.4 
N
on dipping BP pattern 
24 (7) 
 
7 (3) 
 
2 (4) 
 
0.1 
 
0.9 
eG
FR
4  , m
ls/m
in/1.73m
2 
109 (15) 
 
111 (14) 
 
110 (13) 
 
0.1 
 
0.6 
Log
10 U
AC
r  
0.4 (0.6) 
 
0.3 (0.7) 
 
0.2 (1) 
 
0.4 
 
0.1 
U
rine sodium
, m
m
ol/L 
137 (82) 
 
130 (53) 
 
128 (51) 
 
0.3 
 
0.5 
U
rine potassium
, m
m
ol/L 
48 (32) 
 
46 (29) 
 
42 (20) 
 
0.4 
 
0.2 
P
-values are for com
parisons betw
een norm
al and heterozygous
1 and norm
al and hom
ozygous
2 
1B
M
I=B
ody m
ass index 
2M
U
A
C
=m
id upper arm
 circum
ference 3M
D
P
I=m
ulti-dim
ensional poverty index 4eG
FR
=estim
ated glom
erular filtration rate 
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Table 4-2: Regression Analyses Investigating Possible Effect of Thalassemia 
Status on 24-Hour Systolic and Diastolic BP 
 
 
 
24hr SBP 
 
24 hr- DBP 
E, 95% CI p-
value 
 E, 95% CI p-
value 
Age (years) 
0.6 (0.1 to 1.2) 0.021  0.03(-0.3 to 0.4) 0.9 
Male sex 
2.6(0.7 to 4.5) 0.009  0.2(-1.1 to 1.4) 0.9 
BMI (kg/m2) 
0.6 (0.2 to 1) 0.001  0.2(-0.1 to 0.4) 0.2 
PWV (ms-1) 
2.8(1.6 to 4.1) <0.001  2.7(1.9 to 3.6) 
<0.0
01 
eGFR 
(mls/min/1.73m2) 0.1(0.03 to 0.2) 0.006  0.02(-0.02 to 0.06) 0.4 
D+thalassemia 
genotype 0.04(-1.4 to1.5) 1.0  0.1(-0.8 to 1.1) 0.8 
 
Likelihood ratio test for models including vs excluding D+thalassemia genotype p= 1.0 for SBP 
and p=0.8 for DBP. 
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Figures 
Figure 4-1: Study Flow Chart 
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Figure 4-2: Twenty-four hour ABPM measures by alpha thalassemia status 
Data are mean and 95% Confidence Intervals 
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Chapter 5. Research paper IV: Blood Pressure and Arterial 
Stiffness in Kenyan Adolescents with the Sickle Cell Trait 
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ABSTRACT 
The potential association between sickle cell trait (SCT) and increased arterial 
stiffness/blood pressure (BP) has not been evaluated in detail despite its 
association with stroke, sudden death and renal disease. We performed 24-
hour ambulatory BP monitoring and arterial stiffness measurements in 
adolescents raised in a malaria free environment in Kenya.  
Between December 2015 and June 2016, 938 randomly selected adolescents 
that had been continuous residents of Nairobi from birth were invited to 
participate in the study. Standard clinic BP measurement was performed 
followed by 24-hour ambulatory BP monitoring and arterial stiffness 
measurement using an Arteriograph device. SCT status was determined 
using DNA genotyping on contemporaneously collected blood samples. Of 
938 invited, 609 (65%) provided complete data for analysis. SCT was present 
in 103 (17%). Mean 24-hour systolic and diastolic BP, SD was (116, 11.5) and 
(64, 7) mmHg respectively in SCT; and (117, 11.4) and (64, 6.8) in non-SCT. 
Mean pulse wave velocity (PWV), SD was (7, 0.8) and (7, 0.8) ms-1 
respectively in SCT and non-SCT. No differences were observed in PWV and 
any clinic or ambulatory BP derived measures between those with and 
without SCT. These data suggest that SCT does not independently influence 
BP or PWV.  
 
Keywords 
Sickle cell trait; Hypertension; Blood Pressure; Arterial Stiffness 
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The sickle cell trait (SCT), common among populations of African descent1 
due to the protection it offers against malaria2-4, has been associated with 
increased risk of cardiovascular and renal disease.5-8 However the underlying 
mechanisms of this increased risk have not been elucidated clearly, 
hampering measures that can be implemented to reduce risk in carriers. 
Individuals of African descent have relatively higher blood pressure (BP) 
compared to other ethnicities 9, and it is conceivable that increased BP or 
arterial stiffness, which have been shown to precede clinical events similar to 
those seen in SCT, could precede the events observed in SCT carriers.8,10,11 
Alternatively increased arterial stiffness and BP in individuals with SCT could 
result from the yet to be elucidated mechanisms that lead to cardiovascular 
and renal events.  
Previous studies that assessed BP and/or arterial stiffness in individuals with 
SCT had several weaknesses; Rossi-Espagnet et al in a study conducted in 
Colombia in 1968 found no difference in BP between individuals with and 
without SCT.12 However, BP measurements were performed only once at 
home visits; there was a poor response rate in men; and the data were 
susceptible to confounding by malaria, which SCT protects against2-4 and is 
possibly related to BP.13,14 Bayramoglu et al found similar arterial stiffness 
indices in young Turkish adults with and without SCT, but the sample size 
was small.15 Although the studies demonstrating increased cardiovascular 
and renal disease risk in SCT assessed BP at baseline, the BP 
measurements were done in the clinic/office, using manual or automated 
methods.7,8 None of these studies utilized 24-hour ambulatory blood pressure 
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monitoring (ABPM), considered the reference method for BP 
measurement16,17, raising the possibility that subtle but significant differences 
in BP could have been missed.17 ABPM overcomes many of the limitations of 
office/clinic BP measurement.17 ABPM also enables detection of masked 
hypertension (normal clinic BP but elevated 24-hour BP), a cardiovascular 
risk factor18 that is more common in populations of African descent19, the 
same population that has a high prevalence of SCT.  
If arterial stiffness and/or BP are increased in young individuals with SCT they 
could become the target of interventions aimed at reducing future 
cardiovascular and renal events. We conducted a population-based study in 
Nairobi, Kenya to determine whether SCT influences arterial stiffness and BP 
among adolescents who have had minimal exposure to malaria.  
METHODS 
The study was a cross-sectional sample of residents of the Nairobi Urban 
Health and Demographic Surveillance System 20 in Kenya conducted from 
December 2015 to June 2016. The area has a population of approximately 
70,000 and the prevalence of hypertension is high.21 Nairobi, the capital city 
of Kenya was chosen for this study because of 2 reasons: First, Nairobi is 
located at high altitude (1800 meters above sea-level) and there is no 
evidence of malaria transmission.22 This made it possible to study the effect of 
SCT on BP unconfounded by the presence of malaria. This was necessary 
because malaria could influence BP14 and at the same time SCT protects 
against malaria3,4; Second, the population of Nairobi is composed of ethnic 
groups originating in all parts of the country including those whose ancestral 
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lands were endemic for malaria (e.g. Luhya, Luo, Teso, Mijikenda). The sickle 
cell gene frequency is much higher among these ethnic groups.23 In order to 
increase our efficiency in recruiting participants with SCT we limited our 
recruitment to those who identified themselves as genetically derived from 
one of these ethnic groups.  
Population-wide censuses are conducted 4 times a year within the study 
area.20 Using census data we selected all children currently aged 11-17 years 
who had a continuous record of residence in the area since birth. Continuous 
residency was a requirement so as to minimize potential exposure to malaria 
as a result of migration. Trained staff visited all subjects who had been 
selected to participate in the study at their homes. Parents of the children 
were then asked to bring them to the nearer of two study clinics within the 
area to undergo study procedures. Subjects who failed to come to the clinic 
within 3 months of being requested to do so were considered to have refused 
to participate in the study.  
Subjects first underwent an interview where they answered questions about 
their past medical history and their socioeconomic status based on the multi-
dimensional poverty index.24 Weight and height were measured using a 
validated SECA 874™ weighing machine and a portable stadiometer (SECA 
213™) (SECA GMBH, Hamburg, Germany), respectively. Mid-upper arm 
circumference was measured in a standardized manner using TALC™ 
(Teaching Aids at Low Cost, Hertfordshire, UK) tapes. We then took a 
screening BP measurement using a validated automated Omron™ M10-IT 
(Omron Healthcare Europe B.V, Hoofddorp, The Netherlands) BP machine. 
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An appropriately sized cuff was placed on the non-dominant arm after the 
subject had been seated for at least 5 minutes. Three BP measurements 
were taken over a 5-minute period and the mean of the last 2 measurements 
was recorded as the screening BP value. All participants were subsequently 
fitted with an Arteriograph24™ device (Tensiomed Ltd, Budapest, Hungary) 
for 24-hour ABPM as well as pulse wave velocity (PWV) determination.25 The 
devices, which have been calibrated in children26, were programmed to take 
measurements every 20 minutes during daytime hours (0600-2200 hrs) and 
every 40 minutes at night (2200-0600 hrs).  
Laboratory procedures 
We collected 10ml of blood from participants for full blood count, 
determination of sickle hemoglobin status and serum electrolytes. After 
performing automated full blood counts using an ACT 5™ machine (Beckman 
Coulter Inc, Brea, CA), whole blood samples were frozen at -80ºC and then 
transported to the KEMRI-Wellcome Trust Research Programme laboratories 
in Kilifi, Kenya for determination of sickle hemoglobin status. DNA was 
extracted retrospectively from the frozen samples by use of Qiagen™ DNA 
blood mini-kits (Qiagen, Crawley, United Kingdom) and typed for sickle 
hemoglobin using polymerase chain reaction.  
Serum and urine samples collected from participants were frozen at -80ºC 
within 4 hours of collection and later transported to Kilifi, Kenya for analysis. 
We determined sodium and potassium, urea and creatinine levels in these 
samples using ion electrophoresis and the jaffe method, respectively.27 We 
additionally determined albumin levels in the urine samples by 
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immunoturbidometry using a Quantex™ microalbumin kit (Instrumentation 
Laboratory, Barcelona, Spain). 
Statistical methods 
Based on an expected minimum prevalence of 10% SCT in the ethnic groups 
we were studying, a systolic BP standard deviation of 15 mmHg, and 30% 
attrition due to poor quality ABPM data, we estimated that a total of 550 
participants would provide 80% power to detect half of a standard deviation 
(7.5 mmHg) difference in 24 hour systolic BP between individuals with and 
without SCT. 
As there are no published criteria for acceptable ABPM data in children, we 
used guidelines for completeness of ABPM data in adults from the 
International Database of Ambulatory blood pressure in relation to 
Cardiovascular Outcomes study.28 Specifically, ABPM data were considered 
of acceptable quality if they met the following criteria: minimum 10 daytime 
and minimum 5 nighttime readings, where day was defined as 1000-2000 hrs 
and night as 0000-0600 hrs.28 The same time periods were used to determine 
average daytime and nighttime blood pressures and to evaluate dipping 
status. Time weighting was applied in calculating average BP values for all 
time periods.29  
We defined screen positives for hypertension as individuals whose mean of 
the last 2 clinic BP measurements was above the 95th percentile for their age, 
sex and height.16 Confirmed hypertensives were those whose 24hr systolic 
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and/or diastolic BP averages respectively were above the 95th percentile for 
their sex, age and height.16  
We categorized all subjects who were not on anti-hypertensive medication 
using the combination of clinic BP measurements and ABPM into four 
categories: sustained hypertensives (screen positive and confirmed 
hypertensive on ABPM); white coat hypertensives (screen positive, not 
confirmed hypertensive on ABPM); masked hypertensives (screen negative, 
confirmed hypertensive on ABPM) or normotensives (screen negative, not 
confirmed hypertensive on ABPM).30  
Dipping status was defined using ABPM data only, using day and night 
periods as defined above. Subjects were classified using the following four 
categories, based on the night/day ratio of mean systolic and/or diastolic BPs: 
rising or absence of dipping (ratio ≥1.0); mild dipping (0.9 < ratio ≤1.0); 
dipping (0.8 < ratio ≤ 0.9); and extreme dipping (ratio≤0.8).31 
Estimated glomerular filtration rate was calculated using the Schwartz 
formula.32 
Summary statistics computed included means, medians and proportions as 
appropriate. Comparisons between SCT carriers and non-carriers were made 
using Student’s t-test and χ 2 tests as appropriate. Data that were not normally 
distributed were log transformed prior to analysis. We compared ABPM and 
arterial stiffness measures between those with and without the sickle cell trait 
by Student’s t-test. In addition we performed a multivariate regression 
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analysis testing the effect of sickle carrier status on mean 24-hour systolic 
and diastolic BP with sex, age, body mass index, pulse wave velocity and 
estimated glomerular filtration rate as covariates.  
All analyses were conducted using Stata™ Version 12 software (College 
Station, Texas). 
The Kenya Medical Research Institute’s Ethical Review Committee approved 
the study. Written informed consent was obtained from parents of study 
participants. Participating children also provided written assent. The 
corresponding author had full access to all the data in the study and takes 
responsibility for the integrity of the data and the accuracy of the data 
analysis. 
RESULTS 
Of the 938 subjects requested to participate in the study, 686 (73%) 
completed enrollment (Figure 5-1). The 252 adolescents that were not 
recruited into the study were 0.6 years (95% CI 0.3-0.9) older than study 
participants, but with a similar sex distribution (53% female) to those that 
participated in the study. Genotype data was available for 644 subjects, 609 
(95%) of who had complete ABPM data. Sickle cell trait (SCT) was present in 
103 (15%) of participants. The proportion of participants with complete ABPM 
data did not differ by sickle cell trait (91% vs 90%, p=0.817) or any of the 
other demographic and clinical data collected. One participant had Sickle Cell 
Disease (Hemoglobin SS) and was dropped from analyses. None of the 
participants were previously aware of their sickle carrier status.  
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Mean clinic BP, SD among all participants was (98, 11) mmHg systolic and 
(64, 8) mmHg diastolic. The mean 24-hour BP, SD for all participants was 
(117, 11) mmHg systolic and (64, 7) mmHg diastolic. Mean 24-hour Pulse 
Wave Velocity (PWV), SD was (7, 0.8 ms-1). Based on the data accrued, the 
study had >98% power to detect a 5 mmHg difference in systolic BP (0.4 
standard deviations), a 4mmHg (0.5 standard deviations) difference in 
diastolic BP and a 0.4 ms-1 (0.5 standard deviations) difference in PWV 
between those with and those without SCT.  
Table 5-1 displays the characteristics of the participants according to SCT 
carrier status. The mean, SD 24-hour systolic and diastolic BP in subjects 
with SCT was (116, 11.5) and (64, 7) mmHg. In subjects without SCT the 
corresponding 24-hour BP values were (117, 11.4) and (64, 6.8) (p=0.8551 
and 0.9691 for comparison between SCT carriers and non-carriers). There 
were no statistically significant between-group differences in estimated 
glomerular filtration rate, clinic BP, clinic PWV and 24-hour PWV. There were 
no between-group differences in the prevalence of masked hypertension, 
white coat hypertension, or non-dipping status. Urinary sodium and potassium 
were 19.5 mmol/L (95%CI 1.4-37.6, p=0.0352) and 13.5mmol/L (CI 5.8-21.2, 
p=0. 0006) lower in SCT carriers than in non-carriers.  
Figure 5-2 displays distribution of 24-hour, daytime and nighttime blood 
pressures in study participants by SCT carrier status. All measures were 
similar for SCT carriers and non-carriers.  
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Table 5-2 displays the results of regression analyses examining whether SCT 
influenced 24-hour systolic and diastolic BP adjusted for age, sex, body mass 
index, glomerular filtration rate and pulse wave velocity. While age, sex, body 
mass index and glomerular filtration rate were all associated with 24-hour 
systolic BP, there was no association between SCT and 24-hour BP 
measures. Pulse wave velocity displayed the strongest association with both 
systolic and diastolic BP. Additional adjustment for urinary sodium and 
potassium levels made no material difference to the results. 
DISCUSSION 
It has previously been hypothesized that the excess risk of cardiovascular 
disease observed in African populations may be result from pleiotropic effects 
of genetic polymorphisms that protect them from common infections during 
childhood. An elegant example of this is variants of the APOL1 gene, which 
while reducing the risk of trypanosomiasis, increase the risk of hypertension 
associated chronic kidney disease.33 Malaria has exerted the strongest known 
selective pressure on the human genome, SCT being prominent among the 
polymorphisms under positive selection.34 Given the previously documented 
excess cardiovascular and renal events observed in both sickle cell disease 
and SCT, we hypothesized that individuals with SCT would have different BP 
compared to those without SCT.  
In this detailed study of BP phenotypes and arterial stiffness among children 
who were selected because they had had little exposure to malaria 
throughout childhood, we did not find any differences between those with and 
without SCT. Because the exposure measurement was a genetic trait 
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acquired at conception and the participants were ascertained to have 
remained in the same malaria-free environment since birth we believe that 
this study suggests that a direct effect of SCT on BP and indices of arterial 
stiffness is highly improbable within the first 11-17 years of life. 
Estimated glomerular filtration rate and urine albumin to creatinine ratio were 
the same in SCT carriers and non-carriers in this study. In a study conducted 
among blacks in the US showing increased renal events in SCT carriers, most 
participants were recruited at 45 years of age and above8, much older than 
the population we recruited in this study. We however found significantly 
lower urine electrolyte levels in SCT carriers, which could be attributed to 
hyposthenuria (impaired urinary concentrating ability) that has previously 
been described in SCT.35  
 While we failed to detect any meaningful effect of SCT on BP and arterial 
stiffness, the results of this study do have important implications; first it seems 
unlikely that increased BP and arterial stiffness precede or are involved in the 
pathogenesis of cardiovascular and renal events in individuals with SCT. In 
view of this, studies of other biomarkers that could predict the development of 
chronic kidney disease in individuals with SCT are warranted. Because 
individuals with SCT form a significant proportion of the population in many 
developing as well as developed countries, early identification of risk factors 
in this sub-group of individuals could have significant population-wide 
benefits. 
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An alternative to the hypothesis that genetic variations protective against 
infectious diseases predispose to cardiovascular disease is that in some 
instances the infectious diseases themselves may have long-term 
consequences in survivors including the development of hypertension.14 One 
robust way to test such hypotheses is by utilizing mendelian randomization 
techniques in which BP is compared in individuals with and without genetic 
variants that are associated with the infectious disease. An important 
prerequisite for using these variants is that they should not affect the outcome 
(BP) in the absence of the infectious disease (malaria). The results of this 
study suggest that SCT does not influence BP in the absence of malaria and 
can therefore be used as an instrumental variable in MR studies to test the 
malaria-high blood pressure hypothesis.14 SCT is a particularly attractive 
candidate for such studies as it is relatively common in areas with malaria and 
displays a very strong protective effect against mild as well as severe 
malaria2,4 thus reducing sample size requirements for such studies. 
Confirmation of the hypothesis would represent a paradigm shift in 
understanding the pathogenesis of hypertension in many developing country 
settings where malaria is endemic.36  
A major strength of this population-based study was the use of ABPM, which 
is considered the reference standard for blood pressure measurement in 
children.16 The study was well powered to detect very small differences in BP 
and PWV. We also used health and demographic surveillance system records 
that were prospectively collected in order to ascertain residence in a non-
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malaria zone, there being no better method of doing this in sub-Saharan 
Africa.  
A potential limitation of this study was the limited age range of subjects 
recruited, necessitated by the fact that there were no long-term residency 
records for older individuals. Most demographic surveillance systems in Africa 
were established in the late 1990’s to early 2000’s.37 Recruiting older 
individuals would have compromised data on residency status in childhood, 
the period when malaria risk is highest. In addition, older subjects would be 
more likely to have acquired additional risk factors for hypertension, including 
chronic kidney disease that would have confounded the analyses. While BP 
differences are likely to be larger at older ages, it is known that differences in 
adult BP emerge in childhood38,39 and that childhood BP levels are predictive 
of adult BP.40 The absence of even a small difference in carefully measured 
BP and arterial stiffness in our study of adolescents therefore suggests that it 
is very unlikely such differences would emerge in future. 
Although the study was well powered to detect differences in continuous 
variables such as mean nighttime and daytime BP, we were underpowered to 
detect differences in the prevalences of categorical variables such as masked 
hypertension and white coat hypertension. This could form the basis of future 
studies.  
An additional limitation of this study is the fact that as with many BP 
measurement devices, validation studies for the Arteriograph24™ have only 
been done in adults.25 It is however unlikely that measurement error 
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significantly influenced the result, as the oscillometric principle used by the 
device has been validated in children and is particularly suited for pediatric 
ambulatory BP studies.16,41  
Non-responders in this study were slightly older than those who participated, 
but the 0.6-year difference is unlikely to have significantly biased our results. 
We also observed no significant differences between those that provided 
acceptable ABPM data and those that did not suggesting that the data 
presented are representative of the larger population of individuals with sickle 
cell trait. 
In summary, we have demonstrated that the presence of sickle cell trait does 
not influence BP and arterial stiffness in Kenyan adolescents.  
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Table 5-1: Characteristics of study subjects according to sickle trait status, 
Nairobi, Kenya 2015-2016 
 
 
Characteristic 
SCT Non-carrier  
(N=567) 
 SCT 
Carrier 
(N=103) 
 
p-value No (%)  No (%)  
Female sex 323 (57)  49 (48)  0.08 
Complete ABPM data 516 (91)  93 (90)  0.82 
White coat hypertensiona 23 (44)  3 (3.2)  0.59 
Masked hypertensiona 37 (7.2)  8 (8.6)  0.63 
Non dipping BP patterna 17 (3)  2 (2)  0.55 
 Mean (SD)  Mean (SD)  p-value 
Age, years 13.2 (2.2)  13.8 (2.3)  0.093 
BMIb 19 (3)  19 (3)  0.63 
MUAC, cm 23.2 (3.6)  23.5 (3.8)  0.41 
Hemoglobin, mg/dL 13.2 (1.5)  13.4 (1.6)  0.15 
White cell count 5.5 (1.5)  5.6 (1.3)  0.78 
Platelet count 310 (87)  305 (95)  0.64 
Serum sodium (mmol/L) 139 (6)  139 (6)  0.94 
Serum potassium (mmol/L) 4.9 (0.6)  5.0 (0.8)  0.093 
Socioeconomic status 
(MDPI score) 2.2 (1.3) 
 
2.1 (1.3) 
 
0.55 
Clinic BP, mmHg      
  Systolic 98 (11)  99 (13)  0.31 
  Diastolic 64 (8)  64 (9)  0.32 
Pulse wave velocity (ms-1) 7 (0.8)  7.1 (0.8)  0.26 
eGFR (mls/min/1.73m2) 110 (15)  108 (14)  0.12 
UACr  3.6 (18)  3.5 (8)  0.96 
Urine sodium (mmol/L) 136 (73)  119 (45)  0.031 
Urine potassium (mmol/L) 48 (31)  36 (23)  0.0001 
 
BMI=Body mass index; eGFR=estimated glomerular filtration rate; MDPI=multi-dimensional poverty 
index; MUAC=mid upper arm circumference; UACr=Urine albumin to creatinine ratio 
aData on white coat, masked hypertension and non-dipping pattern are based on the 609 
individuals that had complete ABPM data 
b BMI is calculated as Weight(kg)/height(m)2 
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Table 5-2: Predictors of mean 24-hour systolic and diastolic BPs among 
adolescents in Nairobi, Kenya, 2015-2016 
 
Characteristic 
24-hour SBP  24-hour DBP 
E 95% CI p-value  E 95% CI p-value 
Age, years 
0.6 0.07, 1.1 0.027  0.008 –0.3, 0.3 0.96 
Male Sex 
2.4 0.4, 4.3 0.016  –0.06 –1.3, 1.2 0.92 
BMIb 
0.6 0.2, 1 0.001  0.2 –0.09, 0.4 0.21 
eGFR 
(mls/min/1.73m2) 0.08 0.01, 0.15 0.017  0.01 –0.03, 0.05 0.58 
PWV (ms-1) 
2.8 1.6, 4.1 <0.001  2.7 1.9, 3.5 <0.001 
Sickle carrier 
status 0.1 –2.4, 2.6 0.923  0.4 –1.1, 2 0.58 
 
 SBP=systolic blood pressure; DBP= diastolic blood pressure; BMI=Body mass index; 
 eGFR=estimated glomerular filtration rate; PWV= pulse wave velocity 
aMultivariate analyses were conducted using data from participants that had complete 
Ambulatory BP Monitoring data (N=609) 
 bBMI is calculated as Weight(kg)/height(m)2 
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Figure 5-1 Legend: Study flow chart of participants in sickle trait–blood 
pressure study in Nairobi, Kenya 2015-2016. 
Figure 5-2 Legend: 24-hour ABPM measures by sickle cell trait (SCT) carrier 
status in Nairobi, Kenya 2015-2016. For each category of 24-hour, day and 
night measures, the plots on the left are for systolic blood pressure and those 
on the right are for diastolic blood pressure. Error bars represent 95% 
Confidence Intervals. 
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Figure 5-1: Study Flow Chart 
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Figure 5-2: Twenty-four hour ABPM measures by sickle cell trait (SCT) carrier 
status in Nairobi, Kenya 2015-2016 
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Chapter 6. Research paper V: Relationship between childhood 
malaria and adult blood pressure 
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ABSTRACT 
Background 
Childhood malaria may contribute to elevated blood pressure (BP) in adults. 
We tested this hypothesis by conducting Mendelian randomization studies at 
2 sites in Kenya. 
Methods  
We studied lifelong residents of Nairobi, where there is no malaria 
transmission; and Kilifi, which has low/moderate transmission. We compared 
24-hour ambulatory blood pressure monitoring (ABPM) measures by sickle 
cell trait (SCT) and D+thalassemia, genetic variants that protect against 
malaria. Primary analyses utilized ABPM data meeting European Society of 
Hypertension quality criteria.  
Results  
Complete data were available for 542 of 1026 participants in Nairobi and 1136 
of 2371 participants in Kilifi. The frequency of SCT was 15% in Nairobi, 20% 
in Kilifi. In Kilifi, SCT was associated with –2.4mm Hg lower 24-hour Systolic 
BP (95% CI –4.7 to –0.1,p=0.037) and a hypertension odds ratio (OR) of 0.72 
(CI 0.58-1, p=0.05) in linear and logistic regression models adjusted for age, 
sex and kidney function. In population-weighted models, SCT was associated 
with –3.3 mmHg (CI –5.9 to –0.8, p=0.01) lower 24-hour SBP and a 
hypertension OR of 0.64 (CI 0.45-0.91, p=0.014).  D+thalassemia was 
associated with statistically insignificant reductions in BP in Kilifi.  
No differences in ABPM derived measures by SCT/D+thalassemia genotype 
were observed in Nairobi in any of the regression models.  
Conclusion 
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These data suggest that past malaria exposure influences adult BP. 
Elucidation of the underlying mechanisms could yield new therapeutic options 
for hypertension.
                                         
 146 
INTRODUCTION 
Malaria resulted in more than 600,000 deaths worldwide in 2015, 
predominantly in children.1 While malaria’s effects on various organ systems 
have been studied extensively, its potential long-term effects have not gained 
much attention. We recently hypothesized that through its effects in 
pregnancy and childhood, falciparum malaria may contribute to the 
development of high blood pressure (BP) in individuals living in malaria-
endemic areas.2 In the present analysis we tested whether sickle cell trait 
(SCT) and D+thalassemia, genetic variants that confer protection against 
malaria3,4, are associated with lower BP among carriers in Kilifi, Kenya. 
METHODS 
This Mendelian Randomization study was carried out from December 2015 to 
June 2017 among long-term residents of two sites in Kenya with markedly 
different levels of malaria transmission: Nairobi, where there is no evidence of 
malaria transmission5, and Kilifi where there has been low to moderate 
transmission.6,7 We utilized SCT and D+thalassemia, both of which offer 
partial protection against malaria to varying degrees both independently and 
interactively to represent malaria exposure.3,8,9 In Nairobi we recruited 
participants aged ≥11 years from the Nairobi Urban Health and Demographic 
Surveillance System (NUHDSS)10. The Nairobi sample consisted of 
predominantly young participants in order to minimize potential 
misclassification of malaria exposure as residency records were only 
available for those aged ≤16. In Kilifi we recruited participants age ≥11 years 
that had been lifelong residents of Chonyi and Junju locations within the Kilifi 
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Health and Demographic Surveillance System (KHDSS).11 Kilifi participants 
were predominantly of the Chonyi sub-tribe of the Mijikenda ethnic group. 
Study procedures have been previously described.12,13 Briefly participants 
were interviewed, followed by measurement of anthropometric indices. We 
then took a screening BP measurement in the clinic using an Omron™ M10-
IT sphygmomanometer followed by 24-hour ABPM using an Arteriograph24™ 
device. Approximately 10ml of blood was drawn from each participant. All 
laboratory tests except for full blood counts of subjects recruited in Nairobi 
were performed at the KEMRI-Wellcome Trust Research Programme 
laboratories in Kilifi, Kenya. We genotyped for SCT and the common African 
form of D+thalassemia by PCR as described in detail previously.14 
Statistical methods 
A detailed pre-specified analytical plan is presented in the supplementary 
appendix. Separate but identical analyses were conducted for residents of 
Nairobi and Kilifi. We restricted analysis to subjects with ABPM data that met 
either of two criteria for completeness as defined by the International 
Database of Ambulatory blood pressure in relation to Cardiovascular 
Outcomes (IDACO) study15 and the European Society of Hypertension16 
respectively. IDACO criteria require ≥ 10 daytime (1000-2000 hrs) and ≥ 5 
nighttime (0000-0600 hrs) readings.15 ESH criteria require ≥20 daytime (0900 
-2100 hrs) and ≥7 nighttime (0100-0600 hrs) readings.16 The respective time 
periods were used to determine average daytime and nighttime BPs. 24-hour 
BP averages were calculated using all available readings. We predicted that 
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the more precise measurements obtained in the smaller group of subjects 
meeting the more stringent ESH criteria would provide a more accurate 
estimate of the effect sizes if present, but with lower precision compared to 
that obtained using the higher numbers of participants meeting IDACO 
criteria. Prevalent hypertension was diagnosed using previously published 
ABPM cut-offs.16,17 
Summary statistics computed included means, medians and proportions as 
appropriate. We used F2 test and Student’s t-test as appropriate to compare 
variables in individuals with and without SCT. Hardy-Weinberg equilibrium 
was evaluated using F2 test. We performed linear regression to determine 
whether sickle and D+thalassemia genotype separately predicted ABPM 
measures with age, sex and estimated glomerular filtration rate (eGFR) 
specified as a priori covariates. As D+thalassemia modifies the protective 
effect of SCT against malaria8, we tested for statistical interaction between 
these two genes in linear regression models of BP. Logistic regression 
models with similar covariates to those used in the linear regressions were 
used to assess whether SCT and D+thalassemia influenced the odds of ABPM 
diagnosed prevalent hypertension. We repeated the above models, applying 
weights derived from the WHO standard population to compute age-
standardized differences. Pre-specified sub group analyses included 
stratification by sex and 5 age categories and exclusion of participants taking 
anti-hypertensive medication. All analyses were conducted using Stata™ 
Version 12 software (College Station, Texas). We additionally checked 
publicly available databases of GWAS studies for any reported associations 
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(at p <0.05) between SCT and BP among populations that had not been 
exposed to malaria. AOE and JAGS had access to all the study data. AOE 
performed all the statistical analyses.  
The Kenya Medical Research Institute’s Ethical Review Committee approved 
the study. Written informed consent and assent where appropriate was 
obtained from study participants.  
RESULTS 
In Kilifi, we invited 2,790 randomly selected individuals from 9,543 eligible 
persons to participate in the study (Figure 6-1). Study participants (N=2,371) 
were slightly younger than the eligible population (mean age 39 years vs 40 
years, p=0.03), with a higher proportion of men (46% versus 38% p<0.001). 
Individuals who did not consent were on average 9 years older (95% CI 6-13), 
but with a similar sex distribution (54% female) to those that consented. 
Individuals with homozygous sickle cell disease (n=5) were excluded from 
analyses. Complete data were available for 1986 individuals meeting IDACO 
criteria and 1136 meeting ESH criteria (Figure 6-1). None of the participants 
were previously aware of their genetic status. SCT was present in 396 (20%) 
of subjects while 1337 (67%) subjects carried at least 1 D+thalassemia 
mutation, equally distributed in those with and without SCT (69% vs 67%, 
p=0.5). There was no departure from Hardy-Weinberg equilibrium for both 
SCT (p=0.5) and D+thalassemia (p=0.8). The proportion of subjects with 
acceptable ABPM data did not differ by genotype. Participants with 
acceptable ABPM data were older than those with poor quality data (mean +3 
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years [CI 0.1–6, p=0.06] when using IDACO criteria and +4 years [CI 2-6, 
p<0.001] when using ESH criteria). Age standardized 24-hour BP±SD was 
125±15 mmHg systolic and 70±10 mmHg diastolic. Mean 24-hour Pulse 
Wave Velocity (PWV)±SD was 8.2±1.4 ms-1.   
Table 6-1 displays the characteristics of study participants by SCT. As 
expected, mean eGFR was significantly lower in participants with SCT in both 
Kilifi and Nairobi (112±37 mls/min/1.73m2 vs 116±36, p=0.027). Mean HbA1c 
levels were significantly higher in subjects with SCT, this difference persisted 
after controlling for age, sex and blood glucose levels (+0.15% in SCT CI 
0.09-0.24, p<0.001). Similar differences in HbA1c and eGFR were observed 
when comparing participants with homozygous D+thalassemia versus normal 
(Supplementary Table S1). 
Unadjusted summary and age-stratified comparisons of ABPM measures by 
SCT in Kilifi are presented in Supplementary Tables S16-S21. 24-hour SBP 
was slightly reduced in SCT overall; 127±18 mmHg in non-SCT versus 
126±18 in SCT, p=0.3911 (Supplementary Table S17), with larger differences 
observed in women (Supplementary Table S18, S19). 
Table 6-2 displays the effects of SCT on ABPM measures in Kilifi and Nairobi 
separately when adjusting for age, sex and eGFR. In Kilifi, SCT was 
associated with a –1.4 mm Hg (CI –3.2-0.4,p=0.1) reduction in 24-hour SBP 
(IDACO criteria) and –2.4 mm Hg (CI –4.7to –0.1, p=0.037) reduction in 24-
hour SBP when using ESH criteria. Inclusion of an interaction term between 
SCT and D+thalassemia did not improve any of the models (LR test p=0.9 and 
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p=0.8 respectively). There was statistically significant interaction with age 
category (LR test p=0.0003). Age stratified analyses (Table 6-3) revealed a 
numerically negative relationship between SCT and SBP for nearly all age 
categories regardless of ABPM quality criteria used, with the 25-39 years and 
55-70 years categories displaying the largest reductions when using IDACO 
and ESH criteria respectively. We did not detect a statistically significant 
interaction with sex (LR test p=0.21), although sex stratified analyses 
(supplementary Tables S2, S3) suggested a greater SCT associated BP 
reduction in women compared to men.  
Additional adjustment for HbA1c levels, which were unexpectedly higher in 
individuals with SCT (Table 6-1), increased the magnitude of BP reduction 
associated with SCT in Kilifi. (Supplementary Table S14) 
SCT in Kilifi was associated with reduced but statistically insignificant pulse 
wave velocity in a linear regression model adjusted for age, sex and egfr (–
0.03 ms-1, CI –0.14, 0.07, p=0.5). No such reduction was observed in Nairobi.  
Figure 6-2 displays the association between SCT and ABPM measures in age 
weighted regression analyses adjusting for sex and eGFR in Kilifi and Nairobi. 
SCT was associated with lowering of all ABPM measures in Kilifi regardless 
of whether IDACO or ESH criteria were used. Statistically significant 
differences in the linear regressions were only observed when using data that 
met ESH criteria; SCT was associated with –3.3mm Hg lower (CI –5.9 to –
0.8, p=0.01) 24hr SBP and –2.4mm Hg lower (CI –4.1 to –0.7, p=0.005) 24-
hour DBP. Nighttime measurements revealed greater differences compared 
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to day measurements, e.g SCT was associated with –4.3mm Hg lower 
nighttime SBP (CI –7.1 to –1.4, p=0.003) while the effect on daytime SBP was 
–2.7mm Hg (CI –5.2 to –0.01, p=0.049). The adjusted odds ratio for ABPM 
diagnosed hypertension in SCT was 0.72 (CI 0.54-0.94, p=0.018) when using 
IDACO criteria and 0.64 (CI 0.45-0.91, p=0.014) when using ESH criteria. As 
with the unweighted regressions, SCT associated BP reduction appeared to 
be greater in women than in men (Supplementary Figure 1).  
No significant differences by SCT/D+thalassemia status were observed among 
participants in Nairobi in any of the ABPM derived measures (Figure 6-2, 
Table 6-2, Supplementary Tables S2-S15). We have previously published 
results restricted to 11-17 year old Nairobi residents showing that SCT and 
D+thalassemia do not directly influence BP.12,13 
We checked the phenoscanner database for any reported associations (at p 
<0.1) between SCT and BP phenotypes from GWAS studies and found 
none.18  
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DISCUSSION 
We found that polymorphisms associated with partial protection against 
malaria were associated with significantly reduced BP and reduced odds of 
hypertension in Kilifi, an area with malaria transmission, but not in Nairobi, 
where there is no malaria transmission. We observed significant differences 
when using SCT, which confers a higher level of protection against malaria 
episodes than D+thalassemia. This suggests that increased risk of malaria in 
the past is associated with higher BP in the present day.  
The magnitude of BP reduction afforded by SCT was roughly similar to that 
attributed to use of a single anti-hypertensive agent,19,20 but several factors 
suggest that the actual effect of malaria on BP might be greater. Firstly, SCT 
is only associated with 50% reduction in incidence of non-severe malaria3 and 
90% reduction against severe malaria episodes21, and in Kilifi this relative 
protection wanes with age because of the development of immunity in those 
without SCT.22 Secondly, the protection offered by SCT against malaria is 
reduced in individuals with concurrent D+thalassemia8 who comprised 67% of 
our study sample, but we were not powered to detect the effect of this 
interaction on BP. In addition Kilifi has low to moderate malaria transmission.6 
Consequently the estimates obtained in this study likely represent an 
underestimate of the true effect of malaria on BP. 
One strength of this study was the use of ABPM, considered the reference 
standard for BP measurement in children and adults.23 By performing multiple 
repeated measurements ABPM gives more precise estimates of BP16 and we 
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observed the largest differences when using the more stringent ESH criteria 
as well as when using nighttime measurements, which occur under more 
standardized conditions. Nocturnal BP indices are more predictive of 
cardiovascular outcomes than daytime or 24-hour values24,25, and nighttime 
SBP is the single ABP variable most closely related with cardiovascular 
outcomes.16 The Mendelian randomization approach using genetic variants 
that are very strongly associated with malaria is another strength. Study 
participants in Kilifi were of the same ethnicity, minimizing the possibility of 
population stratification explaining the differences observed. An additional 
strength of the study is that we used prospectively collected health and 
demographic surveillance system (HDSS) records to ascertain residence in 
malaria/ non-malaria zones. 
Although Mendelian Randomization is a well-established method for inferring 
causality, several limitations need highlighting that could be resolved using 
longitudinal studies. As we did not have historical malaria data for the 
participants, we could not determine the number and/or severity of episodes 
required to chronically elevate BP. Malaria transmission has been changing 
over time along the Kenyan coast, with a marked reduction observed from the 
year 20007; longitudinal studies would help explain the interaction that we 
observed with age by revealing any cohort effects as a result of changing 
malaria transmission and also determine the age of onset of BP elevation 
following malaria infection. Lastly, longitudinal studies would also determine 
the effect of survivor bias due to differential malaria mortality between the 
genetic groups compared. 
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 We did not study the physiological mechanisms by which malaria could have 
elevated BP. A potential mechanism would be chronic inflammation induced 
by malaria.2 Inflammation has been associated with the development of 
hypertension.26,27 Malaria also causes stunting and malnutrition, which could 
influence BP2 but anthropometric indices such as BMI and MUAC, were 
similar in the groups we studied. Mechanistic studies are also required to 
explain the apparent sex differences that we observed in our study. SCT may 
protect against malaria in pregnancy28, which has been associated with 
gestational hypertensive disorders that place women at risk of chronic 
hypertension. CD4+ and CD8+ T-cells, which play a role in responses to 
malaria29 as well as partially explain sex differences in hypertension30, could 
possibly mediate an interaction with sex. An additional but unlikely 
mechanism leading to BP elevation would be as a result of anti-malarial 
treatment given, but none of the commonly used anti-malarial drugs is known 
to cause long term elevation of BP. Elucidating the mechanisms leading to 
malaria associated BP elevation could inform the design of novel therapies for 
the treatment or prevention of hypertension. 
While we showed that SCT does not influence BP in the absence of malaria 
by studying subjects in Nairobi, the study population there was significantly 
younger than that in Kilifi. Age-standardized comparisons however showed 
that SCT was associated with lower BP only in Kilifi. Comparisons in the 11-
25 year age groups at both sites where we had the best statistical power to 
detect differences revealed a numerically lower BP associated with SCT in 
Kilifi with no such signal detected in Nairobi. Two possible explanations for 
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our inability to detect a statistically significant lower BP associated with SCT 
in Kilifi in the under 25 age category are: (1) these subjects experienced less 
malaria than older cohorts, (2) increased BP due to childhood malaria 
exposure may manifest at older ages. Several other studies that had older 
participants also strongly suggest that SCT does not directly influence BP. 
Naik et al in a study demonstrating increased risk of kidney disease in SCT 
among 15,975 African Americans observed no difference in baseline BP 
based on SCT. Liem et al in an analysis of 1995 African Americans followed 
up for 25 years found no difference in incident hypertension based on SCT.31 
In addition large GWAS studies conducted in adults have not reported SCT 
influencing BP at any significance level as confirmed by our query of the 
PhenoScanner database.18,32,33 For our interpretation to be invalidated, SCT 
or loci in linkage disequilibrium would have to be associated with a large 
reduction in BP that is only detectable in adult life. This combination of factors 
is highly unlikely because (1) none of the loci in the Bantu/CAR haplotype that 
is predominant among individuals with SCT in Kilifi has been associated with 
BP traits, (2) BP differences e.g. between racial groups are detectable in 
childhood/adolescence34, and we did not observe this in the malaria 
unexposed (Nairobi) cohort; and (3) most genetic polymorphisms influencing 
BP tend to have very small effects, making it unlikely that direct effects SCT 
could explain the differences that we observed.  
In summary, we have demonstrated that exposure to malaria in childhood is 
associated with higher BP in adult life. One implication is that malaria 
elimination would lead to health benefits beyond those currently described. In 
                                         
 157 
addition, elucidating the mechanisms leading to BP elevation as a result of 
malaria infection could yield new therapeutic options for hypertension.   
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65 
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4 
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4 
21 
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4 
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H
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–3.9 
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–3.9 
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–5.7 
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–2.7 
–8.6,3.1 
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126 
1 
–6.5,8.4 
0.2 
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N
airobi 
 
 
N
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al 
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H
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us 
n=375 
 
N
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H
eterozygous 
n=306 
 
H
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n=63 
C
haracteristic 
 
n 
%
 
 
n 
%
 
 
n 
%
 
 
n 
%
 
 
n 
%
 
 
n 
%
 
Age 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11-24y 
 
285 
44 
 
449 
45 
 
162 
33 
 
354 
77 
 
236 
77 
 
50 
81 
25-39y 
 
50 
8 
 
92 
9 
 
28 
7 
 
33 
7 
 
14 
5 
 
1 
2 
40-55y 
 
134 
20 
 
170 
17 
 
75 
20 
 
30 
7 
 
26 
9 
 
5 
8 
>55y 
 
185 
28 
 
292 
29 
 
110 
29 
 
32 
7 
 
30 
10 
 
5 
8 
Fem
ale 
 
368 
56 
 
512 
51 
 
205 
55 
 
223 
49 
 
165 
54 
 
33 
53 
Sm
oker 
 
55 
9 
 
84 
8 
 
28 
8 
 
11 
2 
 
8 
3 
 
3 
5 
Previously diagnosed 
hypertensive 
 
91 
14 
 
127 
14 
 
37 
16 
 
43 
9 
 
30 
10 
 
4 
6 
O
n anti-hypertensive 
m
edication 
 
16 
2 
 
25 
3 
 
8 
2 
 
5 
1 
 
6 
2 
 
1 
2 
 
 
m
ean 
sd 
 
m
ean 
sd 
 
m
ean 
sd 
 
m
ean 
sd 
 
m
ean 
sd 
 
m
ean 
sd 
successful BP
 
inflations 
 
44 
10 
 
45 
10 
 
45 
10 
 
50 
9 
 
50 
8 
 
52 
8 
BM
I kg/m
2 
 
21 
4 
 
21 
4 
 
21 
4 
 
20 
4 
 
20 
4 
 
20 
4 
H
bA1c 
 
5.0 
0.8 
 
5.1 
0.6 
 
5.2 0.6 
 
5.2 
1 
 
5.4 
1 
 
5.6 
1.4 
eG
FR
 
 
117 
44 
 
116 
38 
 
111 
38 
 
117 
24 
 
115 
24 
 
117 
20 
U
AC
R
 
 
3 
5.8 
 
3.9 
17 
 
3.9 
15 
 
1.5 
2.3 
 
1.2 
2.3 
 
0.9 
1.9 
U
rine sodium
 
 
116 
51 
 
117 
60 
 
121 
53 
 
129 
75 
 
126 
55 
 
119 
50 
U
rine potassium
 
 
57 
42 
 
61 
41 
 
65 
43 
 
48 
32 
 
45 
30 
 
41 
23 
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B
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ESH
 C
riteria 
 
ID
AC
O
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riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=659) 
 
 (N
=275) 
 
(N
=1046) 
 
(N
=399) 
AB
PM
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easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–3.7  
–7.1, –0.4 
0.03  
–0.2 
–4.6, 4.2 
0.9 
 
–1.9  
–4.5, 0.6 
0.1 
 
–1.3 
 –5.0, 2.3 
0.5 
24 hour D
BP
 
–1.9  
–2.8, 0.1 
0.08  
0.9 
–2.1, 3.8 
0.6 
 
–0.7 
–2.3, 0.8 
0.4 
 
0.1 
–2.3, 2.4 
1 
N
ighttim
e SB
P
 
–4.3  
–8.0, –0.6 
0.02  
0.6 
–3.9, 5.2 
0.8 
 
–2.0 
–4.9, 0.8 
0.2 
 
–2.1 
–5.8, 1.7 
0.3 
N
ighttim
e D
B
P
 
–2.0  
–4.2, 0.1 
0.07  
1.6 
–1.5, 4.7 
0.3 
 
–0.7 
–2.4, 1.0 
0.4 
 
–0.3 
–2.8, 2.1 
0.8 
D
aytim
e SB
P
 
–3.1  
–6.4, 0.2 
0.07  
–1.3 
–5.9, 3.4 
0.6 
 
–1.4 
–3.9, 1.2 
0.3 
 
–2.4 
–6.3, 1.6 
0.2 
D
aytim
e D
BP
 
–1.6  
–3.9, 0.6 
0.2  
–0.1 
–3.4, 3.2 
0.9 
 
–0.8 
–2.6, 0.9 
0.3 
 
–1.1 
–3.8, 1.6 
0.4 
 SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
Linear regression m
odels adjusted for age, sex and estim
ated glom
erular filtration rate 
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ESH
 C
riteria 
 
ID
AC
O
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riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=473) 
 
 (N
=241) 
 
(N
=919) 
 
(N
=378) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–0.7  
–3.7, 2.3 
0.6  
1.8 
–2.7, 6.3 
0.4 
 
–0.8  
–3.2, 1.7 
0.5 
 
1.3 
 –2.2, 5.0 
0.5 
24 hour D
BP
 
–0.7  
–2.7, 1.3 
0.5  
0.8 
–2.3, 3.8 
0.6 
 
–0.7 
–2.3, 0.8 
0.4 
 
0.3 
–2.1,2.6 
0.8 
N
ighttim
e SB
P
 
–1.6  
–5.1, 1.8 
0.4  
1.4 
–3.3, 6.2 
0.6 
 
–1.1 
–3.7, 1.6 
0.4 
 
0.7 
–3.1,4.5 
0.7 
N
ighttim
e D
B
P
 
–1.4  
–3.6, 0.8 
0.2  
0.3 
–3.0, 3.7 
0.9 
 
–1.1 
–2.8, 0.6 
0.2 
 
–0.6 
–3.1, 2.0 
0.6 
D
aytim
e SB
P
 
–0.3  
–3.4, 2.9 
0.9  
1.5 
–3.3, 6.3 
0.5 
 
–0.4 
–3.0, 2.2 
0.8 
 
1.7 
–2.1, 5.6 
0.4 
D
aytim
e D
BP
 
–0.2  
–2.4,2 
0.9  
0.9 
–2.5, 4.2 
0.6 
 
–0.4 
–2.1, 1.4 
0.7 
 
1.1 
–1.6, 3.8 
0.4 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
Linear regression m
odels adjusted for age, sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S4. Effect of A
lpha thalassem
ia on Am
bulatory blood pressure indices in K
ilifi and N
airobi 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=1125) 
 
 (N
=514) 
 
(N
=1961) 
 
(N
=771) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–0.5  
–1.8, 0.9 
0.5  
1.6 
–0.2, 3.4 
0.09 
 
–0.9  
–1.9, 0.2 
0.1 
 
0.7 
–0.7, 2.2 
0.3 
24 hour D
BP
 
–0.2 
–1.1, 0.7 
0.7  
1.0 
–0.2, 2.2 
0.1 
 
–0.3 
–1.0, 0.3 
0.3 
 
0.6 
–0.4, 1.5 
0.3 
N
ighttim
e SB
P
 
–0.5  
–2.0,1.0 
0.5  
0.7 
–2.5, 4.0 
0.7 
 
–0.6 
–1.8, 0.5 
0.3 
 
0.7 
–0.8, 2.3 
0.3 
N
ighttim
e D
B
P
 
–0.2  
–1.1,0.7 
0.7  
0.6 
–1.7, 2.9 
0.6 
 
–0.3 
–1.0, 0.4 
0.4 
 
0.7 
–0.3, 1.7 
0.2 
D
aytim
e SB
P
 
–0.4  
–1.7, 1.0 
0.6  
0.8 
–1.1, 2.7 
0.4 
 
–0.9 
–2.0, 0.1 
0.08 
 
0.1 
–1.5, 1.7 
0.9 
D
aytim
e D
BP
 
–0.1  
–1.0,0.8 
0.8  
0.5 
–0.9, 1.8 
0.5 
 
–0.3 
–1.0, 0.4 
0.4 
 
0.1 
–1.0, 1.2 
0.9 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
Linear regression m
odels adjusted for age, sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S5. Effect of A
lpha thalassem
ia on Am
bulatory blood pressure indices in W
om
en in K
ilifi and N
airobi 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=653) 
 
 (N
=275) 
 
(N
=1044) 
 
(N
=395) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–1.0  
–2.8, 0.9 
0.3  
1.1 
–1.3, 3.5 
0.4 
 
–1.2  
–2.6, 0.2 
0.08 
 
0.7 
–1.4, 2.7 
0.5 
24 hour D
BP
 
–0.7 
–1.8, 0.5 
0.3  
0.9 
–0.7, 2.5 
0.3 
 
–0.6 
–1.5, 0.2 
0.2 
 
0.3 
–1.0, 1.7 
0.6 
N
ighttim
e SB
P
 
–0.9  
–2.9,1.2 
0.4  
0.7 
–1.8, 3.2 
0.6 
 
–0.6 
–1.8, 0.5 
0.3 
 
0.7 
–0.8, 2.3 
0.3 
N
ighttim
e D
B
P
 
–0.5  
–1.7,0.7 
0.4  
0.9 
–0.9, 2.6 
0.3 
 
–0.3 
–1.0, 0.4 
0.4 
 
0.7 
–0.3, 1.7 
0.2 
D
aytim
e SB
P
 
–0.9  
–2.8, 1.0 
0.3  
0.3 
–2.2, 2.8 
0.8 
 
–1.2 
–2.5, 0.2 
0.1 
 
–0.04 
–2.2, 2.2 
1 
D
aytim
e D
BP
 
–0.6  
–1.8, 0.7 
0.4  
0.5 
–1.3, 2.3 
0.6 
 
–0.5 
–1.4, 0.4 
0.3 
 
–0.1 
–1.6, 1.4 
0.9 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
Linear regression m
odels adjusted for age, sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S6. Effect of A
lpha thalassem
ia on Am
bulatory blood pressure indices in M
en in K
ilifi and N
airobi 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=472) 
 
 (N
=239) 
 
(N
=917) 
 
(N
=376) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
0.3 
–1.6, 2.2 
0.8  
2.2 
–0.5, 4.9 
0.1 
 
–0.4  
–1.9, 1.1 
0.6 
 
0.7 
–1.4, 2.9 
0.5 
24 hour D
BP
 
0.5 
–0.7, 1.7 
0.4  
1.2 
–0.6, 3.0 
0.2 
 
–0.01 
–0.9, 0.9 
1 
 
0.7 
–0.6, 2.1 
0.3 
N
ighttim
e SB
P
 
0.03  
–2.1, 2.2 
1  
3.0 
0.2, 5.9 
0.04 
 
–0.1 
–1.7, 1.5 
0.9 
 
0.7 
–0.8, 2.3 
0.3 
N
ighttim
e D
B
P
 
0.2  
–1.2, 1.6 
0.8  
2.3 
0.3, 4.3 
0.03 
 
–0.01 
–1.0, 1.0 
1 
 
0.7 
–0.3, 1.7 
0.2 
D
aytim
e SB
P
 
0.4  
–1.6, 2.3 
0.7  
1.3 
–1.6, 4.2 
0.4 
 
–0.7 
–2.2, 0.9 
0.4 
 
0.2 
–2.1, 2.4 
0.8 
D
aytim
e D
BP
 
0.6  
–0.8, 1.9 
0.4  
0.5 
–1.5, 2.5 
0.6 
 
–0.09 
–1.1, 1.0 
0.9 
 
0.3 
–1.3, 1.8 
0.8 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
Linear regression m
odels adjusted for age, sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S7.  Age specific effects of SC
T on B
P in N
airobi participants  
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24 hour m
easures 
 
N
ight tim
e m
easures 
 
D
aytim
e m
easures 
ESH
 
C
riteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age, yr 
N
 
SB
P
 
C
I 
D
BP
 
C
I 
 
SB
P
 
C
I 
D
BP
 
C
I 
 
SB
P
 
C
I 
D
BP
 
C
I 
11-24 
389 
0.4 
–2.5, 3.4 
0.7 
–1.2, 2.6 
 
1.1 
–1.9, 4 
0.8 
–1.2, 2.8 
 
–0.5 
–3.8, 2.7 
0.1 
–2.2, 2.3 
25-39 
31 
9.7 
–3.6, 23 
–1.1 
–9.3, 7.1 
 
3.1 
–9.2, 16 
2.1 
–6.2, 11 
 
0.2 
–11, 12 
–3.2 
–13, 6.0 
40-54 
50 
3.8 
–12, 20 
–3.3 
–14, 7.3 
 
–1.8 
–21, 17 
–5.1 
–18, 8 
 
6.9 
–9.3, 23 
2.7 
–9.2, 15 
>55 
46 
5.8 
–18, 30 
6.7 
–9.0, 22 
 
9.6 
–15, 34 
12 
–5.3, 29 
 
4.5 
–19, 28 
5.0 
–11, 21 
ID
AC
O
 
C
riteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age, yr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age, yr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11-24 
607 
–0.5 
–2.9, 2.0 
0.1 
–1.5, 1.6 
 
–1 
–3.4, 1.5 
–0.6 
–2.3, 1.1 
 
–0.9 
–3.7, 1.8 
–0.3 
–2.1, 1.6 
25-39 
42 
–2.9 
–14, 8.6 
–2.9 
–11, 5.0 
 
–1.3 
–13, 11 
–0.3 
–8.4, 7.8 
 
–3.8 
–16, 8.4 
–4.7 
–14, 4.6 
40-54 
65 
2.2 
–10, 15 
–2.1 
–11, 6.7 
 
–2.1 
–16, 12 
–5.4 
–15, 4.0 
 
4.6 
–8.0, 17 
1.1 
–8.5, 11 
>55 
63 
4.6 
–14, 23 
4.1 
–7.5, 16 
 
8.2 
–11, 27 
7.7 
–4.4, 20 
 
1.1 
–18, 20 
1.8 
–10, 14 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
Linear regression m
odels adjusted for age, sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S8. Effect of SC
T on A
m
bulatory blood pressure indices in K
ilifi and N
airobi-population w
eighted analyses 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=1127) 
 
 (N
=527) 
 
(N
=1965) 
 
(N
=788) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–3.3  
–5.9, –0.8 
0.01  
1.7 
–4.5, 7.9 
0.6 
 
–1.8  
–3.8, 0.2 
0.08 
 
0.3 
 –4.7, 5.3 
0.9 
24 hour D
BP
 
–2.4  
–4.1, –0.7 
0.01  
1.2 
–2.9, 5.3 
0.6 
 
–1.1 
–2.4, 0.2 
0.1 
 
–0.3 
–3.5, 3.0 
0.9 
N
ighttim
e SB
P
 
–4.3  
–7.1, –1.4 
0.003  
1.7 
–4.7, 8.1 
0.6 
 
–2.1 
–4.3, 0.1 
0.06 
 
–0.2 
–5.6, 5.2 
0.9 
N
ighttim
e D
B
P
 
–2.9  
–4.7, –1.1 
0.002  
1.9 
–2.6, 6.5 
0.4 
 
–1.3 
–2.7, 0.2 
0.08 
 
–0.2 
–4, 3.6 
0.9 
D
aytim
e SB
P
 
–2.6  
–5.2, –0.01 
0.05  
1.4 
–5.0, 7.9 
1 
 
–1.2 
–3.2, 0.8 
0.2 
 
0.1 
–5, 5.1 
1 
D
aytim
e D
BP
 
–1.9  
–3.7, –0.1 
0.04  
0.9 
–3.4, 5.1 
0.7 
 
–0.9 
–2.3, 0.5 
0.2 
 
–0.3 
–3.7, 3.1 
0.9 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
W
H
O
 standard population w
eighted linear regression m
odels adjusted for sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S9. Effect of SC
T on A
m
bulatory blood pressure indices in W
om
en in K
ilifi and N
airobi-population w
eighted analyses 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=659) 
 
 (N
=275) 
 
(N
=1046) 
 
(N
=399) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–4.5  
–8.2, –0.9 
0.02  
2.8 
–6.9, 13 
0.6 
 
–2.0  
–4.7, 0.7 
0.3 
 
1.6 
–7.5, 11 
0.7 
24 hour D
BP
 
–2.8  
–5.1, –0.4 
0.02  
3.2 
–3.3, 9.6 
0.3 
 
–0.9 
–2.7, 0.9 
0.3 
 
1.6 
–4.2, 7.4 
0.6 
N
ighttim
e SB
P
 
–5.3  
–9.3, –1.3 
0.01  
3.5 
–6.4, 13 
0.5 
 
–2.1 
–5.1, 1 
0.2 
 
1.4 
–7.7, 11 
0.8 
N
ighttim
e D
B
P
 
–3.3  
–5.8, –0.8 
0.01  
4.2 
–2.7, 11 
0.2 
 
–1 
–3.0, 1.0 
0.3 
 
2 
–4.0, 7.9 
0.5 
D
aytim
e SB
P
 
–3.7  
–7.3, –0.1 
0.05  
1.5 
–8.6, 12 
0.8 
 
–1.7 
–4.3, 1.0 
0.2 
 
0.4 
–9.0, 9.9 
0.9 
D
aytim
e D
BP
 
–2.3  
–4.7, 0.2 
0.07  
1.7 
–5, 8.4 
0.6 
 
–1.0 
–2.8, 0.8 
0.3 
 
0.4 
–6.0, 6.8 
0.9 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
W
H
O
 standard population w
eighted linear regression m
odels adjusted for sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S10. Effect of SC
T on A
m
bulatory blood pressure indices in M
en in K
ilifi and N
airobi-population w
eighted analyses 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=473) 
 
 (N
=241) 
 
(N
=919) 
 
(N
=378) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–1.6  
–5.0, 1.9 
0.4  
3.6 
–2.9, 10 
0.3 
 
–1.5  
–4.1, 1.1 
0.3 
 
3.0 
–2.2, 8.1 
0.3 
24 hour D
BP
 
–1.8  
–4.2, 0.7 
0.2  
2.3 
–2.3, 6.9 
0.3 
 
–1.4 
–3.2, 0.4 
0.1 
 
1.7 
–3.0, 6.4 
0.5 
N
ighttim
e SB
P
 
–3.3  
–7.7, 1.0 
0.1  
1.9 
–4.9, 8.8 
0.6 
 
–2.6 
–5.6, 0.4 
0.09 
 
1.2 
–4.1, 6.5 
0.7 
N
ighttim
e D
B
P
 
–2.6  
–5.5, 0.3 
0.08  
2.7 
–3.0, 8.5 
0.3 
 
–2.1 
–4.1, –0.2 
0.03 
 
1.1 
–4.5, 6.7 
0.7 
D
aytim
e SB
P
 
–0.5  
–4.2, 3.2 
0.8  
4.9 
–1.9, 12 
0.2 
 
–0.4 
–3.2, 2.5 
0.8 
 
4.3 
–1.7, 10 
0.2 
D
aytim
e D
BP
 
–1.1  
–3.8, 1.6 
0.4  
2.9 
–1.1, 7.0 
0.2 
 
–0.6 
–2.8, 1.6 
0.6 
 
2.7 
–1.7, 7 
0.3 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
W
H
O
 standard population w
eighted linear regression m
odels adjusted for sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S11. Effect of Alpha thalassem
ia on Am
bulatory blood pressure indices in K
ilifi and N
airobi-population w
eighted analyses 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=1125) 
 
 (N
=514) 
 
(N
=1961) 
 
(N
=771) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–0.9  
–2.3, 0.7 
0.3  
2.4 
–3.1, 7.9 
0.4 
 
–1.4  
–2.5, –0.3 
0.01 
 
0.7 
–4.3, 5.6 
0.8 
24 hour D
BP
 
–0.3 
–1.4, 0.7 
0.6  
1.6 
–2.1, 5.3 
0.4 
 
–0.6 
–1.4, 0.1 
0.1 
 
0.3 
–2.9, 3.5 
0.9 
N
ighttim
e SB
P
 
–1.0  
–2.7, 0.7 
0.2  
2.0 
–4.2, 8.1 
0.5 
 
–1.4 
–2.7, –0.2 
0.03 
 
0.5 
–5.0, 6 
0.9 
N
ighttim
e D
B
P
 
–0.7  
–1.8, 0.5 
0.2  
1.9 
–2.1, 6.0 
0.4 
 
–0.8 
–1.6, 0.04 
0.06 
 
0.5 
–2.9, 4.0 
0.8 
D
aytim
e SB
P
 
–0.8  
–2.2, 0.8 
0.3  
1.8 
–3.2, 6.9 
0.5 
 
–1.5 
–2.7, –0.4 
0.01 
 
–0.01 
–4.7, 4.7 
1 
D
aytim
e D
BP
 
–0.1  
–1.2, 1.0 
0.9  
1.1 
–2.4, 4.7 
0.5 
 
–0.5 
–1.4, 0.3 
0.2 
 
–0.3 
–3.5, 3.0 
0.9 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
W
H
O
 standard population w
eighted linear regression m
odels adjusted for sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S12. Effect of Alpha thalassem
ia on Am
bulatory blood pressure indices in W
om
en in K
ilifi and N
airobi-population 
w
eighted analyses 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=653) 
 
 (N
=275) 
 
(N
=1044) 
 
(N
=395) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–0.8  
–2.8, 1.3 
0.5  
2.0 
–5.4, 9.5 
0.6 
 
–1.5  
–3.0, 0.04 
0.06 
 
0.7 
–6, 7.3 
0.8 
24 hour D
BP
 
–0.5  
–1.8, 0.8 
0.4  
1.4 
–3.5, 6.3 
0.6 
 
–0.8 
–1.7, 0.2 
0.1 
 
–0.3 
–4.5, 4.0 
0.9 
N
ighttim
e SB
P
 
–0.5  
–2.6, 1.6 
0.7  
0.7 
–7.5, 8.9 
0.9 
 
–1.5 
–3.2, 0.2 
0.08 
 
–0.1 
–7.3, 7.0 
1 
N
ighttim
e D
B
P
 
–0.4  
–1.8, 1 
0.5  
1.2 
–4.2, 6.7 
0.7 
 
–0.8 
–1.9, 0.2 
0.1 
 
–0.1 
–4.7, 4.5 
1 
D
aytim
e SB
P
 
–0.9  
–3.0, 1.1 
0.4  
1.1 
–5.8, 7.9 
0.8 
 
–1.5 
–3, –0.004 
0.05 
 
–0.6 
–7.0, 5.7 
0.9 
D
aytim
e D
BP
 
–0.4  
–1.8, 0.9 
0.5  
0.8 
–4.0, 5.5 
0.7 
 
–0.6 
–1.6, 0.4 
0.2 
 
–1.2 
–5.5, 3.1 
0.6 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
W
H
O
 standard population w
eighted linear regression m
odels adjusted for sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S13. Effect of Alpha thalassem
ia on Am
bulatory blood pressure indices in M
en in K
ilifi and N
airobi-population w
eighted 
analyses 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=472) 
 
 (N
=235) 
 
(N
=917) 
 
(N
=371) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–0.7  
–2.8, 1.5 
0.6  
4.1 
–0.1, 8.3 
0.06 
 
–1.5  
–3.1, 0.2 
0.09 
 
2.1 
–1.7, 5.9 
0.3 
24 hour D
BP
 
0.3 
–1.5, 2.0 
0.8  
2.6 
–0.4, 5.7 
0.09 
 
–0.4 
–1.7, 0.9 
0.5 
 
1.4 
–1.3, 4.1 
0.3 
N
ighttim
e SB
P
 
–1.7  
–4.5, 1.1 
0.2  
4.1 
–0.8, 8.9 
0.1 
 
–1.9 
–3.9, 0.05 
0.06 
 
2.3 
–2.1, 6.7 
0.3 
N
ighttim
e D
B
P
 
–0.9  
–2.9, 1.2 
0.4  
3.4 
–0.06, 6.9 
0.05 
 
–1.1 
–2.5, 0.4 
0.1 
 
1.7 
–1.4, 4.8 
0.3 
D
aytim
e SB
P
 
–0.1  
–2.3, 2.1 
0.9  
3.9 
–0.4, 8.1 
0.08 
 
–1.4 
–3.2, 0.4 
0.1 
 
2.2 
–1.5, 5.9 
0.2 
D
aytim
e D
BP
 
0.8 
–1, 2.5 
0.4  
2.0 
–1.2, 5.2 
0.2 
 
–0.3 
–1.7, 1.1 
0.7 
 
1.2 
–1.6, 4.0 
0.4 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
W
H
O
 standard population w
eighted linear regression m
odels adjusted for sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=992) 
 
 (N
=516) 
 
(N
=1702) 
 
(N
=775) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–3.0  
–5.4, –0.6 
0.01  
0.5 
–2.6, 3.6 
0.7 
 
–2.1  
–4.0, –0.2 
0.03 
 
–0.2 
 –2.8, 2.4 
0.9 
24 hour D
BP
 
–1.9  
–3.4, –0.3 
0.02  
0.5 
–1.6, 2.6 
0.7 
 
–1.1 
–2.3, 0.06 
0.06 
 
–0.05 
–1.7, 1.6 
1 
N
ighttim
e SB
P
 
–3.6  
–6.2, –0.9 
0.008  
0.7 
–2.5, 4.0 
0.7 
 
–2.2 
–4.2, –0.2 
0.03 
 
–0.9 
–3.6, 1.7 
0.5 
N
ighttim
e D
B
P
 
–2.4  
–4.0, –0.7 
0.005  
0.6 
–1.7, 2.8 
0.6 
 
–1.4 
–2.6, –0.1 
0.04 
 
–0.6 
–2.4, 1.1 
0.5 
D
aytim
e SB
P
 
–2.7  
–5.1, –0.2 
0.03  
–0.1 
–3.4, 3.2 
1 
 
–1.8 
–3.8, 0.1 
0.07 
 
–0.5 
–3.2, 2.3 
0.7 
D
aytim
e D
BP
 
–1.5  
–3.1, 0.2 
0.08  
0.1 
–2.2, 2.4 
0.9 
 
–1.0 
–2.3, 0.3 
0.1 
 
–0.2 
–2.1, 1.7 
0.8 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
Linear regression m
odels adjusted for age, sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
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B
PM
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ESH
 C
riteria 
 
ID
AC
O
 C
riteria 
 
Kilifi 
 
N
airobi 
 
Kilifi  
 
N
airobi  
 
 (N
=1092) 
 
 (N
=508) 
 
(N
=1918) 
 
(N
=765) 
AB
PM
 m
easure 
Effect,     
m
m
 H
g 
95%
 C
I p value  
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
 
Effect,     
m
m
 H
g 
95%
 C
I p value 
24 hour S
B
P
 
–2.5  
–4.8, –0.2 
0.03  
0.6 
–2.4, 3.7 
0.7 
 
–1.3  
–3.1, 0.5 
0.2 
 
–0.3 
 –2.8, 2.3 
0.8 
24 hour D
BP
 
–1.4  
–2.8, 0.1 
0.07  
0.6 
–1.5, 2.6 
0.8 
 
–0.7 
–1.8, 0.5 
0.3 
 
–0.02 
–1.7, 1.6 
1 
N
ighttim
e SB
P
 
–3.1  
–5.7, –0.6 
0.02  
0.9 
–2.3, 4.1 
0.6 
 
–1.5 
–3.4, 0.5 
0.1 
 
–0.9 
–3.5, 1.7 
0.5 
N
ighttim
e D
B
P
 
–1.8  
–3.3, –0.2 
0.03  
0.7 
–1.6, 2.9 
0.6 
 
–0.9 
–2.0, 0.3 
0.2 
 
–0.6 
–2.4, 1.2 
0.5 
D
aytim
e SB
P
 
–2.0  
–4.3, 0.4 
0.1  
–0.01 
–3.3, 3.3 
1 
 
–0.9 
–2.7, 0.9 
0.3 
 
–0.5 
–3.3, 2.2 
0.7 
D
aytim
e D
BP
 
–1.0  
–2.6, 0.6 
0.2  
0.1 
–2.2, 2.5 
0.9 
 
–0.6 
–1.8, 0.7 
0.4 
 
–0.2 
–2.1, 1.7 
0.9 
SB
P: S
ystolic blood pressure 
D
BP
: D
iastolic blood pressure 
Linear regression m
odels adjusted for age, sex and estim
ated glom
erular filtration rate 
Supplem
entary tables 
S16. U
nadjusted age specific Systolic and D
iastolic B
P by SC
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A
C
O
 C
riteria) 
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A
. A
ge specific systolic B
P
 by S
C
T in K
ilifi all (ID
A
C
O
) 
A
ge 
group 
N
 
%
 
SC
T 
24-hour S
ystolic B
P (S
D
) 
 
N
ighttim
e S
ystolic B
P (SD
) 
 
D
aytim
e systolic BP (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
879 
18 
119(12) 
119(13) 
0.8 
 
109(12) 
109(13) 
0.6 
 
127(13) 
127(14) 
0.7 
25-39  
165 
21 
123(14) 
120(13) 
0.3 
 
114(15) 
112(14) 
0.5 
 
130(15) 
128(13) 
0.4 
40-54
  
372 
20 
125(17) 
124(14) 
0.7 
 
118(18( 
115(15) 
0.3 
 
130(18) 
131(15) 
0.7 
55-69 
385 
20 
136(21) 
133(21) 
0.3 
 
130(24) 
127(23) 
0.4 
 
140(21) 
139(20) 
0.6 
≥70 
185 
24 
143(21) 
145(23) 
0.6 
 
140(24) 
141(27) 
0.9 
 
145(22) 
149(23) 
0.3 
A
ll 
1986 
20 
126(18) 
126(18) 
0.9 
 
118(20) 
118(21) 
1 
 
132(18) 
133(18) 
0.6 
    
B
. A
ge specific diastolic B
P
 by S
C
T in K
ilifi all (ID
A
C
O
) 
 A
ge 
group 
N
 
%
 
SC
T 
24-hour D
iastolic B
P (SD
) 
 
N
ighttim
e D
iastolic BP
 (SD
) 
 
D
aytim
e D
iastolic B
P (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
879 
18 
64(7) 
65(8) 
0.3 
 
57(8) 
58(8) 
0.3 
 
70(9) 
70(9) 
0.5 
25-39  
165 
21 
70(10) 
68(8) 
0.4 
 
64(10) 
63(9) 
0.6 
 
74(11) 
73(9) 
0.5 
40-54
  
372 
20 
72(12) 
71(10) 
0.3 
 
68(12) 
66(11) 
0.2 
 
76(13) 
75(11) 
0.4 
55-69 
385 
20 
76(13) 
75(13) 
0.4 
 
72(13) 
70(14) 
0.2 
 
80(14) 
79(13) 
0.6 
≥70 
185 
24 
78(13) 
79(15) 
0.6 
 
75(13) 
75(16) 
1 
 
80(14) 
82(15) 
0.3 
A
ll 
1986 
20 
70(12) 
70(12) 
0.7 
 
64(13) 
64(13) 
1 
 
74(12) 
74(12) 
0.7 
 
Supplem
entary tables 
S17. U
nadjusted age specific Systolic and D
iastolic B
P by SC
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 C
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A
. A
ge specific systolic BP
 by S
C
T in K
ilifi all (ES
H
) 
A
ge 
group 
N
 
%
 
SC
T 
24-hour S
ystolic B
P (S
D
) 
 
N
ighttim
e S
ystolic B
P (SD
) 
 
D
aytim
e systolic BP (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
478 
20 
119(11) 
119(13) 
0.7 
 
109(11) 
110(13) 
0.6 
 
126(12) 
126(13) 
0.9 
25-39  
84 
24 
124(16) 
119(12) 
0.2 
 
117(18) 
110(13) 
0.1 
 
130(16) 
125(13) 
0.3 
40-54
  
216 
21 
126(18) 
123(15) 
0.2 
 
120(19) 
115(16) 
0.1 
 
131(19) 
129(16) 
0.5 
55-69 
236 
21 
134(20) 
132(20) 
0.4 
 
130(23) 
126(21) 
0.3 
 
139(20) 
137(21) 
0.6 
≥70 
126 
23 
145(21) 
144(22) 
0.9 
 
143(27) 
141(26) 
0.7 
 
147(21) 
149(21) 
0.7 
A
ll 
1140 
21 
127(18) 
126(18) 
0.4 
 
120(21) 
118(20) 
0.3 
 
132(18) 
132(18) 
0.6 
  
B
. A
ge specific diastolic BP
 by S
C
T in K
ilifi all (ES
H
) 
A
ge 
group 
N
 
%
 
SC
T 
24-hour D
iastolic B
P (SD
) 
 
N
ighttim
e D
iastolic BP
 (SD
) 
 
D
aytim
e D
iastolic B
P (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
478 
20 
64(7) 
65(8) 
0.3 
 
58(7) 
59(8) 
0.3 
 
69(8) 
70(9) 
0.4 
25-39  
84 
24 
72(11) 
67(7) 
0.1 
 
67(12) 
61(8) 
0.05 
 
75(12) 
72(8) 
0.2 
40-54
  
216 
21 
74(12) 
71(10) 
0.07 
 
70(12) 
67(11) 
0.1 
 
77(13) 
73(11) 
0.08 
55-69 
236 
21 
76(13) 
75(13) 
0.4 
 
73(13) 
70(12) 
0.2 
 
79(13) 
79(13) 
0.8 
≥70 
126 
23 
78(12) 
80(14) 
0.6 
 
76(14) 
76(16) 
1 
 
81(13) 
83(13) 
0.3 
A
ll 
1140 
21 
71(12) 
70(11) 
0.5 
 
66(13) 
65(12) 
0.3 
 
75(12) 
74(12) 
0.9 
 
Supplem
entary tables 
S18. U
nadjusted age specific Systolic and D
iastolic B
P by SC
T in W
om
en in K
ilifi (ID
A
C
O
 C
riteria) 
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A
. A
ge specific systolic BP
 by S
C
T in K
ilifi w
om
en (ID
A
C
O
) 
A
ge 
group 
N
 
%
 
SC
T 
24-hour S
ystolic B
P (S
D
) 
 
N
ighttim
e S
ystolic B
P (SD
) 
 
D
aytim
e systolic BP (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
338 
16 
115(9) 
115(10) 
0.6 
 
106(10) 
105(11) 
0.6 
 
123(10) 
122(11) 
0.4 
25-39  
94 
26 
120(15) 
118(14) 
0.6 
 
112(16) 
111(16) 
0.8 
 
126(15) 
124(13) 
0.5 
40-54
  
279 
19 
123(17) 
122(14) 
0.7 
 
116(19) 
114(14) 
0.5 
 
129(18) 
129(15) 
0.9 
55-69 
250 
18 
134(20) 
131(22) 
0.4 
 
129(23) 
126(24) 
0.4 
 
138(19) 
137(21) 
0.6 
≥70 
97 
21 
143(23) 
143(21) 
1 
 
141(25) 
141(22) 
0.9 
 
144(23) 
146(23) 
0.9 
A
ll 
1058 
19 
125(19) 
124(18) 
0.6 
 
118(21) 
117(20) 
0.6 
 
130(18) 
130(18) 
0.8 
  
B
. A
ge specific diastolic BP
 by S
C
T in K
ilifi w
om
en (ID
A
C
O
) 
A
ge 
group 
N
 
%
 
SC
T 
24-hour D
iastolic B
P (SD
) 
 
N
ighttim
e D
iastolic BP
 (SD
) 
 
D
aytim
e D
iastolic B
P (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
338 
16 
63(7) 
63(8) 
0.8 
 
57(7) 
57(8) 
0.9 
 
68(8) 
69(8) 
0.9 
25-39  
94 
26 
68(10) 
67(9) 
0.6 
 
64(11) 
63(11) 
0.7 
 
72(11) 
71(9) 
0.6 
40-54
  
279 
19 
71(12) 
70(9) 
0.4 
 
67(12) 
66(10) 
0.4 
 
74(12) 
73(9) 
0.3 
55-69 
250 
18 
75(12) 
75(14) 
0.7 
 
72(13) 
71(14) 
0.5 
 
78(13) 
78(14) 
0.9 
≥70 
97 
21 
77(12) 
78(14) 
0.8 
 
74(12) 
76(13) 
0.6 
 
79(14) 
80(15) 
0.8 
A
ll 
1058 
19 
70(12) 
70(12) 
0.9 
 
65(13) 
65(13) 
1 
 
74(12) 
73(12) 
0.8 
  
Supplem
entary tables 
S19. U
nadjusted age specific Systolic and D
iastolic B
P by SC
T in w
om
en in K
ilifi (ESH
 C
riteria) 
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A
. A
ge specific systolic BP
 by S
C
T in K
ilifi w
om
en (E
S
H
) 
Age 
group 
N
 
%
 
SC
T 
24-hour S
ystolic B
P (S
D
) 
 
N
ighttim
e S
ystolic B
P (SD
) 
 
D
aytim
e systolic BP (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
215 
17 
115(9) 
114(8) 
0.6 
 
106(10) 
106(11) 
0.9 
 
122(10) 
121(8) 
0.5 
25-39  
49 
24 
122(18) 
114(13) 
0.2 
 
116(20) 
106(14) 
0.1 
 
126(18) 
120(13) 
0.3 
40-54
  
168 
23 
125(19) 
122(15) 
0.4 
 
119(20) 
115(15) 
0.2 
 
130(19) 
127(15) 
0.5 
55-69 
155 
19 
135(21) 
130(23) 
0.3 
 
130(23) 
124(23) 
0.2 
 
138(20) 
135(23) 
0.5 
≥70 
72 
15 
145(24) 
145(18) 
1 
 
143(28) 
144(22) 
0.9 
 
147(23) 
147(18) 
1 
A
ll 
659 
19 
126(20) 
123(18) 
0.1 
 
120(23) 
116(20) 
0.1 
 
131(19) 
128(18) 
0.2 
  
B
. A
ge specific diastolic BP
 by S
C
T in K
ilifi w
om
en (E
S
H
) 
 Age 
group 
N
 
%
 
SC
T 
24-hour D
iastolic B
P (SD
) 
 
N
ighttim
e D
iastolic BP
 (SD
) 
 
D
aytim
e D
iastolic B
P (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
215 
17 
63(6) 
63(7) 
0.9 
 
57(7) 
58(8) 
0.7 
 
68(7) 
68(8) 
0.9 
25-39  
49 
24 
70(12) 
65(8) 
0.2 
 
67(12) 
60(9) 
0.06 
 
73(13) 
69(9) 
0.3 
40-54
  
168 
23 
73(13) 
69(10) 
0.1 
 
70(12) 
67(10) 
0.2 
 
76(14) 
72(11) 
0.1 
55-69 
155 
19 
76(13) 
74(15) 
0.5 
 
74(13) 
70(14) 
0.2 
 
79(14) 
79(16) 
0.9 
≥70 
72 
15 
77(12) 
80(10) 
0.6 
 
76(13) 
79(12) 
0.5 
 
79(13) 
81(9) 
0.7 
A
ll 
659 
19 
71(12) 
69(12) 
0.2 
 
67(13) 
66(12) 
0.3 
 
74(13) 
73(12) 
0.3 
Supplem
entary tables 
S20. U
nadjusted age specific Systolic and D
iastolic B
P by SC
T in M
en in K
ilifi (ID
A
C
O
 C
riteria) 
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A
. A
ge specific systolic BP
 by S
C
T in K
ilifi m
en (ID
A
C
O
) 
Age 
group 
N
 
%
 
SC
T 
24-hour S
ystolic B
P (S
D
) 
 
N
ighttim
e S
ystolic B
P (SD
) 
 
D
aytim
e systolic BP (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
541 
20 
121(13) 
121(14) 
1 
 
111(13) 
111(14) 
0.6 
 
130(14) 
129(14) 
0.6 
25-39  
71 
15 
127(12) 
126(6) 
0.8 
 
117(14) 
114(8) 
0.5 
 
134(13) 
135(9) 
0.9 
40-54
  
93 
25 
130(15) 
128(13) 
0.6 
 
122(16) 
117(16) 
0.2 
 
136(16) 
136(13) 
0.9 
55-69 
135 
24 
138(23) 
136(20) 
0.6 
 
131(25) 
129(22) 
0.6 
 
144(24) 
142(20) 
0.6 
≥70 
88 
28 
144(19) 
147(26) 
0.5 
 
140(23) 
141(31) 
0.9 
 
146(20) 
152(24) 
0.2 
A
ll 
928 
22 
127(17) 
128(19) 
0.5 
 
118(19) 
119(21) 
0.6 
 
134(18) 
135(18) 
0.5 
 
B
. A
ge specific diastolic BP
 by S
C
T in K
ilifi m
en (ID
A
C
O
) 
Age 
group 
N
 
%
 
SC
T 
24-hour D
iastolic B
P (SD
) 
 
N
ighttim
e D
iastolic BP
 (SD
) 
 
D
aytim
e D
iastolic B
P (SD
) 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
 
N
on-SC
T 
SC
T 
p-
value 
11-24 
541 
20 
65(8) 
65(8) 
0.4 
 
57(8) 
58(9) 
0.3 
 
71(9) 
71(9) 
0.6 
25-39  
71 
15 
72(9) 
71(3) 
0.9 
 
64(10) 
63(5) 
0.7 
 
77(11) 
78(7) 
0.7 
40-54
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Figure 6-2: Age Standardized± Effect of SCT on ABPM Indices in Kilifi and 
Nairobi 
A: Kilifi 
 
B.  Nairobi 
 
±WHO population weighted linear regression models with adjustment for sex and estimated glomerular 
filtration rate. Plots to the left of the vertical dashed lines refer to participants who met IDACO criteria. 
Plots to the right of the vertical dashed lines refer to participants who met ESH criteria. 
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; IDACO: International Database for 
Ambulatory blood pressure in relation to Cardiovascular Outcomes; ESH: European Society of 
Hypertension
Supplementary Figure 1: Age Standardized± Effect of SCT on ABPM 
indices by sex in Kilifi  
 187 
A: Women (N=1058 IDACO, 659 ESH)
 
B.  Men (N=928 IDACO, 481 ESH)
 
±WHO population weighted linear regression models with adjustment for sex and estimated 
glomerular filtration rate. Plots to the left of the vertical dashed lines refer to participants who 
met IDACO criteria. Plots to the right of the vertical dashed lines refer to participants who met 
ESH criteria. 
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; IDACO: International Database 
for Ambulatory blood pressure in relation to Cardiovascular Outcomes; ESH: European 
Society of Hypertension
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Chapter 7. Discussion and Conclusion 
In this chapter I summarize the main findings of this body of work, its 
strengths and limitations, its implications, and my opinion of what direction 
future studies should take. 
A. Increased risk of malaria is associated with increased blood pressure and 
increased odds of hypertension- replication and mechanistic studies needed 
The main finding was that of an association between increased risk of malaria 
and increased blood pressure. The Mendelian Randomization approach that I 
used is a particular strength because genetic variants are acquired at 
conception, eliminating the possibility of reverse causation. Genetic variants 
are also generally not associated with other potential confounding variables. 
The main finding in the work presented has the potential to radically improve 
current knowledge about the development of hypertension if it can be 
confirmed through additional studies. This would strengthen the argument 
outlined in Chapter 1 that environmental factors play a role in the 
development of hypertension in this setting. Viral, parasitic, fungal and 
bacterial infections are very common in sub-Saharan Africa. Existing data 
showing that HIV increases risk of hypertension as a result of inflammation as 
well as due to the body fat abnormalities induced by anti retroviral 
medications.1-4 The findings in this thesis suggest that another common 
infection, malaria, may also be responsible for blood pressure elevation. It is 
quite likely that other infections contribute to increased cardiovascular risk in 
sub-Saharan Africa but this is yet to be clearly demonstrated. While the work 
in this thesis failed to show any evidence of genetic factors in driving the 
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incidence of hypertension, I only looked at 2 polymorphisms (sickle cell trait 
and alpha thalassemia). This work does not therefore contradict the prevailing 
opinion that a combination of genetic and environmental factors contributes to 
the burden of hypertension in sub-Saharan Africa.  
 As previously mentioned (discussion section of Chapter 6), the contribution of 
malaria to elevated blood pressure might be considerably higher than that 
demonstrable in the studies in this thesis. This is because (a) Kilifi is a low-
moderate transmission area and therefore participants in this study will have 
been exposed to lower levels of malaria infection than in other parts of the 
continent; (b) the instrumental variables used to represent malaria risk do not 
completely protect against malaria; I would expect that with complete 
protection from malaria the difference in blood pressure between the two 
groups would have been greater. 
It is worth reviewing at this point some important limitations about the study 
when considering the findings: 
- There was a significant difference in the age distributions of the cohorts 
in Kilifi and Nairobi respectively. Because Kilifi participants were older 
than those in Nairobi, the possibility that sickle cell trait could directly 
influence BP in older individuals was not ruled out. However as 
mentioned in the discussion section of Chapter 6, based on studies 
conducted in other parts of the world where there is no malaria 
transmission, the possibility that sickle cell trait could directly influence 
blood pressure is very small. 
- Given that sickle cell trait and alpha thalassemia are protective against 
a major childhood killer (malaria) in Kilifi, the potential for survivor bias 
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exists in the analyses performed. It is possible that malaria had a 
different effect on blood pressure among children who died compared 
to those who survived the infection but the study design did not allow 
this comparison to be made 
- The mechanism for blood pressure elevation due to malaria was not 
elucidated. I had hypothesized that malaria would result in increased 
arterial stiffness as the mechanism leading to increased blood 
pressure.5 Data from the Framingham Heart Study showed that 
increased arterial stiffness precedes the development of hypertension.6 
However in my studies I found numerically lower pulse wave velocity in 
individuals with sickle cell trait in Kilifi and this was not statistically 
significant despite having sufficient statistical power for that outcome. 
- In addition, the specific exposure leading to BP elevation could not be 
ascertained because SCT, which I used as an instrumental variable 
representing malaria exposure protects against both severe and non-
severe malaria, while not protecting against symptomless 
parasitaemia.7 SCT may also protect against malaria in pregnancy and 
this could have explained the differences observed. 
- The sample size was insufficient for interaction analyses for example to 
ascertain if there was an interaction with alpha thalassemia. 
Definitive linkage of malaria infection to elevated blood pressure would 
require the following in order to satisfy the Bradford Hill criteria8: 
i) Replication at other sites of malaria transmission  
  To improve efficiency these sites would need to have malaria 
transmission at levels higher than that documented in Kilifi. Settings that 
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meet this criterion include Eastern Uganda, Northwestern Tanzania, the 
Democratic Republic of the Congo and Nigeria.9 The populations in these 
settings also have high frequencies of other malaria-protective 
polymorphisms, which would enable the use of alternative instrumental 
variables if a Mendelian randomization approach is used. One 
disadvantage though of using alternative polymorphisms is that none of 
the malaria protective polymorphisms discovered to date provides more 
protection and/or is more common than sickle cell trait10 meaning that 
much larger sample sizes will be required. 
ii) Use of alternative study designs 
In the introduction to this thesis (Chapter 1) as well as the hypothesis 
paper (Chapter 3), I discussed some of the alternative study designs that 
can be used to test the hypothesis. Given the findings of the MR study that 
I conducted it is worth articulating these alternative study designs in detail, 
and the extent to which they could be useful in confirming or refuting the 
hypothesis. These include: 
C. Long term observational studies 
There are several cohort studies enrolling children with malaria in sub-
Saharan Africa and Asia. These can be used to examine and confirm if the 
hypothesis is true in various ways: 
      - A classical cohort analysis could be performed comparing blood 
pressure in those known to have suffered malaria during follow up versus 
those who did not 
 - In areas of the world where complete elimination of malaria has been 
achieved recently, comparison of blood pressure in individuals born before 
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and after the date of elimination could add to the evidence of malaria 
influencing blood pressure. One such country is Sri Lanka, which was 
certified by the World Health Organization as being malaria free in 
September 2016. 
x Randomized studies 
If blood pressure can be included as an outcome measure in clinical trials 
of anti-malarial drugs, differential effects on blood pressure according to 
randomization arm could be shown for interventions that are superior to 
the control. One such trial where blood pressure as an outcome could be 
included is the planned phase IV cluster randomized trial of the RTS,S 
vaccine targeting a population of over 1 million that will be conducted in 
Ghana, Kenya and Malawi. 
Studies of controlled human infection with malaria have recently begun to 
be conducted in Africa.11 While the exposure to malaria in these studies is 
very brief, they can be used to determine the short-term effects of malaria 
on blood pressure as well as examine possible pathophysiologic 
mechanisms for any blood pressure changes observed.  
iii) Elucidation of the mechanisms leading to blood pressure elevation.  
Malaria is known to cause inflammation, and inflammation has been linked 
to the development of hypertension. One likely candidate inflammatory 
marker that could result in hypertension from malaria is angiopoietin-2 
(Ang-2) as discussed in the hypothesis paper (Chapter 3).  Recently 
published studies have also linked other related angiopoietin like proteins 
to the development of coronary artery disease, additionally demonstrating 
clinical efficacy of monoclonal antibodies targeting them.12,13 Similar 
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studies are required in the case of malaria and these could yield new 
drugs to help control high blood pressure and reduce the burden of 
cardiovascular disease in Africa. If the mechanism of blood pressure 
elevation involves inflammatory cytokines, then trials of anti-inflammatory 
agents including statins during or before malaria infections could provide a 
method of preventing the adverse cardiovascular consequences of malaria 
infection. As an example, patients who were on statin therapy before 
suffering from pneumonia had better outcomes than those who were not 
on the drugs. 14 
Additional implications if malaria does cause hypertension are as follows: 
(i) The cost benefit ratio of malaria prevention/elimination strategies will be 
modified. Trials of malaria vaccines have so far been only modestly 
successful in preventing malaria in children15, leading to questions as to 
whether they are a worthwhile investment. If it can be confirmed that malaria 
has an additional adverse cardiovascular consequence on the health of 
populations exposed to the parasite, then the benefits of even a modest 
reduction in incidence would increase, improving the justification for use of 
vaccines that may not have 100% efficacy. 
(ii) The arbitrary division of tropical diseases into “infectious diseases” and 
“non-communicable diseases” is reductionist and a wider perception of 
health as the product of genes, environment including exposure to infection 
should be considered. 
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B. Ambulatory blood pressure monitoring can be performed in an African 
setting- but challenges exist 
As demonstrated in the 4 papers that report primary data, I was able to 
successfully perform ambulatory blood pressure monitoring (ABPM) in both 
rural and urban-based participants of various ages. There has been limited 
work utilizing ambulatory blood pressure monitoring in an African setting. The 
studies in this thesis are a significant addition to the data so far available and 
can be put to many more additional uses in future. One important use will be 
in determining the prognostic ability of ABPM in predicting cardiovascular 
outcomes as well as what thresholds to use for diagnosing hypertension. This 
also includes determining whether blood pressure measurements conducted 
in childhood/adolescence tracks into adult life as this has not yet been 
demonstrated in African populations. Ambulatory blood pressure monitoring 
has been shown to be superior in predicting cardiovascular outcomes mainly 
in Western populations. A recent study from the US found that ABPM 
thresholds for diagnosing hypertension developed using data from European, 
Japanese and South American populations do not predict cardiovascular risk 
accurately in African Americans.16 
 Several patterns were observed that are in keeping with what has been seen 
in other parts of the world where ABPM has been adopted on a larger scale: 
- ABPM measurements were as expected more precise than one-off 
measurements performed at home or in the clinic. This was evident 
from the narrower confidence intervals observed when using ABPM 
measures compared to screening/office BP measurements. A similar 
pattern of results was seen in the seminal PAMELA study17 ,a Danish 
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study18 and a large Spanish study (N=104,639)19 . The precision 
afforded by ABPM enabled me to detect a small but significant 
difference in BP by sickle cell trait in Kilifi, which would have required a 
much larger sample size to detect using screening measurement 
methods. 
- The relationship between screening BP measurements and ABPM 
values differed by age. Younger participants in general had higher 
ABPM derived BP values compared to their clinic BP values while in 
older participants this pattern was reversed. As a result of this masked 
hypertension was more common in younger participants while white 
coat hypertension was more common in older participants, as has 
been observed in studies conducted in developed countries.20 It is 
thought that the higher ambulatory values in younger participants could 
be related to the fact that they are more physically active than older 
individuals and this would directly affect ambulatory BP values 
especially the daytime components. One way to determine if increased 
physical activity is responsible for these differences would be to 
perform actigraphy where participants’ motor activity and position are 
recorded simultaneously with ABPM. Apart from elucidating the 
reasons behind the age-related patterns, the clinical relevance of white 
coat hypertension and masked hypertension in an African setting 
needs to be established. Studies conducted in western populations 
demonstrated a progressive increase in cardiovascular risk when 
moving from normotension (normal clinic and ambulatory blood 
pressure) to white-coat hypertension (elevated clinic BP but normal 
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ambulatory BP) to masked hypertension (normal clinic BP but elevated 
ambulatory BP) and finally sustained hypertension (elevated clinic and 
ambulatory BP).21 
Apart from the need for local evidence about its superiority in predicting 
cardiovascular outcomes, several difficulties that I encountered during my 
studies will need to be considered before widespread adoption of the 
technique can be recommended in Africa. 
- Expense- Purchasing the ABPM devices took a significant proportion 
of the study budget (~£ 50,000) despite the fact that I obtained 
discounts for bulk purchases. Until cost-effectiveness studies 
unequivocally demonstrate a clear advantage to using ABPM for 
diagnosing and managing hypertension, the high cost of the devices 
will likely prevent the technique from being widely adopted. 
- Participant discomfort- although I did not formally study participants’ 
reactions about undergoing ABPM, a significant number reported that 
the repeated inflations were discomforting and that they were unlikely 
to accept to undergo repeat measurements. Whether the discomfort 
could have interfered with sleep patterns and therefore influenced the 
results reported is difficult to ascertain. It is also possible that 
discomfort resulted in the significant number of measurement errors 
observed as evidenced by the proportion of participants providing data 
that met neither of the 2 recognized quality control criteria. It must be 
mentioned however that both sets of criteria were arbitrarily decided 
upon and no outcome data are available to determine the minimum 
number of ABPM readings needed to predict cardiovascular outcomes 
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within reasonable limits. In the Mendelian Randomization study in Kilifi, 
no statistically significant effects were observed when using the less 
stringent quality control criteria, suggesting that more accurate 
measurements resulting from a higher number of inflations are likely to 
be more predictive of cardiovascular outcomes. Advances in clinic BP 
measurement could also mean that reliance on ABPM is no longer 
necessary. In the SPRINT trial22, participants underwent Automated 
Office BP (AOBP) measurement23 where they were left alone in a quiet 
room for 5 minutes after which the BP machine automatically took 3 BP 
readings. However, the relationship between AOBP and ABPM has not 
been clearly elucidated and a comparison of ABPM measures done 
midway through the SPRINT trial with clinic BP values was markedly 
different from that found in other studies.24,25 Another unknown issue 
about ABPM measurements is their reliability, i.e. consistency of 
measurements in the same person. It is possible that a person might 
behave differently on repeat measurement, given previous experience 
and discomfort to the extent that radically different readings are 
obtained. This possibility has however not been studied. Another cause 
of lack of reliability in ABPM measurements could be lack of 
standardization of the software used for calculating the various outputs 
from the device as was classically demonstrated by Rossen et al using 
the popular Spacelabs™ ABPM device.26 
Recommendations on use of ABPM in Research Studies and Clinical Practice 
Based on the findings in this thesis there are clear advantages to using ABPM 
in epidemiological research and I would recommend that it be used more 
  198 
widely for this purpose. However, there are insufficient data to suggest that it 
is both cost-effective and acceptable in clinical practice and I would 
recommend additional studies on these two aspects before ABPM can be 
adopted in routine clinical practice in sub-Saharan Africa.  
C. Sickle cell trait and alpha thalassemia do not directly influence blood 
pressure- unlikely to contribute to ethnic differences in cardiovascular 
disease 
The Nairobi component of my study was designed specifically to determine 
whether Sickle Cell Trait and alpha thalassemia would be appropriate genetic 
instruments to use as a proxy for determining whether malaria risk is 
associated with changes in blood pressure in Kilifi. These studies however 
brought up an important topic worth discussing: are ethnic differences in the 
risk of cardiovascular disease related to intrinsic biologic differences between 
the groups? To answer this question, the effects of any of these biologic 
variations need to be studied within the specific ethnic groups in which they 
are highly prevalent. Sickle cell trait and alpha thalassemia are among the 
most common polymorphisms in populations of African descent due to the 
protection they provide against malaria, and the more severe forms of these 
polymorphisms (sickle cell disease and thalassemia major) are associated 
with significant cardiovascular disease. So does this selective advantage 
against malaria come at the cost of increased cardiovascular risk? 
Biomedical essentialism, the concept that intrinsic biologic differences explain 
racial (or other) disparities in health had been in a period of decline until the 
turn of the century.27 However with the advent of molecular epidemiology and 
the Human Genome Project, this concept has again assumed widespread 
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importance.28 However, as has been pointed out by several authors27,29 this 
concept suffers from one major flaw: there is no scientific consensus on the 
definition of race or ethnic group. It is now recognized that the concept of 
ethnicity has been largely shaped by cultural and political considerations, and 
that the generation of scientific theories and hypotheses as well as the 
conduct and reporting of research are often influenced by cultural, social and 
economic factors. 28,30 With no clear biological definition of ethnicity, it follows 
that any attempt to ascribe differences in the prevalence of cardiovascular 
disease to ethnicity would encounter serious difficulty. Despite the huge effort 
that has been put into genome wide association studies to find genetic causes 
of cardiovascular disease, the majority of studies have either reported 
negative findings or variants with very small effects that on average only 
explain ~1% of the phenotypic variance in cardiovascular related traits.31 The 
negative findings in the studies that I performed in Nairobi add to the evidence 
against there being a large contribution of genetics to the development of 
cardiovascular disease. One limitation though of the Nairobi studies was that I 
examined for differences in a young population where the risk of hypertension 
is low, although as argued in the discussion sections of Chapters 4-6, 
differences in BP can usually be detected during childhood and adolescence. 
 The corollary of there being minimal contribution of intrinsic factors 
underlying the development of cardiovascular disease is that it is likely that 
environmental factors are the main players. The advantage of this is that 
environmental factors are more amenable to modification in order to reduce 
the risk of cardiovascular disease (although it should be noted that with the 
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advent of gene editing technology, the potential for modifying intrinsic genetic 
causes of disease will soon be available). 
 
D. How do we interpret these findings in view of previous studies 
demonstrating that factors related to urbanization are responsible for 
increased blood pressure? 
Malaria has been present in Africa for thousands of years. How then do we 
reconcile the apparently contradictory findings of an almost complete absence 
of hypertension in Africa prior to urbanization and the finding in my studies of 
an increased risk of hypertension associated with malaria? I would like to 
propose two possible explanations: 
- Hypertension causation is multi-factorial 
It is now well known that the hypertension phenotype results from multiple 
factors, genetic and environmental operating within and between 
generations. Most etiological studies have looked at a single risk factor 
rather than combinations of risk factors, due to the complex study designs 
required to study combinations of risk factors. We therefore do not know 
which permutations of risk factors and at what dose are required to result in 
hypertension. It is possible that malaria only raises blood pressure in the 
presence of other dietary and lifestyle factors that are present now but were 
not there previously. This can be examined by conducting larger scale 
studies with measurement of these factors. However as argued by Geoffrey 
Rose, such an approach will only enable the detection of differences within 
the current range of variation in these factors in the population.32 If as it is 
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likely, previous populations had a markedly different distribution of these 
factors, it will be difficult to make any comparisons with previous studies.  
- Traditional methods for measuring blood pressure were inaccurate 
It is quite evident now that casual methods of blood pressure 
measurement suffer from many shortcomings leading to increasing use of 
more standardized methods such as ambulatory blood pressure 
monitoring and automated office blood pressure measurement. Random 
misclassification arising from the methods used to measure blood 
pressure may have accounted for the failure to detect differences in blood 
pressure based on exposure to malaria. 
A final explanation for the apparent contradiction is that my interpretation that 
malaria raises blood pressure could be wrong. This will be borne out by future 
studies. 
E. Public Health Relevance of the Findings in this Thesis and Potential 
Interventions 
In summary, the major public health implications of the findings in this thesis 
are as follows: 
- Hypertension is at least as common in Kilifi as it is in urban parts of 
Kenya. Interventions to reduce blood pressure levels in the Kilifi 
population are likely to reduce the high burden of cardiovascular 
disease in the area. 
- The findings of the Mendelian Randomization study present a 
reasonably robust case for an association that is likely to have 
profound effects on health in Africa. The implications are 
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  i) It is necessary to confirm the finding and obtain more precise estimates 
of the effect size and relationship with age, sex and other malaria protective 
genes 
  ii) It is necessary to tease out the mechanism of action by which malaria 
leads to blood pressure elevation in order to develop new therapeutic agents 
If confirmed as outlined above the findings will add further scientific and 
economic weight to the case for malaria control and elimination. 
F. Proposed Future Work 
In this final section I briefly outline a summary of what my next research 
projects would be based on the findings in this thesis. These are of course 
dependent upon obtaining funding to carry out the research. 
- Confirmation of, and elucidating the pathophysiological basis of the malaria-
high blood pressure hypothesis by repeating Mendelian Randomization 
studies in a different site with higher malaria transmission intensity; and by 
including blood pressure as an outcome in the forthcoming multi-site RTSS 
malaria vaccine trial. Proteomic techniques in humans as well as animal 
models of malaria infection could be used to elucidate mechanisms of blood 
pressure elevation. 
- Additional studies on the clinical utility of ambulatory blood pressure 
monitoring compared to existing and newer methods for screening blood 
pressure measurement.   
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Reporting format 
While there are no specific guidelines for reporting Mendelian randomization (MR) 
studies, the principles outlined in the Strengthening the Reporting of OBsErvational 
studies (STROBE)1 guidelines as well as the STROBE Extension for Genetic 
Association studies (STREGA)2 will be used. In addition Boef et al published a 
review of the quality of reporting of MR studies3 and I will also be guided by 
recommendations that were made that paper.  
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Outcome measures 
The primary outcome measures will be linear regressions to determine the age, sex 
and estimated glomerular filtration rate (eGFR) adjusted effect of SCT on 24-hour, 
daytime and nighttime systolic blood pressures obtained by ambulatory blood 
pressure monitoring using the arteriograph device. Numerous studies have shown 
that the more precise measurements resulting from repeated inflations and more 
standardized procedures in ABPM (as outlined in chapter 1) make it a much better 
predictor of cardiovascular events than other BP measurement methods.4 The 
justification for adjusting for age, sex and eGFR is given in section 4 on confounders 
and model building. 
Secondary outcome measures will be: 
a) Comparison of the primary outcome measures using alpha thalassemia rather 
than sickle trait to represent malaria exposure 
b) Comparison of the diastolic components of the primary outcome measures 
c) Estimation of the odds ratio for prevalent hypertension in those with and 
without SCT and those with and without alpha thalassemia, using ABPM 
cutoffs. Hypertension is diagnosed by any one of the following criteria in 
individuals aged ≥16 years: 4,5  
i) 24-hours systolic BP ≥130 mmHg and/or 24-hour diastolic BP ≥ 90 mm 
Hg 
ii) Daytime systolic BP ≥135 mm Hg and/or daytime diastolic BP ≥ 85 mm 
Hg 
iii) Nighttime systolic BP ≥ 120 mm Hg and/or nighttime diastolic BP ≥ 70 
mm Hg 
d) Weighted regression analyses of the primary and secondary outcomes using 
WHO standard population weights6 adjusting for sex and eGFR 
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Adjustment for multiple testing will not be necessary in this scenario of a limited 
number of clinically relevant pre-specified tests (e.g. compared to GWAS studies)7 
Sample size estimation 
The initial sample size calculation outlined at the start of the study was based on a 
two-sample t-test comparing mean 24-hour systolic blood pressure in those with and 
without the sickle cell trait (SCT). The following assumptions were made: 
- That the prevalence of SCT would be ≥15% 
- That the standard deviation of 24-hour systolic BP would be ≤20 mm Hg 
- That 85% of subjects selected to participate in the study would consent to do 
so 
- That 85% of those consenting to participate would provide data that met 
quality control criteria (see section 2 below) 
Based on these assumptions I calculated that I would need to approach 1084 
participants (resulting in ~783 subjects with complete data) at each of 2 sites in Kilifi 
in order to detect a statistically 5mm Hg difference in 24-hour systolic BP and a 
0.5ms-1 difference in aortic pulse wave velocity between individuals with and without 
the sickle cell trait. The 2 sites were chosen so as to enable the examination of a 
dose-response effect in BP as they have traditionally had differing malaria 
transmission intensities. 
An interim analysis at the mid-point of the study (December 2016) revealed an issue 
that had not been previously considered; there was a high prevalence of thalassemia 
mutations with only ~25% of recruited subjects not having any thalassemia 
mutations. Coinheritance of SCT and alpha thalassemia may negate the protective 
effect of SCT against malaria episodes.8  We considered that this might reduce the 
power of the study to determine the main outcome. 
In order to increase power to detect an effect it was agreed to limit recruitment to one 
site in Kilifi (the one with higher malaria transmission) and double the recruitment 
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target for that site to 2168 individuals. Any dose-response effect would be examined 
by looking for differential effect sizes based on sickle and thalassemia status, which 
provide different levels of protection against malaria. 
No formal sample size estimation was made for linear regression analyses (see 
section on confounders below). The literature suggests that the major consideration 
for sample size calculations in linear regression models is to ensure that there are at 
least 2-50 subjects per variable in the model9, a requirement that would almost 
certainly be achieved if most of the assumptions stated above held true. 
If the final results of the study differ from the assumptions made at the outset, I will 
conduct a post hoc analysis to determine what power there was to detect statistically 
significant differences based on the data accumulated. 
Causal diagram, confounders and model building 
The theoretical basis for the malaria-high blood pressure hypothesis has been 
published previously.10 Briefly, the primary hypothesis to be tested is that individuals 
exposed to more malaria disease in their childhood (represented by those having 
haemoglobin AA) will have higher 24-hour systolic blood pressure than those who 
were exposed to less malaria disease (represented by those having haemoglobin AS 
[SCT]). Additional analyses related to the primary hypothesis will examine the effect 
of alpha thalassemia mutations, which on their own confer less protection against 
malaria compared to the SCT, and when inherited in combination with the SCT result 
in a reduction of the protective effect of SCT against malaria.8,11-13  
 The proposed causal diagram, drawn purely for purposes of informing the analytical 
plan is as below. 
Figure 1. Causal diagram for the malaria high blood pressure hypothesis 
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In this directed acyclic graph (DAG) the arrows can be interpreted as causal 
relations. The term acyclic is somewhat misplaced here because the relationship 
between arterial stiffness and high blood pressure is bidirectional i.e. arterial stiffness 
can lead to high blood pressure14 and high blood pressure can lead to increased 
arterial stiffness15,16. The bidirectional nature of this particular relationship appears to 
be partially related to age but as this is not the subject of this study there will be 
limited examination of the issue. For purposes of this analysis however it is important 
to note that both increased arterial stiffness and blood pressure are hypothesized 
outcomes of malaria. Arterial stiffness and blood pressure are also on each other’s 
causal pathway, therefore it would be wrong to adjust analyses assessing the 
relationship between malaria and either outcome for either blood pressure or arterial 
stiffness. Similarly, because malnutrition and stunting are on the causal pathway 
from malaria to either outcome, adjustment for body mass index (BMI) and other 
anthropometric indices (e.g mid upper arm circumference) would be inappropriate. 
 a)  Confounders 
The principle of Mendelian randomization holds that because comparisons are 
based on genetic traits acquired at conception, any relationships between the 
genetic trait and the outcome are unlikely to be confounded by other exposures as 
these will be randomly distributed between carriers and non-carriers of the trait.17 
Inﬂamma&on,	
stun&ng,	
malnutri&on	
SCT/a+	
thalassemia			 Arterial	s&ﬀness	
High	blood	
pressure	
Childhood
Malaria	
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However age, sex, and BMI are known to have a very strong influence on BP and 
other cardiovascular diseases18, and are usually adjusted for as ‘fixed covariates’ in 
MR/Genome wide association studies e.g in Palmer et al19, Ehret et al20 and 
Ferrence et al21. I have outlined above why it would be inappropriate to adjust for 
BMI. Confounding can also occur if the genetic trait influences the outcome through 
a pathway that is independent of the exposure (pleiotropy) as illustrated in figure 2 
below. 
Figure 2: Illustrating confounding due to pleiotropy. 
 
Apart from adjustment for age and sex I will perform adjustment for 2 additional 
covariates that also have a strong influence on BP as justified below: 
  i. Kidney function 
Sickle cell trait has been associated with impaired kidney function as measured by 
decline in estimated glomerular filtration rate (eGFR) and albuminuria.22 This 
association was independent of blood pressure elevation. Another abnormality that 
appears in individuals with SCT is decreased urinary concentrating ability 
(hyposthenuria) that leads to lower than normal urinary sodium levels.23 We 
confirmed the presence of hyposthenuria among adolescents with sickle cell trait 
who had been continuous residents of Nairobi, Kenya where they were not exposed 
to malaria.24 Impaired kidney function is associated with elevations in blood pressure 
as a result of sodium retention25, increased activity of the renin-angiotensin system26, 
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increased sympathetic activity27, secondary hyperparathyroidism28, impaired nitric 
oxide synthesis29 and increased prevalence of nocturnal non-dipping BP pattern.30 It 
is also possible that kidney disease could arise from hypertension.31 The direction of 
the relationship between BP and kidney function, like that of arterial stiffness and BP, 
has been the subject of debate.32 However, evidence from genetic studies suggests 
that the relationship between decreased renal function and blood pressure elevation 
is more likely to operate in the direction of decreased renal function resulting in high 
blood pressure. In a large (n>200,000) genome wide association study (GWAS), loci 
that were associated with BP elevation and cardiovascular disease showed no 
association with kidney disease or kidney function.20 If SCT compromises renal 
function and this in turn leads to elevated BP, this would result in a bias toward a null 
result when using SCT as a proxy for testing the malaria-high blood pressure 
hypothesis. As can be seen in Figure 3, impaired kidney function is associated with 
both the exposure and the outcome, but is not on the causal pathway from malaria to 
the outcome. Kidney function is therefore a confounder that should be adjusted for in 
regression analyses.  
 
 
 
 
 
 
 
 
 
Appendix 1: Analysis Plan for Mendelian Randomization Study 
 213 
Figure 3. Illustrating confounding effect of eGFR in subjects with SCT 
 
 
In the primary analysis I will use eGFR as the measure of Kidney function. I will 
check to see that eGFR is associated with SCT and with BP in a univariate linear 
regression model and after adjusting for age and sex. If no association is present 
between SCT and eGFR then it will not be included as a predictor variable in the 
model examining the effect of malaria (SCT) on BP. eGFR will be calculated using 
the Schwartz formula in children and the CKD-EPI formula in adults.33,34 While the 
CKD-EPI formula was derived from a general population of adults, no study has 
been conducted to generate a formula for GFR from children free of chronic kidney 
disease. The Schwartz formula was derived from children with chronic kidney 
disease, and this may result in a distortion of the eGFR in children participating in 
this study. In sensitivity analyses (described further down), I will assess the effect of 
additional adjustment for urine albumin levels, which have been causally associated 
with increased BP when eGFR is normal35, also checking to see that there is no 
collinearity with eGFR. 
Acute renal failure is a known presentation of severe malaria and repeated episodes 
could result in chronic pyelonephritis and elevated BP. However, in a study 
conducted in Kilifi, renal failure was a very rare outcome among children admitted 
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with malaria (2 out of 1,844).36 As this falls on the causal pathway between malaria 
and high blood pressure, it does not qualify as a confounder. 
 ii. Glucometabolic status 
Glucometabolic status, measured using glycosylated haemoglobin (HbA1c) is 
strongly associated with increased arterial stiffness, blood pressure and 
cardiovascular and renal disease in both diabetic and non-diabetic subjects.18,37-40 
This association is independent of body mass index.18,38 Because HbA1c levels like 
BP track over time i.e they tend to remain constant over time in an individual, it is 
possible to predict individuals at risk of developing hypertension based on their blood 
sugar levels taken as many as 18 years earlier 41. This also reduces the problem of 
time-varying confounding. At the same time, SCT has been associated with reduced 
HbA1c levels, even when using assay methods that have been standardized to 
ensure accurate measurement of HbA1c in subjects with hemoglobinopathies.42 It is 
not clear whether this association is a laboratory artefact or real. Based on this 
HbA1c, as a marker for glucometabolic status, is a potential confounder of the 
relationship between SCT and BP/arterial stiffness as shown in Figure 3. As with 
kidney function, I will perform univariate and adjusted analyses to confirm the 
existence of an association between SCT and HbA1c and before including it as 
covariate in the main regression model. 
Figure 3. Confounding role of HbA1c 
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b) Effect modifier:  Thalassemia  
Alpha thalassemia, in which there is reduction in the amount of alpha hemoglobin, is 
common in regions where malaria transmission occurs. Williams et al8 have 
demonstrated a negative epistatic effect when alpha thalassemia is coinherited with 
SCT. The effect of coinheritance of the mutations is to reduce the malaria protective 
effect of SCT to about 27% (from 50%) for uncomplicated malaria and to 44% (from 
80%) for severe malaria.8 Put simply, the presence of alpha thalassemia reduces the 
protective effect of SCT against both uncomplicated and severe malaria by about 
half. The frequency of any thalassemia mutation (i.e homozygous or heterozygous) 
is ~70% in the Kilifi population. If the malaria-high blood pressure hypothesis is true, 
then the largest BP difference based on SCT will be seen in individuals without any 
alpha thalassemia mutations. However, because of the high frequency of alpha 
thalassemia mutations, there will be very few individuals for this stratified analysis 
resulting in loss of statistical power. I will instead include alpha thalassemia as an 
interaction term (interacting with SCT) in the main regression model and examine 
whether its inclusion changes the effect estimate for SCT in predicting BP. From this 
model, I will also examine the effect estimates for SCT in those with and without 
alpha thalassemia mutations. I expect these to be different from those obtained in 
the model that does not include thalassemia as an interaction term. 
In a related analysis, I will run a linear regression model examining the effect of 
alpha thalassemia on BP with the same covariates used in the main analysis for 
SCT. Because alpha thalassemia confers less protection against malaria than SCT, 
it is expected that the effect estimate in this model will be lower than that of SCT. 
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b) Model building 
I will conduct forward stepwise regression, sequentially adding the specified 
covariates (age, sex, eGFR and hbA1c) in the model. The criteria for determining 
whether a candidate covariate improves the model will be a likelihood ratio of ≤0.05 
or a change of ≥10 % in the effect estimates (regression coefficient for SCT) when 
comparing the model with and without the candidate covariate.    
c) Pleiotropy 
In order to make valid conclusions that malaria affects/does not affect BP, the 
regression models described above shall be applied to data obtained from lifelong 
residents of Nairobi where there is no malaria transmission.  
I will in addition examine the published literature on genome association studies 
conducted in malaria free regions and that include populations that have a high 
prevalence of SCT (e.g African Americans) to find out whether any of these studies 
have found an association between SCT and BP. 
d) Testing for Cohort effects 
Malaria incidence in Kilifi has been changing over time and this may influence results 
obtained. Data on the changing levels of transmission go back to 1990 and they 
show that a significant drop in transmission in Kilifi began around 1999-2000.43 In 
addition, because blood pressure rises with age, it is possible that the effects of 
malaria on outcome measures may be more apparent later in life. While it will be 
impossible to determine the individual contributions of changing malaria exposure 
and aging to any differences observed in outcome measures, I will attempt to display 
these differences by performing comparisons of the outcomes by sickle trait in 5-7 
age categories.  
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Potential  Sources of Bias 
a) Subjects aware of their exposure status 
Screening for sickle cell trait is not routinely done in Kilifi. It is, however, possible that 
first degree relatives of individuals with homozygous (HbSS) sickle cell disease, 
which almost always has severe clinical manifestations, would infer that they have at 
least a 50% probability of having SCT if they are siblings of the affected individual 
and nearly 100% probability of having SCT if they are parents of the affected 
individual. If these individuals then altered their behaviour with regard to avoiding 
malaria (e.g less likely to use bed nets or seek treatment for possible malaria) then 
this could bias the result toward the null. We will have no way of measuring this 
possibility, but given the 2% prevalence of sickle cell disease in the population and 
the multiple probabilities involved in the pathway to increased malaria exposure, the 
magnitude of misclassification bias due to this factor is likely to be minute. 
b) Subjects aware of their outcome status 
On the other hand, many more individuals are likely to have had their blood pressure 
measured and possibly diagnosed as being hypertensive. Management of 
hypertension involves lifestyle and diet modification, and drugs. As these will be 
applied equally in those with and without SCT, their effect would be to bias the result 
of the study towards the null. We have only one measure that we can use to 
determine the existence of this bias, urinary sodium levels. I will compare urinary 
sodium excretion in individuals previously diagnosed as hypertensive with that of 
those not previously diagnosed as hypertensive. Significantly lower levels of urinary 
sodium in those previously diagnosed as hypertensive (and not on medication e.g 
diuretics) after controlling for eGFR, will suggest that they could have decreased 
their salt consumption. Consideration will be given to excluding individuals previously 
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diagnosed as hypertensive from the regression analyses. Including these individuals 
in the analyses and then adjusting for (or stratifying by) urinary sodium, drug intake, 
or previous diagnosis of hypertension would lead to collider bias45 as the so-called 
confounder would be a common effect of the exposure (malaria) and the outcome 
(BP). 
What data to include/exclude in the analyses 
There are 2 internationally recognized quality control criteria used for ABPM data 
which are based on completeness of observations. The International Database of 
Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) study46 
defined ABPM data as acceptable if they include ≥ 10 daytime and ≥ 5 nighttime 
readings, where daytime is defined as 1000-2000 hrs and nighttime as 0000-0600 
hrs.46 The guidelines from the European Society of Hypertension (ESH) are more 
stringent; they require ≥20 daytime and ≥7 nighttime readings where daytime is 
defined as 0900 to 2100 hrs and nighttime as 0100 to 0600 hours.4 It is important to 
note that these criteria were arbitrarily set by experts and were not based on 
outcome studies. As this study is taking place in a rural African setting, where the 
practical complexities of ABPM are increased, it is likely that the more stringent 
criteria will exclude a large proportion of the data obtained, The ESH criteria are 
however likely to yield higher quality data with less (random) misclassification bias. 
For these reasons, I propose a primary analysis that uses data evaluated by the 
ESH criteria and a secondary analysis that uses data evaluated by the IDACO 
criteria. 
 
 
 
 
Appendix 1: Analysis Plan for Mendelian Randomization Study 
 219 
REFERENCES 
 
1. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Medicine 
2007;4:e297-e. 
2. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association 
Studies (STREGA): an extension of the STROBE statement. PLoS Med 2009;6:e22. 
3. Boef AG, Dekkers OM, le Cessie S. Mendelian randomization studies: a review of the 
approaches used and the quality of reporting. Int J Epidemiol 2015;44:496-511. 
4. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on 
ambulatory blood pressure monitoring. J Hypertens 2013;31:1731-68. 
5. Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension 
guidelines for the management of high blood pressure in children and adolescents. J Hypertens 
2016;34:1887-920. 
6. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age Standardization 
of Rates: A New WHO Standard. GPE Discussion Paper Series 2001;31:1-14. 
7. Cook RJ, Farewell VT. Multiplicity Considerations in the Design and Analysis of Clinical 
Trials. JR Statist Soc A 1996;159:93. 
8. Williams TN, Mwangi TW, Wambua S, et al. Negative epistasis between the malaria-
protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet 2005;37:1253-7. 
9. Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression 
analyses. J Clin Epidemiol 2015;68:627-36. 
10. Etyang AO, Smeeth L, Cruickshank JK, Scott JA. The Malaria-High Blood Pressure 
Hypothesis. Circ Res 2016;119:36-40. 
11. Enevold A, Lusingu JP, Mmbando B, et al. Reduced risk of uncomplicated malaria episodes 
in children with alpha+-thalassemia in northeastern Tanzania. Am J Trop Med Hyg 2008;78:714-20. 
12. Mockenhaupt FP, Ehrhardt S, Gellert S, et al. Alpha(+)-thalassemia protects African children 
from severe malaria. Blood 2004;104:2003-6. 
13. Piel FB, Weatherall DJ. The alpha-thalassemias. N Engl J Med 2014;371:1908-16. 
14. Kaess BM, Rong J. Aortic stiffness, blood pressure progression, and incident hypertension. 
JAMA 2012;308:875-81. 
Appendix 1: Analysis Plan for Mendelian Randomization Study 
 220 
15. Guo J, Fujiyoshi A, Masaki K, et al. The role of initial and longitudinal change in blood 
pressure on progression of arterial stiffness among multiethnic middle-aged men. J Hypertens 
2017;35:111-7. 
16. Chen W, Li S, Fernandez C, et al. Temporal Relationship Between Elevated Blood Pressure 
and Arterial Stiffening Among Middle-Aged Black and White Adults: The Bogalusa Heart Study. Am J 
Epidemiol 2016;183:599-608. 
17. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute 
to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22. 
18. Stamler J, Stamler R, Rhomberg P, et al. Multivariate analysis of the relationship of six 
variables to blood pressure: findings from Chicago community surveys, 1965--1971. J Chronic Dis 
1975;28:499-525. 
19. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic 
heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 
2013;347:f4262. 
20. International Consortium for Blood Pressure Genome-Wide Association S, Ehret GB, Munroe 
PB, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease 
risk. Nature 2011;478:103-9. 
21. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and Risk of 
Cardiovascular Disease and Diabetes. N Engl J Med 2016;375:2144-53. 
22. Naik RP, Derebail VK, Grams ME, et al. Association of sickle cell trait with chronic kidney 
disease and albuminuria in African Americans. JAMA 2014;312:2115-25. 
23. Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y. Complications associated 
with sickle cell trait: a brief narrative review. Am J Med 2009;122:507-12. 
24. Etyang AO, Wandabwa CK, Kapesa S, et al. Blood Pressure and Arterial Stiffness in Kenyan 
Adolescents with the Sickle Cell Trait. Am J Epidemiol 2017. 
25. Khan S, Floris M, Pani A, Rosner MH. Sodium and Volume Disorders in Advanced Chronic 
Kidney Disease. Adv Chronic Kidney Dis 2016;23:240-6. 
26. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-
aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 
2011;22:1603-9. 
Appendix 1: Analysis Plan for Mendelian Randomization Study 
 221 
27. Neumann J, Ligtenberg G, Klein, II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity 
in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004;65:1568-
76. 
28. Raine AE, Bedford L, Simpson AW, et al. Hyperparathyroidism, platelet intracellular free 
calcium and hypertension in chronic renal failure. Kidney Int 1993;43:700-5. 
29. Passauer J, Pistrosch F, Bussemaker E, Lassig G, Herbrig K, Gross P. Reduced agonist-
induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular 
nitric oxide. J Am Soc Nephrol 2005;16:959-65. 
30. Portaluppi F, Montanari L, Massari M, Di Chiara V, Capanna M. Loss of nocturnal decline of 
blood pressure in hypertension due to chronic renal failure. Am J Hypertens 1991;4:20-6. 
31. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet 
2017;389:1238-52. 
32. Lewis JB. Blood pressure control in chronic kidney disease: is less really more? J Am Soc 
Nephrol 2010;21:1086-92. 
33. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with 
CKD. J Am Soc Nephrol 2009;20:629-37. 
34. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration 
rate. Ann Intern Med 2009;150:604-12. 
35. Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension 
and blood pressure progression. Circulation 2005;111:1370-6. 
36. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. 
N Engl J Med 1995;332:1399-404. 
37. McEniery CM, Wilkinson IB, Johansen NB, et al. Nondiabetic Glucometabolic Status and 
Progression of Aortic Stiffness: The Whitehall II Study. Diabetes Care 2017;40:599-606. 
38. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 
2012;380:601-10. 
39. Johansen NB, Rasmussen SS, Wiinberg N, et al. Associations between glycaemic 
deterioration and aortic stiffness and central blood pressure: the ADDITION-PRO Study. J Hypertens 
2017:1-. 
Appendix 1: Analysis Plan for Mendelian Randomization Study 
 222 
40. Florey CV, Uppal S, Lowy C. Relation between blood pressure, weight, and plasma sugar 
and serum insulin levels in schoolchildren aged 9-12 years in Westland, Holland. Br Med J 
1976;1:1368-71. 
41. Salomaa VV, Strandberg TE, Vanhanen H, Naukkarinen V, Sarna S, Miettinen TA. Glucose 
tolerance and blood pressure: long term follow up in middle aged men. BMJ 1991;302:493-6. 
42. Lacy ME, Wellenius GA, Sumner AE, et al. Association of Sickle Cell Trait With Hemoglobin 
A1c in African Americans. JAMA 2017;317:507-15. 
43. O'Meara WP, Bejon P, Mwangi TW, et al. Effect of a fall in malaria transmission on morbidity 
and mortality in Kilifi, Kenya. Lancet 2008;372:1555-62. 
44. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham 
Study. Am J Public Health 1988;78:676-9. 
45. Cole SR, Platt RW, Schisterman EF, et al. Illustrating bias due to conditioning on a collider. 
Int J Epidemiol 2010;39:417-20. 
46. Thijs L, Hansen TW, Kikuya M, et al. The International Database of Ambulatory Blood 
Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. Blood 
Press Monit 2007;12:255-62. 
 
Appendix 2: Standard Operating Procedures used in data collection 
SOP Title: Study Specific Procedure (SSP) for informed consent for SHINDA 
 Version: Original SSP SHINDA-001 
 
 
 
NOTE: This is a CONTROLLED document. Any documents that are not stamped in red “APPROVED” are 
not controlled. Anyone using an uncontrolled copy is responsible for checking that they have the latest 
revision of the document prior to use. 
 
223 
                          
                              
 
 
Study Specific Procedure 
 
 
SSP No: SSP SHINDA-001 
Version: Original 
Supercedes: None 
Effective Date: 31/10/2015 
 
Long title:  Study Specific Procedure (SSP) for informed consent for Shinikizo la 
Damu (ShinDa) 2: Investigating the role of malaria in elevating blood pressure and 
pulse wave velocity in Kenyan children and adults Short title: SHInikizo lA DAmu 
(SHINDA II) study 
  
 
PREPARER 
 
NAME SIGNATURE DATE 
   
 
REVIEWING 
AUTHORITY 
 Anthony Etyang   
QA UNIT 
AUTHORITY    
 
APPROVAL 
AUTHORITY 
 Anthony Etyang   
 
 
 
 
 
 
 
 
 
 
 
 
KENYA MEDICAL RESEARCH INSTITUTE / 
WELLCOME TRUST RESEARCH PROGRAMME       
(Center for Geographic Medicine Research – Coast) 
Appendix 2: Standard Operating Procedures used in data collection 
SOP Title: Study Specific Procedure (SSP) for informed consent for SHINDA 
 Version: Original SSP SHINDA-001 
 
 
 
NOTE: This is a CONTROLLED document. Any documents that are not stamped in red “APPROVED” are 
not controlled. Anyone using an uncontrolled copy is responsible for checking that they have the latest 
revision of the document prior to use. 
 
224 
 
 
 
1. GOALS AND SCOPE/RESPONSIBILITY:  
This SOP outlines the process of obtaining consent from participants in the SHINDA II 
study. Consistent and appropriate use of the SOP will increase the quality of the study by 
ensuring compliance to the ethical standard requiring that participants provide informed 
consent to take part in the study. 
 
1.1. Overall goals 
• This SSP aims to ensure that voluntary informed consent is obtained form each 
participant in accordance with national e.g. PPB, institutional (KEMRI ERC and KEMRI 
Wellcome Trust Research Programme), ICH-GCP and international guidelines for ethical 
conduct of research. Towards this goal, the SSP provides information on the development 
of the informed consent process, training and monitoring of staff involved, administration 
of consent and (where applicable) materials used to support consent. 
• This SSP describes the way the consent process will be administered, with adequate 
supportive information, to ensure the following: 
• All relevant information is DISCLOSED in an appropriate language 
• The potential participant COMPREHENDS the information and understands how 
their involvement in the study differs from normal clinical care 
• The potential participant males a VOLUNTARY DECISION about whether or 
not to participate and understands that he/she can agree and later withdraw, 
without influence from forms of undue inducement or coercion 
• Since the design of and information and consent form (ICF) is part of a wider consent 
process, the SSP aims to guide study teams in key elements of the consenting process, in 
addition to the development and use of ICFs 
 
1.2. Scope/Responsibility 
• This SSP describes the process to be followed for obtaining written or verbal informed 
consent from subjects/guardians taking part in the research study SHINDA. 
• This study is under the direction of Anthony Etyang and the lay summary is appended 
• This SSP applied to the following study staff that have been delegated the task of 
obtaining informed consent appropriately from participants in research studies: 
• Trained field workers: 
• Study clinicians: 
• Study Nurses: 
• Monitoring of adherence to this SSP is the responsibility of Sailoki Kapesa and 
Christopher Wandabwa or other designees of the PI Anthony Etyang 
 
1.3. Acronyms and terms used in this document 
CCC – Communication and Consent Committee 
ICF – Information and Consent Form 
GCP – Good Clinical Practice 
ICH - International Conference on Harmonization 
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PI – Principal Investigator 
CSC - Centre Scientific Committee  
SOP – Standard Operation Procedure: detailed written instructions to achieve uniformity of 
the performance of study specific consent procedures 
SSP – Study Specific Procedures 
SERU – Scientific and Ethical Review Unit (KEMRI Nairobi, under the National Council for 
Science and Technology or NCST) 
CLG – Community Liaison Group: a group of community liaison offices who coordinate 
community engagement activities in Kilifi within the KEMRI-Wellcome Trust Programme 
CAST groups – Community engagement Advisory groups for Studies: a group set up by the 
CLG manager including community liaison officers and members of HSSR (Health Systems 
and Social Research group) who work on research ethics. The group will support planning an 
implementation of community engagement activities when projects are ready to start, 
including community consultation, outreach, communicating with participants, informed 
consent, resolving emerging community issues in studies and feedback of research findings 
at the end of a study. 
SHINDA II - SHinikizo lA DAmu study II: short title for Investigating the role of 
malaria in elevating blood pressure and pulse wave velocity in Kenyan children 
and adults 
 
ASSENT: An affirmative agreement of a child/minor (less than 18 years of age) or an 
individual with impaired consent capacity to participate in research. Mere failure to object 
i.e. absence of affirmative agreement should not be construed as assent 
DESIGNEE: A person designated by another individual to act on the latter’s behalf 
INFORMED CONSENT: The permission, voluntary given by an individual who understands 
the purpose and nature of the study, what participation in the study requires of the individual, 
the nature of the risks and what benefits are intended to result from participation in the study 
INFORMATION AND CONSENT FORM: a document comprising: 1) An information sheet 
containing all the information required for a potential subject/guardian to make an informed 
decision on whether to participate in a study, and 2) A form on which informed consent is 
documented by the dated signature of a subject/guardian, investigator/designees and witness 
(where applicable). In the KEMRI Wellcome Trust Research Programme, obtaining a 
signature from those who do not agree to research is not recommended given risks of 
perceived coercion in this community 
ICF AMENDMENT – Changes to the ICF, which have implications for the study 
participants or for data analysis and which need prior approval of the CCC and by KEMRI 
CSC and SERU e.g. strengthened translations 
WITNESS – A person who attends the entire informed consent process if the subject or the 
subject’s guardian cannot read and/or write. The witness should be the study investigator or a 
member of the study team or any other person whose main professional responsibilities are 
involved in the conduct of the study.  
 
 
2. DEVELOPMENT OF THE ICF AND CONSENT PROCESS: 
The ICFs to be used in the Shinda II study were developed by the study investigators 
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with guidance from the Communications and Consent Committee. The KEMRI Scientific 
and Ethical Review Unit has approved all the documents that will be used in the study. 
 
3. TRAINING OF STAFF INVLED IN THE INFORMED CONSENT PROCESS AND 
MONITORING AND EVALUATION OF THE CONSENT PROCESS 
3.1. Trainees: Field workers, study nurses and study clinicians will perform the informed 
consent process for the study. These recruiters will be trained in the informed consent 
process. 
3.2. Trainers: Communication for informed consent and study specific informed consent 
training will be run in conjunction with CLG with support from Anthony Etyang and his 
designees Sailoki Kapesa and Christopher Wandabwa 
3.3. Content: the training objectives for the communication for informed consent training, 
the study specific informed consent process training process and training curriculum to 
be used are detailed in the appendix. Included is the training curriculum for recruiters 
(health centre workers and health action leaders). 
3.4. Training evaluation: The training will be evaluated by a person designated by the CLG 
through appropriate role-plays and dry runs prior to study initiation. 
3.5. Monitoring: Sailoki Kapesa and Christopher Wandabwa and community facilitators 
attached to the study through supportive supervision will monitor the informed consent 
process regularly. Monitoring will be performed in the following way: 
3.5.1. Through fortnightly review of completed ICFs by Sailoki Kapesa and Christopher 
Wandabwa or other designee 
3.6. Documentation of training: Completing a post-training evaluation and signing of a 
personal training log will document training activities. 
 
4.0 ADMINISTRATION OF INFORMED CONSENT 
• Informed consent in the Shinda II study shall be obtained at the participants’ homes 
(Kilifi) and in the study clinic (Nairobi) 
• The recruiter shall approach the randomly selected participants and explain: 
a. the purpose of the research 
b. the procedures that the study will entail 
c. the fact that participation is voluntary 
d. the fact that a participant can withdraw from the study at any time that they feel 
like 
• The participants shall be given a copy of the information and consent form to read. If 
they agree to participate, both the participant and recruiter will be required to sign the 
consent document in duplicate. One copy will remain with the participant and the other 
will be retained by the study team. 
  
5.0 ENSURING THE QUALITY OF THE CONSENT PROCESS 
• The study team will ensure that the consent process is being adhered to by ensuring the 
consent forms are properly signed and by obtaining feedback from participants regarding the 
consenting process. The PI/designee will oversee this process. 
• The study quality assurance mechanisms will ensure that checking adherence to this SSP 
during the monitoring process adheres to the procedures described in this document. 
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• Understanding of the participant/parent/guardian/legally acceptable representative will be 
continuously assessed during follow up visits by checking that the participant understand that 
they are participating in research and remember what this entails 
• The consent process for this study will be supported by and overlap with a broader 
community engagement strategy that is being carried out by the CAST.  
• The investigator/designee will document the informed consent process in the participant’s 
source documents and comment about nay issues that may influence decisions to allow 
participants to continue participating in research 
 
6.0 MATERIALS 
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APPENDICES: 
APPENDIX 1 
Objectives for Communication for Informed Consent Training and Study Specific 
Informed Consent Training: 
At the end of the training, participants will be equipped with knowledge and skills to 
• Communicate effectively about KEMRI’s core values and its roles 
• Address common rumors in the community about research, KEMRI and its roles 
• Explain the difference between medical research and treatment 
• Appreciate the importance of research in development of new knowledge 
• Understand key principles of research ethics and how to apply them 
• Undertake a true informed consent process 
• Understand the general community entry approaches as defined in the KWTRP’s 
community engagement strategy 
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APPENDIX 2 
Training curriculum for informed consent process for SHINDA study 
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1.0 PURPOSE / INTRODUCTION:  
This SOP outlines the protocol for collecting blood samples from participants in the 
SHINDA 2 study in the Kilifi and Nairobi Health and Demographic Surveillance System 
area. 
 
2.0 SCOPE / RESPONSIBILITY:  
 
2.1 Scope: 
The SOP will apply to the SHINDA II study. 
 
2.2 Responsibility: 
1.1.1 SHINDA study field workers 
1.1.2 SHINDA study investigators 
 
3.0 SAFETY/RISK ASSESSMENT:  
3.1 Handling blood specimens: 
3.1.1 There is risk of blood borne infections especially from needle stick 
injuries when handling blood samples. 
3.1.2 To minimize risk, non-sterile gloves will be provided for field workers 
 
4.0 DEFINITIONS: Provide definitions for all important words and abbreviations 
referenced in this procedure.  
4.1 BP = Blood pressure 
4.2 PWV= pulse wave velocity 
4.3 SHINDA = SHINikizo la DAmu, study of hypertension in Nairobi and Kilifi 
4.4 KHDSS = Kilifi Health and Demographic Surveillance System 
4.5 NUHDSS= Nairobi Urban Health and Demographic Surveillance System 
4.6 KEMRI/WT = Kenya Medical Research Institute/ Wellcome Trust 
4.7 APHRC= African Population and Health Research Center 
 
5.0 SPECIMEN: Provide the specifics of the specimen that will be required in carrying out 
this procedure.  
5.1 Blood sample 
5.1.1 EDTA and serum samples 
 
6.0 EQUIPMENT / MATERIALS/ REAGENTS:  
6.1 Equipments 
6.1.1 Sample carrier container 
6.1.2 Blood collection bottles (cryovials, EDTA and SST bottles) 
6.1.3 Non-sterile gloves 
 
6.2 Materials 
6.2.1 Consent form 
6.2.2 Study information form 
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6.2.3 24 hour ABPM/PWV information sheet 
6.2.4 Visit  Data collection forms (BP, Urine, blood) 
6.2.5 Sample labels 
 
6.3 Reagents 
6.3.1 NONE 
 
7.0 METHODOLOGY:  
 
7.1 Principle 
7.1.1 Hypertension is increasingly becoming a major health issue in Sub-
Saharan Africa 
7.1.2 Inflammation is thought to be a leading risk factor for developing 
hypertension 
7.1.3 In this study we aim to determine whether past exposure to malaria affects 
blood pressure.  
 
7.2 Timetable 
All study participants to receive 2 visits, where the following activities should be 
performed in the following order: 
First visit: 
1. Explanation of aims of study and requirements of participation 
2. Consent procedure 
3. Blood pressure measurement 
4. Complete first questionnaire (Visit 1 Data Collection Form) 
5. Spot urine collection 
6. Blood collection 
7. Weight measurement 
8. Height measurement 
9. Mid upper arm circumference (MUAC) measurement 
 
At the end of the day, return all samples and paperwork to the laboratory 
 
 FIRST VISIT 
7.3 Consent form 
7.3.1 Complete in accordance with Study Specific Procedure (SSP) for 
informed consent for ShinDa II 
 
7.4 Blood pressure/Pulse Wave Velocity 
7.4.1 Complete in accordance with SOP – Shinda – Blood Pressure/Pulse Wave 
Velocity Measurement 
7.4.2 This should be completed for ALL participants 
 
7.5 Completing the Visit 1 Data Collection Form 
7.5.1 This is to be completed on the first visit, by a trained field worker, using 
the “Visit 1 Data Collection Form”. Complete ALL fields on the form. 
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7.5.2 Date of birth and age – give best estimate of date of birth/age if not 
known. Write ‘estimated’ on the form if exact information is not available 
7.5.3 For female participants: 
7.5.3.1 Last menstrual period/Pregnancy. Because sodium levels can be 
affected by pregnancy, this question is important.  
7.5.3.2 If participants are pregnant, they must be excluded from the study 
– no further procedures should be undertaken. 
7.6 Blood collection 
7.6.1 Participant should have given informed consent prior to procedure 
7.6.2 Explain procedure to participant 
7.6.3 Document the time that the blood sample was taken on the data collection 
form AND on the participant’s 24 hour BP/PWV leaflet 
7.6.4 Barcode labels are to be placed on each tube during collection as shown 
below  
   
 
AWI-Gen H3Africa 
Genomic and Environmental Risk Factors for Cardiometabolic Disease in Africans 
 
SOP 003_01 
 
Title Blood Collection, Processing, Storage and Transport 
Code SOP 003_01 
Effective date 2 Sep 2013 
 
1.  Purpose 
The purpose of this document is to provide guidelines as to the procedures involved in the 
collection, storage and shipping of blood samples for the AWI-Gen project. 
 
2. Scope 
It will cover all the procedures, from the collection of blood samples, to the transportation of these 
samples should they be required for processing or analysis outside of your facilities. 
 
3. Responsibilities 
It is the responsibility of each centre to have in its employ a sk lled phlebotomist to draw blood 
samples from the participants. Relevant staff should ensure that all tubes are labelled, handled, 
processed and stored as instructed in this SOP. For local storage of samples, centres are responsible 
for reserving space for approximately 16 000 cryovials (1.5ml) at -80°C. This is equivalent to 197 nine 
by nine storage boxes. Buffy coat will be shipped to the SBIMB for DNA extraction. 
 
4. Definitions 
Please refer to the glossary of terms. 
 
5. Procedure 
Barcode labels are to be placed onto each tube during collection as in the diagram below : 
 
 
 
Sticker 
 
7.6.5 Please ensure that the barcodes match on the tubes and the questionnaire. 
One purple topped 4ml, and one 6ml yellow capped tubes will be collected 
for a total of 10ml blood. 
7.6.6 Purple capped tubes (EDTA). These are for full blood count and DNA 
genotyping 
7.6.6.1 One 4 ml purple capped tube is to be collected from each 
participant  
7.6.6.2  Purple top tubes should be 50-60% full. Do not overfill tubes.  
7.6.6.3 Gently mix specimen by inverting 5-10 times and place it on a 
rocker if available for up to 30 minutes, then refrigerate at 2-8°C or 
place in cool box.   
7.6.6.4 Refrigerated EDTA blood is stable for full blood count (FBC) and 
genotyping for up to 24 hours. Clotted or hemolyzed specimens are 
unacceptable. Check for clots by using a clean wooden applicator 
stick and gently swirling blood in tube.  
7.6.6.5 EDTA microtainers must be shaken 10-15 times to overcome the 
surface tension within the tube  
7.6.6.6 EDTA samples are to reach the lab within 6 hours of collection. 
Once in the KEMRI CCR lab, 1-1.5ml from the EDTA tube is to 
be aliquoted into each of two barcoded cryovials (2ml) that are to 
be refrigerated at negative 80ºC as soon as possible, awaiting 
shipment to Kilifi for genotyping and HbA1c testing. The samples 
should be processed within 1 hour of delivery to the lab. 
7.6.6.7 The remaining sample in the EDTA tube (approximately 1ml) will 
be for running a full blood count test at CCR lab. 
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7.6.7 Yellow capped tubes (SST). These are for serum electrolytes. Part of 
these samples will be stored for future analyses. One 6ml SST tube will be 
used to collect at least 3ml of blood from each participant. 
7.6.7.1 Immediately after collection, mix SST tubes by inverting 8-10 
times  
7.6.7.2 For clot formation to occur, tubes must be mixed well. 
7.6.7.3  Avoid hemolysis of the specimen during collection and mixing 
7.6.7.4  Allow blood to clot by placing tube vertically in a rack at room 
temperature until the separation is visible. 
7.6.7.5 Store in refrigerator at 2-8ºC awaiting transfer to CCR lab 
7.6.7.6 Transfer to lab within 4 hours of collection 
7.6.7.7 At the lab the sample will be centrifuged and 2 aliquots, each 500 
µl to be harvested and placed in barcoded labeled cryovial 
7.6.7.8 Cryovials are to be transferred to -80ºC freezer as soon as possible 
to await shipment to Kilifi 
7.6.7.9 Remaining sample in SST tube for serum electrolyte testing 
Notes:  
• It is the responsibility of the laboratory technician/manager in charge of the processing to 
ensure the participant cryovial barcodes correctly matches the Vacutainers barcode for 
the participant whose sample is being aliquoted for cryopreservation.  
• For the CCR- Nairobi printed results, the participant identifier barcode must reflect on the 
result sheet for unique identity and any back reference desired at any point in the course 
of the study. 
 
Please complete checklist at bottom of Data Collection Form 1, to ensure that all required 
actions are complete. 
 
SECOND VISIT 
(This should take place as close as possible to 24 hours after the time ABPM/PWV was 
started on the first day 
7.7 Completing the Visit 2 Data Collection Form 
7.7.1 This is to be completed on the SECOND visit, by a trained field worker, 
using the “Visit 2 Data Collection Form”. Complete ALL fields on the 
form. 
7.7.2 The purpose of the questionnaire is to determine how complete the 24 
BP/PWV measurement was and sleeping and waking times. 
 
Please complete checklist at bottom of Data Collection Form 2, to ensure that all required 
actions are complete. 
 
7.8 Returning to Lab at end of day 
7.8.1 At the end of the day, return all samples to the KEMRI-WT top lab 
(Kilifi)/ CCR lab (Nairobi)  
7.8.2 Please ensure that all samples are labelled and forms are appropriately 
filled out  
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7.8.3 Document the date and time that samples arrive in the lab in both: 
7.8.3.1 The main laboratory logbook 
7.8.3.2 The sample request form 
7.8.4 Please ensure that all paperwork is signed 
7.8.5 Please file all paperwork to remain as hard copy evidence even after 
inputting data into computer database 
 
 
 
 
8.0 APPENDICE S: This section is to be used for inserting figures, tables, diagrams or 
forms referenced in the SOP.  
 
Include copies of the Data Collection forms 1 and 2, and the lab request form 
 
9.0 REFERENCES:  
Provide a list of the guidance documents, cross-references, higher-level procedures or 
publications that have contributed to the generation of this procedure.  
Start typing here… 
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10.0 PURPOSE / INTRODUCTION: This SOP outlines the protocol for collecting urine 
samples and anthropometric data in the field from participants in the SHINDA 2 study in 
the Kilifi and Nairobi Health and Demographic Surveillance System area. 
 
 
11.0 SCOPE / RESPONSIBILITY:  
 
2.3 Scope: 
The SOP will apply to the SHINDA II study. 
 
2.4 Responsibility: 
1.1.3 SHINDA study field workers 
1.1.4 SHINDA study investigators 
 
12.0 SAFETY/RISK ASSESSMENT:. 
12.1 Handling urine specimens: 
12.1.1 There is minimal risk to field workers of handling urine bottles whose 
exteriors have been contaminated with urine. 
12.1.2 To minimize risk, non-sterile gloves will be provided for field workers 
12.1.3 All urine samples are to be transported in sealed sample containers from 
the time of sample collection to being logged at the laboratory 
 
13.0 DEFINITIONS:  
13.1 BP = Blood pressure 
13.2 SHINDA = SHINikizo la DAmu, study of hypertension in Nairobi and Kilifi 
13.3 KHDSS = Kilifi Health and Demographic Surveillance System 
13.4 MUAC= Mid upper arm circumference 
13.5 NUHDSS= Nairobi Urban Health and Demographic Surveillance System 
13.6 KEMRI/WT = Kenya Medical Research Institute/ Wellcome Trust 
13.7 ‘Spot’ urine sample = urine sample collected as one-off, small sample 
 
 
14.0 SPECIMEN:  
14.1 ‘Spot’ urine sample 
14.1.1 Small (<30 ml) urine sample 
 
 
15.0 EQUIPMENT / MATERIALS/ REAGENTS:  
 
15.1 Equipment 
15.1.1 Sample carrier container 
15.1.2 Spot urine collection bottle 
15.1.3 Non-sterile gloves 
15.1.4 Omron M10-IT digital automatic blood pressure monitor 
15.1.5 4x AA batteries for above blood pressure monitor 
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15.1.6 Weighing scales 
15.1.7 Seca 213 Stadiometer (height measuring equipment) 
15.1.8 MUAC tape 
 
15.2 Materials 
15.2.1 Consent form 
15.2.2 Study information form 
15.2.3 24 hour ABPM/PWV information sheet 
15.2.4 Visit 1 Data collection form 
15.2.5 Visit 2 Data collection form 
15.2.6 Sample labels 
 
15.3 Reagents 
15.3.1 NONE 
 
16.0 METHODOLOGY:  
 
16.1 Principle 
16.1.1 Hypertension is increasingly becoming a major health issue in Sub-
Saharan Africa 
16.1.2 Salt intake is thought to be a leading risk factor for developing 
hypertension 
16.1.3 In this study we aim to determine whether salt intake as measured in the 
urine affects blood pressure.  
 
16.2 Timetable 
All study participants to receive 2 visits, where the following activities should be 
performed in the following order: 
First visit: 
10. Explanation of aims of study and requirements of participation 
11. Consent procedure 
12. Blood pressure measurement 
13. Complete first questionnaire (Visit 1 Data Collection Form) 
14. Spot urine collection 
15. Weight measurement 
16. Height measurement 
17. Mid upper arm circumference (MUAC) measurement 
At the end of the day, return spot urine samples to laboratory 
 
At the end of the day, return all samples and paperwork to the laboratory 
 
 FIRST VISIT 
16.3 Consent form 
16.3.1 Complete in accordance with Study Specific Procedure (SSP) for 
informed consent for ShinDa II 
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16.4 Blood pressure/Pulse Wave Velocity 
16.4.1 Complete in accordance with SOP – Shinda – Blood Pressure/Pulse Wave 
Velocity Measurement 
16.4.2 This should be completed for ALL participants 
 
16.5 Completing the Visit 1 Data Collection Form 
16.5.1 This is to be completed on the first visit, by a trained field worker, using 
the “Visit 1 Data Collection Form”. Complete ALL fields on the form. 
16.5.2 Date of birth and age – give best estimate of date of birth/age if not 
known. Write ‘estimated’ on the form if exact information is not available 
16.5.3 For female participants: 
16.5.3.1 Last menstrual period/Pregnancy. Because potassium level 
in the urine could be affected by presence of blood, and sodium 
levels can be affected by pregnancy, this question is important.  
16.5.3.2 If participants are pregnant or during the menstrual phase 
of their period, they must be excluded from the study – no further 
procedures should be undertaken. 
 
16.6 Spot urine collection 
16.6.1 Participant should have given informed consent prior to procedure 
16.6.2 Explain procedure to participant 
16.6.3 Ensure that this is NOT the first urination of the day 
16.6.3.1 If it is, ask the participant to void immediately. You can 
then collect a urine sample after 30-60 minutes 
16.6.4 Affix the participant's specimen label, marked onto one of the small spot 
urine containers. Use spot urine container with a lid, to avoid spillage. Ask 
the participant to produce a urine sample into the container, so that it is 
around ¾ full. Any remaining urine is discarded in the participant’s usual 
manner. 
16.6.4.1  Female collection 
16.6.4.2  Wash hands thoroughly with soap and water. Dry with a 
paper towel 
16.6.4.3  With one hand, gently spread genital skin folds apart 
16.6.4.4  Using an antiseptic skin towelette, wash vulva, wiping 
from front to back and discard towelette in the sanitary bin 
16.6.4.5  Repeat, wiping from front to back 
16.6.4.6 Void the first portion of urine into toilet. 
16.6.4.7  Void the midstream portion into a 30ml sterile container 
provided, being careful not to touch the inside of the container  
16.6.4.8 Stop collection when container is about half full and void 
the remaining urine stream into the toilet  
16.6.4.9 Screw cap tightly and wash hands. Give the filled container 
to the designated staff member 
16.6.4.10 Male collection 
16.6.4.11 Wash hands thoroughly with soap and water. Dry with a 
paper towel  
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16.6.4.12 Gently pull back foreskin, (if uncircumcised) and cleanse 
glans penis with an antiseptic skin towelette  
16.6.4.13 Void first portion of urine into the toilet, and then void the 
midstream portion into the urine container, being careful not to 
touch the inside of the container 
16.6.4.14 Stop collection when the container is about halfway to 3-
quarters full. Complete void into the toilet  
16.6.4.15  Screw the cap onto the container and wash hands  
16.6.4.16  Give the filled container to the designated staff member 
16.6.5 Processing of urine samples 
16.6.6 Handle the urine sample with non-sterile gloves. Place the sample in the 
sample collection coolbox or refrigerator. Ensure that sample lid is firmly 
screwed on before placing in coolbox/refrigerator. 
16.6.7 Ensure that the coolbox has ice packs in it 
16.6.8 Document the time that the spot urine sample was produced on the data 
collection form AND on the participant’s 24 hour BP/PWV leaflet.  
16.6.9 If a participant is unable to void for the "spot" urine, ask the participant to 
take some fluids (e.g. 2 glasses of water), and wait until the participant is 
able to try again. Proceed with the remainder of the visit until the 
participant indicates that he or she is able to void.  
16.7 Weight 
16.7.1 Only to be measured at the first visit 
16.7.2 Participant should have given informed consent prior to procedure 
16.7.3 Explain procedure to participant 
16.7.4 Remove participant’s shoes and minimise heavy clothing 
16.7.5 The floor surface on which the scale rests must be hard, flat, and must not 
be carpeted or have other soft materials. 
16.7.6 Participant should be asked to stand still on centre of scale, as standing 
off-centre may affect the measurement 
16.7.7 Measure weight to nearest 0.1 kg 
16.7.7.1 For scales weighing to 2 decimal points: if  0.05kg & above 
round up; if <0.05kg  round down 
16.7.8 Say weight out loud and write it down immediately on the data collection 
form (check that order of digits is not inverted) 
16.7.9 Show weight to participant 
16.7.10Self-reported weights are not acceptable in ambulatory participants. 
Refusals to be weighed should be recorded as refusals. Only participants 
who are not ambulatory (e.g., amputees) may self-report their weight. Be 
sure to note this on the form. The reading of the scales is to be done by the 
field worker. 
 
16.8 Height 
16.8.1 Only to be measured at the first visit 
16.8.2 Participant should have given informed consent prior to procedure 
16.8.3 Explain procedure to participant 
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16.8.4 Construct Seca stadiometer. Ensure that all pieces are firmly in place to 
prevent errors 
16.8.5 The floor surface must be hard, flat, and should not be carpeted or have 
other soft materials.  
16.8.6 Remove participant’s shoes/socks and heavy garments; remove hair 
ornaments; compress braids 
16.8.7 Participant stands upright in centre of board in the feet positions indicated, 
with heels together touching the back plate; hands by side 
16.8.8 Back of participant’s head, shoulders, buttocks, calves & heels must touch 
the backboard 
16.8.9 Participants must look forward; direction of gaze is at 90 degrees to 
vertical plane 
16.8.10Ask the participant to take in a deep breath for full height 
16.8.11Lower head-board onto top of participant ’s head; read and call out height 
to nearest 0.1cm 
16.8.12Record height as soon as possible on the data collection form. 
16.8.13Show height to participant 
16.8.14Disassemble the Seca stadiometer. Please ensure that at the end of the day, 
the stadiometer is completely disassembled (using instructions on bottom 
of foot plate) and returned to its carry-case. 
16.8.15Self-reported heights are not acceptable in ambulatory participants and 
should not be recorded. Only persons who are not ambulatory (e.g., 
amputees) may self-report their heights. Be sure to note this on the form. 
 
16.9 MUAC measurement 
16.9.1 Only to be measured at the first visit 
16.9.2 Measure the upper arm length as below: 
16.9.3 Position the subject: Direct the subject to turn away from you. Ask him or 
her to stand upright with the weight evenly distributed on both feet, the 
right arm bent 90º at the elbow, and the right palm facing up. 
Demonstrate the correct position if necessary.  
16.9.4 Mark the measurement site: Locate the end of the spine of the right 
scapula by following the scapula out to the arm until it makes a sharp V-
turn to the front of the body. Using a biro pen, make a horizontal line on 
the uppermost edge of the posterior border of the spine extending from the 
acromion process (see picture 16.9.4 below).  
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    16.9.4 Marking spine extending from acromion process 
16.9.5 Take the measurement: Hold the zero end of the measuring tape at this 
mark and extend the tape down the posterior surface of the arm to the tip 
of the olecranon process, the bony part of the mid-elbow (picture 16.9.5a). 
Take the measurement to the nearest 0.1 cm. IMPORTANT: The tape 
must be centered on the posterior surface of the arm. Exhibit 16.9.5b 
shows the correct placement of the measuring tape centered on the 
posterior surface of the arm; whereas Exhibit 16.9.5c shows the measuring 
tape placed incorrectly.  
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16.9.5b ✓Correct tape 
placement for upper arm length 
16.9.5a Subject 
position for upper arm 
length and midpoint 
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16.9.6 Note down this result. Keep the measuring tape in position.  
16.9.7 Mark the midpoint: While holding the tape in place, make a horizontal 
mark at the midpoint and cross this mark with a perpendicular line 
(Exhibit 16.9.7). You may need to remove the tape in order to complete 
the cross mark (+). IMPORTANT: The vertical line must be centered on 
the posterior surface of the arm. This mark defines the site at which both 
the arm circumference will be measured. Finally, tell the SP to relax the 
right arm. Proceed to the arm circumference measure.  
✗16.9.5c Incorrect  tape 
placement for upper arm 
length 
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16.9.8 Take the MUAC measurement: Continue to stand facing the right side of 
the subject. Do not stand behind the subject for this measurement. Wrap 
the MUAC tape around the arm at the level of the upper arm mid-point 
mark Make sure the numbers are the right side up. Make sure the tape is 
flat around the skin and that it is not too tight or too loose. When the tape 
is in the correct position read and call out the measurement to the nearest 
0.1cm. Write down this measurement in the questionnaire.  
  
 
 
 
 
 
16.9.7 Marking upper 
arm length mid point 
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Figure 5.5. Child Mid-Upper Arm Circumference Measurement
4.  Place tape at tip of 
shoulder
5.  Pull tape past tip of 
bent elbow
6.  Mark midpoint2.  Tip of shoulder
3.  Tip of elbow
1.  Locate tip of 
shoulder 
7.  Correct tape tension
8.  Tape too tight
9.  Tape too loose 10.  Correct tape position for arm circumference
How to weigh and measure children: assessing the nutritional status of young children in UN (1986)
TAK ING MEASUREMENTS PART 5 .
Artwork proof 3  8/8/01 2:59 pm  Page 35
 
 
 
 
 
 
 
Please complete checklist at bottom of Data Collection Form 1, to ensure that all required 
actions are complete. 
 
SECOND VISIT 
(This should take place as close as possible to 24 hours after the time of the spot urine on 
previous day) 
16.10 Completing the Visit 2 Data Collection Form 
16.10.1This is to be completed on the SECOND visit, by a trained field worker, 
using the “Visit 2 Data Collection Form”. Complete ALL fields on the 
form. 
16.10.2The purpose of the questionnaire is to determine how complete the 24 
BP/PWV measurement was and sleeping and waking times. 
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Please complete checklist at bottom of Data Collection Form 2, to ensure that all required 
actions are complete. 
 
16.11 Returning to Lab at end of day 
16.11.1Nairobi: All samples are to be shipped to CCR lab at KEMRI offices in 
Mbagathi. Motorcycle rider will be on hand to transport the samples 
16.11.2Kilifi:At the end of the day, return all samples to the KEMRI-WT top lab 
16.11.3Please ensure that all samples are labelled and forms are appropriately 
filled out  
16.11.4Document the date and time that samples arrive in the lab in both: 
16.11.4.1 The main laboratory logbook 
16.11.4.2 The sample request form 
16.11.5Please ensure that all paperwork is signed 
16.11.6At the end of the day input all of the paperwork onto the database 
 
 
 
 
17.0 APPENDICE S: This section is to be used for inserting figures, tables, diagrams or 
forms referenced in the SOP.  
 
Include copies of the Data Collection forms 1 and 2, and the lab request form 
 
18.0 REFERENCES:  
Provide a list of the guidance documents, cross-references, higher-level procedures or 
publications that have contributed to the generation of this procedure.  
Start typing here… 
 
  
1. Elliott P, Stamler R. Manual of operations for "INTERSALT", an international 
cooperative study on the relation of sodium and potassium to blood pressure. Controlled 
clinical trials. 1988;9(2 Suppl):1S-117S. Epub 1988/06/01.
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2.0 PURPOSE / INTRODUCTION:  
Shinda is a project whose objective is to determine pulse wave velocities and ambulatory 
blood pressure values in individuals exposed and not exposed to malaria. This document 
outlines the procedure for conducting 24hr PWV and ABPM to ensure that the results 
obtained are valid. 
 
3.0 SCOPE / RESPONSIBILITY:  
This applies to all clinically trained staff involved in 24 hr ABPM/PWV measurement as part 
of the Shinda study. 
 
4.0 DEFINITIONS:  
Blood pressure 
      Ambulatory blood pressure monitoring 
      Pulse wave velocity 
      Standard blood pressure measurement 
       Subject/Patient 
  
5.0 EQUIPMENT / MATERIALS/ REAGENTS:  
1. Computer/Tablet/netbook running windows 7 or later and Microsoft office 
2. Arteriograph 24 PWV/ABPM machine 
3. 4 fully charged AA size alkaline batteries 
4. Crepe bandage for securing BP cuff on arm 
  
6.0 METHODOLOGY:  
Indications for conducting 24h ABPM/PWV.  
a) 24h ABPM/PWV is to be conducted on all individuals who have been selected to 
participate in the Shinda II study  
b) Preparing for arteriograph measurement       
 i. Take height and weight of the subject as described in SOP for taking 
anthropometric measurements        
 ii. Measure also the mid upper arm circumference (MUAC) 
c) Setting up the Arteriograph monitor 
d) Open the software icon “24 TensioWin” on the computer/tablet. There is no password 
e) Click on New to open the “Patient details” interface. 
f)  Enter the subject’s names, date of birth, height, weight, MUAC, ID and sex into the 
computer software. Press OK to return to previous interface  
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g) Click on the “set up protocol and device” button and select a program. Daytime 
measurements should be taken every 20 minutes while nightitime measurements should 
be taken every 40 minutes. 
h)  Click “send” to transfer the subject’s information to the device. At this point a window 
will appear with the cuff size based on the arm circumference. 
- while the transfer is proceeding the word ‘connect’ will appear on the arteriograph 
screen 
- at the bottom right corner of the computer/tablet screen, the serial number of the 
device being programmed will appear. As there might be more than one device within 
range in the room, please confirm that the right device is being programmed by 
confirming the serial number located on the back of the device 
i) Wrap the indicated cuff around the bare arm or on light clothing. 
j) Place the device close to the computer and ensure that the device is connected via 
Bluetooth. 
k)  Inform the subject that the measurement will begin in 5 minutes time and should sit/lie 
calmly. The subject should relax the arm and avoid any arm movement once the cuff 
starts to inflate. 
Please ensure that your computer time and date is accurate as this is the time 
that will be recorded on the arteriograph and it will be synchronized with 
that of the computer 
a. Attaching monitor on patient 
I. Ensure that you have a fully charged set of AA batteries for every 
examination. Please check battery voltage will be shown on the display as 
soon as you install all the batteries. If the voltage measurement is less than 
3.5V replace the batteries with a new set and repeat the check. 
II. Explain procedure to patient verbally. In addition give them the 24h 
ABPM/PWV information sheet as well as diary. 
III. Place the appropriate sized cuff on the patient’s non-dominant arm. Unlike 
standard blood pressure monitors, the air tube is made to face up rather than 
down overlying the brachial artery. This is done so as to facilitate the air 
tube going under the patient’s clothes. The patient may wear some light 
clothing (e.g a thin shirt) under the cuff to prevent itching/sweat. Secure the 
cuff using a crepe bandage to prevent it from slipping downward during the 
course of the measurement.  
IV. Connect the airtube to the monitor and secure the monitor on the patient 
using the carry pouch and waist/shoulder straps. 
V. Demonstrate to the patient how to remove and reattach the device/cuff when 
they need to take a bath. 
VI. The patient should not operate any buttons on the device. 
VII. Ensure that the monitor is switched on and that the first inflation is 
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successful before leaving the patient. 
b. Removing monitor from patient 
Disconnect the airtube from the monitor. Remove the crepe bandage and cuff from the 
patient’s arm. Remove the carry pouch as well as the monitor from the patient. Switch off 
the monitor to avoid it attempting to take measurements when not connected. DO this by 
pressing the START button 4 times when you will see ‘OFF’ on the LCD display. 
c. Downloading data from monitor to computer 
Open the software icon “24 TensioWin” on the computer/tablet. Follow the instructions 
to transfer the data to the computer. 
Select the individual patient and then follow these instructions in order to export a report 
of the 24h ABPM/PWV: 
i. On the right side of the window you will see the name of the participant and 
details of when the test started and ended. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii. Click on the “Graph view” tab 
iii. This will show you a graph of the subjects BP measurements 
iv. Click on the “Data” tab at the top of this window as shown below. This will 
display the subjects individual readings that were taken over the 24 hour 
period as shown below 
Graph view 
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Data view 
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v. Click on the export data tab at the top of this window as shown below 
 
 
 
 
 
vi. Save the report using the patient’s PID as the file name. It will be saved in 
Microsoft word TXT format 
vii.  
d. Entering 24 hr ABPM data into database 
I. Open the patient’s 24h ABPM report saved in the previous step in TXT 
format. At the same time open the blank excel spreadsheet that has the 
same name (PID) as the TXT file that you have opened. Select the table of 
BP readings in the TXT file. Make sure you have selected the entire table 
to include all the readings for the period. The columns in the table will 
consist of the following:Time; T SBPbr DBP pulse PP MAP SBPao 
AIXao PPao PWVao PWVsd 
II. Copy this table into the excel spreadsheet. Confirm once more that the 
excel file has the same name (PID) as the TXT file you have copied from. 
Save the excel file. Then transfer this file into the study database. 
Export data tab 
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Enter any additional information present on the participant diary under the ‘Note’ column 
 
  
7.0 APPENDICES: This section is to be used for inserting figures, tables, diagrams or forms 
referenced in the document.  
 
8.0 REFERENCES:  
Please review the instruction manuals for the Arteriograph 24 for more details.  
 
9.0 DOCUMENT CHANGE HISTORY  
This section is to be completed by the Quality Management or designee  
 
Version Table: 
Version 1: 
Title: Ambulatory Blood Pressure/PWV 
Monitoring for the SHINDA II study 
Dated: 
12 
October 
2015 
SOP No.:  
 
No. 
Pages: 
Version 2:  
Title:  
Dated: 
 
SOP No.: 
 
No. 
Pages: 
Version 3: 
Title: 
Dated: 
 
SOP No.: 
 
No. 
Pages: 
 
 
SOP Review and Updating Logs 
 
DATE NAME OF REVIEWER SIGNATURE REASON FOR REVIEW 
 
 
   
 
 
   
    
 
 
 
 
DOCUMENT COPY CONTROL 
 
SOP DISTRIBUTION 
DATE SECTION RECEIVED BY 
   
   
Appendix 2: Standard Operating Procedures used in data collection 
SOP Title: Standard Operating Procedure (SOP) for ABPM/PWV measurement for SHINDA II 
 Version: Original SSP SHINDA-001 
 
 
NOTE: This is a CONTROLLED document. Any SOPs that are not stamped in red “APPROVED” are not controlled. 
Anyone using an uncontrolled copy is responsible for checking that they have the latest revision of the SOP prior to use. 
 
 
261 
   
   
   
 
 
 
 
 
 
 
